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Phantasie ist wichtiger als Wissen,  
denn Wissen ist begrenzt. 
 
Albert Einstein 
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1 INTRODUCTION 
 
The ability to coordinate complex physiological processes with a constantly changing 
environment is a prerequesite for any form of life. Every organism has to sense external 
parameters in order to react in an appropriate manner. Breaking down life to its unit – the cell, 
we can start to study and try to understand the molecular basis of the senses. 
Each single cell of the approximately 10
14 that make up a human organism has to 
communicate with its environment. Comparable to a computer a cell has to process input 
information and to convert it into an appropriate output. In the cellular context a broad variety 
of receptors sense external stimuli (input) such as hormones or contacts with other cells. We 
refer to the processing and transmission of information as signal transduction. Many 
individual pathways transmit signals along linear tracks from receptors to the nucleus and 
other other cell compartments and subsequently resulting in a discrete cell response. Since 
these pathways interact and interfere with each other, signal transduction resembles rather a 
network than a single chain of command (Downward, 2001; Pawson, 1995). Through 
amplification, desensitization, signal branching and integration a network-like structure 
allows the fine tuning of responses which is fundamental for embryonic development as well 
as in adult life (Bray, 1995; Gschwind et al., 2001; Hunter, 1995).  
About one fifth of the estimated 32.000 human genes encode proteins involved in signal 
transduction including receptors, adaptors and effector enzymes. In this fundamentally 
important process particular importance is attributed to reversible protein phosphorylation 
which is a central theme in virtually all aspects of cellular function (Cohen, 2002). The 
addition of a highly charged phosphoryl group to an amino acid can modify protein function 
in every conceivable way, for instance by altering enzymatic activity and most important by 
facilitating or disrupting protein-protein interactions. The simplicity, flexibility and 
reversibility of phosphorylation coupled to the availability of ATP as phosphoryl donor 
explains why evolution has favoured this mechanism as general concept in regulation of 
cellular function. 
Protein phosphorylation moved into spotlight of scientific interest as early as 50 years ago 
when phosphorylation was discovered to regulate glycogen phosphorylase (Fischer and 
Krebs, 1966). With the rise of molecular biology and techniques such as DNA cloning and 
sequencing, the number of identified kinases, which are enzymes able to transfer phosphoryl 
groups from ATP to target proteins, increased rapidly and led to the speculation that the 
vertebrate genome might encode as many as 1000 kinases (Hunter, 1995; Pawson, 1994). 1 Introduction  2 
Nowadays, completion of the human genome project revealed about 520 kinases (Manning et 
al., 2002b). Although the total sum does not reach earlier predictions, it is still a striking large 
number which further emphasizes the importance of protein phosphorylation. Taking also the 
130 phosphatases into account that were identified so far, more than two percent of all human 
genes are directly involved in phosphorylation and dephosphorylation. 
 
1.1 MAPKs 
 
Almost all eukaryotic protein phosphorylation is conducted by a single superfamily of 
eukaryotic protein kinases (ePKs) sharing a conserved catalytic domain. ePKs are among the 
largest of protein families, comprising more than 1.5 % of all eukaryotic genes (Manning et 
al., 2002a). According to a recent extension of Hanks’ and Hunter’s taxonomy the human 
kinome can be divided into nine broad groups, 134 families and 196 subfamilies (Hanks and 
Hunter, 1995; Manning et al., 2002b). The STE group of kinases is one of these nine main 
groups and consists of the mitogen activated protein kinase (MAPK) families. The name STE 
refers to the first MAPK identified as a signal transduction enzyme in yeast. 
 
 
 
Figure 1: MAPK cascades. Overview of MAPK cascades according to Garrington and Johnson 
(Garrington and Johnson, 1999).  1 Introduction  3 
1.1.1  The MAPK Family 
 
Mitogen-activated protein kinases are evolutionarily conserved enzymes found in virtually all 
eukaryotes (Manning et al., 2002a). A broad variety of stimuli elicit activation of MAPKs 
which regulate a large number of cellular processes in part by activating the transcriptional 
machinery (Kyriakis and Avruch, 2001; Pearson et al., 2001b). The activation of MAPKs is 
regulated through a three-tethered cascade composed of the MAPK itself, an activating 
MAPK kinase (MAPKK) and an upstream MAPK kinase kinase (MAPKKK) (Chang and 
Karin, 2001). 
Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-
regulated kinases (ERK) 1 and 2, c-Jun amino-terminal kinases (JNK1-3), p38 proteins (α,β,γ 
and δ) and ERK5 (Garrington and Johnson, 1999) (Fig. 1). All of these are activated by 
specific MAPKKs of which each, however, can be activated by more than just one 
MAPKKK, increasing the diversity and complexity of MAPK signalling. Presumably each 
MAPKKK confers responsiveness to a distinct class of stimuli. For instance, activation of 
ERK2 by growth factors depends on the MAPKKK c-Raf, but others may activate ERK2 in 
response to pro-inflammatory stimuli (Chang and Karin, 2001). The situation is even more 
complex with JNK and p38 cascades which respond to many stimuli and can be activated by 
over-expression of at least a dozen of MAPKKKs whose physiological functions and 
specificities still remain elusive. At least four MAPKKKs, for example, were implicated in 
JNK activation by tumour necrosis factor and interleukin 1. 
One of the most explored functions of MAPK signalling is the regulation of gene expression 
by direct or indirect phosphorylation and subsequent activation of transcription factors. In 
response to mitogens the concerted action of MAPKs has been shown to induce the 
immediate early genes fos and jun (Hazzalin and Mahadevan, 2002; Whitmarsh and Davis, 
2000). 
 
1.1.2  Signal Transduction by MAPK 
 
The mechanism activated by mitogenic epidermal growth factor (EGF) illustrates some 
principles of signal transmission from the cell surface to the nucleus and the central role of 
MAPKs within this process (Fig. 2). By binding to its receptor EGF induces receptor 
dimerisation and autophosphorylation on tyrosines (Schlessinger, 2000a; Schlessinger, 2002). 
The phosphorylated and thus activated receptor binds adaptor proteins such as Grb2 and Shc. 1 Introduction  4 
The small adaptor proteins subsequently recruit the nucleotide exchange factor Sos to the 
membrane and thereby into proximity of Ras, a small monomeric, membrane-anchored 
GDP/GTP binding protein. It is well established that after Sos induced Ras activation which is 
accomplished by the induced exchange of GDP to GTP Ras attracts the kinase c-Raf to the 
membrane and subsequently contributes to its activation (Vojtek et al., 1993). C-Raf is a 
MAPKKK and thus represents the starting point of the MAPK cascade. 
 
 
Figure 2: MAPK activation by extracellular stimuli. Epidermal growth factor (EGF) binds to its 
receptor (EGFR). Recruitment of adaptor proteins and Sos leads to the activation of Ras, which in 
turn activates the MAPK cascade. 
Activated c-Raf, in turn, activates a second kinase MEK1 by phosphorylating it at two serine 
residues (Huang et al., 1993; Zheng and Guan, 1994). This modification activates MEK1 to 
phosphorylate both ERK1 and ERK2 on regulatory threonine and tyrosine residues in their 
activation loop (Derijard et al., 1995). The Raf-MEK1-ERK1/2 pathway is also called the 
‘classical’ or ‘mitogenic’ MAPK cascade. Once activated ERK1 and ERK2 homodimerise, 
translocate to the nucleus and phosphorylate additional kinases, transcription factors and cell 
cycle regulators (Cobb et al., 1994; Khokhlatchev et al., 1998). An important downstream 
target of ERK is the Elk-1 transcription factor which participates in the transcriptional control 
of the fos proto-oncogene. Together with Jun proteins c-Fos forms the activating protein 1 
(AP-1) dimer, an important transcription factor that induces several genes required for cell 
cycle progression (Shaulian and Karin, 2001). 
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1.1.3 ERK5 
 
ERK5 is the only member of the fourth and least known MAPK subgroup. ERK5 differs 
considerably from other MAPKs in that it contains an unusually long carboxy-terminal tail of 
hitherto unknown function (Fig. 3) (Lee et al., 1995; Zhou et al., 1995). This 400 amino acid 
long extension also gave rise to its alternative designation as big MAP kinase 1 (BMK1). 
ERK5 is activated by diverse stimuli such as cellular stress and growth factors (Abe et al., 
1996; Kato et al., 2000). The MAPKK MEK5 has been shown to specifically phosphorylate 
and thereby activate ERK5 (Kato et al., 1997; Lee et al., 1995). However, the other 
components involved in the signalling cascade that ultimately leads to the activation of ERK5 
are only partly known.  
 
 
Figure 3 : ERK5 contains a unique C-terminal tail. The structures of ERK5 and its closest 
homologue ERK2 are presented schematically. The ATP binding sites and the TEY activation 
motives are indicated. The tail of ERK5 contains two proline-rich domains (PR I and II). 
Many of the ERK5 activating stimuli also affect other MAPK family members. Synergistic 
actions of both the ERK1/2 and the ERK5 pathways have for example been reported in the 
induction of cell transformation (Pearson et al., 2001a). On the other hand, downstream 
effects exerted by activated ERK5 and ERK1/2 can in many cases be clearly distinguished 
from each other (Cavanaugh et al., 2001; Watson et al., 2001). Kato and colleagues (Kato et 
al., 1998) have, for example, demonstrated that ERK5 but not ERK2 is essential for 
proliferation and cell cycle progression in HeLa cells. More recently, Karihaloo et al 
(Karihaloo et al., 2000) have shown that ERK5 mediates EGF-induced morphogenesis in 
renal epithelial cells whereas ERK2 activity is critically involved in cell motility upon 
stimulation with hepatocyte growth factor. 
ERK5 still remains one of the least characterised MAPKs and research has just started to shed 
some light on its functions. The embryonically lethal phenotype of ERK5 knock-out mice that 
die between day 10.5 and 12.5 with cardiovascular defects points to an essential role for 1 Introduction  6 
ERK5 signalling in development and especially in angiogenesis (Regan et al., 2002; Sohn et 
al., 2002).  
 
1.1.4  The Paradox of MAPK Signalling 
 
MAPK cascades pose a particular problem in signal transduction because they often serve as 
common conduit for myriads of diverse stimuli but still lead to highly defined and distinct 
cellular responses. Research of the last years has shed some light to the solution to this 
apparently paradoxical situation. Several distinct but not mutually exclusive mechanisms 
guarantee specificity of MAPK signalling on different levels. These include the process of 
activation and the interpretation of a certain activation profile. In yeast, the STE5 protein 
serves as a scaffold that organises the three required components of a pheromone-responsive 
MAPK cascade and its upstream activator into a module. Two analogous mammalian scaffold 
proteins were identified in the regulation of JNK (Whitmarsh et al., 1998).  
Critical parameters in the determination of signal identity and ultimate cell fate are duration 
and amplitude of MAPK activation (Marshall, 1995). Almost a decade ago it was 
demonstrated that depending on the activation profile of MAPK rat phaeochromocytoma cells 
commit themselves either to differentiation or proliferation (Cowley et al., 1994; Traverse et 
al., 1992; Traverse et al., 1994). Just recently the immediate early gene product c-Fos was 
identified as a molecular sensor for the duration of MAPK activation. Only sustained MAPK 
activity leads to c-Fos activation because this requires MAPK-dependent transcriptional 
activation of the fos gene and subsequent stabilisation of the c-Fos protein by MAPK-
mediated phosphorylation. Transient MAPK activity induces fos transcription to some extent 
but declines before appearance of the c-Fos protein which consequently remains 
unphosphorylated and instable (Murphy et al., 2002). 
Since the profile of MAPK activation is critical for the definition of a specific cellular 
response a large group of phosphatases tightly regulates MAPK activity and in the same time 
allows fine tuning of the signal.  
 
1.2  Phosphatases in the Regulation of MAPKs 
 
Phosphatases are the main antagonists of kinase function. They can be roughly divided into 
three main groups according to their specificity: phosphotyrosine-specific, 
phosphothreonine/serine-specific or dual specific phosphatases. Among the superfamily of 1 Introduction  7 
eukaryontic protein kinases MAPKs are unique in that their activation loop must be 
phosphorylated on tyrosine and threonine to force the kinase into its active conformation 
(Canagarajah et al., 1997). Conversely, MAPKs are completely inactivated by 
dephosphorylation of either phosphoamino acid residue. Thus, all three types of phosphatases 
potentially neutralise MAPK activity (Keyse, 2000; Saxena and Mustelin, 2000). 
 
1.2.1  Dual Specificity and Serine/Threonine-specific Phosphatases 
 
The first type of phosphatases found to have specificity for MAPKs were the dual specificity 
phosphatases, a group whose founding member was the VH 1 protein encoded by Vaccinia 
virus (51). These so-called MAP kinase phosphatases (MKPs) differ from each other in their 
expression pattern and expression kinetics following stimulation. Most MKP genes are silent 
in resting cells, but highly inducible in response to growth factors and stress stimuli that both 
also activate MAPK family members (Fig. 4). Pac-1, for instance, is a lymphocytic MKP and 
becomes detectable 30 minutes after stimulation and MAPK activation. Pac-1 like most 
MKPs resides in the nucleus and is thus ideally suited for dephosphorylating activated MAPK 
and thereby resetting the MAPK pathway. 
Activated MAPKs are also substrates for the purely serine/threonine-specific phosphatases 
PP2A and PP2C that merely remove phosphate from the phosphothreonine in the MAPK 
activation loop (Alessi et al., 1995; Millward et al., 1999; Takekawa et al., 1998). PP2A has 
been highly conserved in evolution as indicated by the comparison of homologues from yeast 
and man. PP2A has been implicated in a wide variety of cellular functions and in the 
regulation of more than 30 kinases (Millward et al., 1999). In contrast to MKPs PP2 
phosphatases are localised in the cytosol. The first implication for PP2A in the regulation of 
MAPKs came from genetic studies on photoreceptor development in Drosophila 
melanogaster (Wassarman et al., 1996). PP2A does not only counteract MAPK but also 
MAPKKs activation. Noteworthy, the viral SV40 small t oncogene induces MAPK activation 
by presumably interfering with the action of PP2A (Sontag et al., 1993). However, the 
importance of PP2A in controlling MAP kinases seems to vary greatly between cell types and 
depends on the functional context. Moreover, PP2A which affects a large pool of diverse 
substrates is considered to act in concert with phospho-tyrosine specific phosphatases (PTPs). 
These PTPs contain a kinase-interacting motif (KIM) that confers a high intrinsic specificity 
for MAPKs (Pulido et al., 1998).  
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1.2.2  KIM-containing Tyrosine-specific Phosphatases 
 
STEP, PTP-SL and HePTP form the family of PTPs containing a KIM. This short stretch of 
amino acids enables them to bind MAPKs. Interestingly, at least STEP and PTP-SL exist in 
many different forms ranging from short cytoplasmic to long variants that span the membrane 
up to three times (Hendriks et al., 1995; Lombroso et al., 1991; Ogata et al., 1995; Shiozuka et 
al., 1995). This diversity is caused by alternative splicing as well as variable start codon usage 
(Boulanger et al., 1995; Bult et al., 1997; Sharma and Lombroso, 1995). KIM containing 
PTPs (KIM PTPs) are generally characterised by their exclusively non-nuclear localization 
and a very restricted expression. HePTP, for instance, is expressed in bone marrow, spleen, 
lymph nodes and myeloid as well as lymphoid lineages, while PTP-SL is found in brain, lung 
and heart and STEP only in brain. The first indication for a role of KIM PTPs in cell 
proliferation and differentiation came from studies in haematopoietic cells that were obtained 
from patients with myelodysplastic syndrome. The HePTP gene was found to be located on 
the long arm of chromosome 1 which is often found in extra copies in this disease and 
correlates with reduced haematopoiesis and an increased risk of acute leukaemia (Boulanger 
et al., 1995; Bult et al., 1997; Zanke et al., 1994). Indeed, amplification of the HePTP gene 
was reported in a case of acute myeloid leukaemia. Conversely, deletions of the region 
comprising the HePTP gene have been reported in non-Hodgkin lymphomas and chronic 
lymphoproliferative disorders (Mitelman et al., 1990). Together these findings suggest that 
excess of KIM PTPs may correlate with reduced proliferation (e.g. HePTP in myodysplasia) 
and loss of KIM PTPs with increased cell proliferation and/or survival. The anticipated 
influence of these phosphatases would then directly reflect their effect on mitogenic MAPK 
signalling. 
The KIM that targets the PTP to MAPK contains a serine which is subject to phosphorylation 
by protein kinase A (PKA). This modification was shown to interrupt MAPK binding 
(Blanco-Aparicio et al., 1999; Saxena et al., 1999b). Thus, pathways activating PKA can 
interfere with the activity of MAPKs by inhibiting KIM PTP-mediated negative regulation. 
Tanoue  et al. identified docking motifs in MAPKs that were highly conserved and that 
mediate interaction with substrates and activating MAPKKs (Tanoue et al., 2000; Tanoue et 
al., 2001). This domain was also shown to mediate the interaction of ERK2 with PTP-SL 
(Tarrega et al., 2002). Attention was drawn to this motif by the observation that the so-called 
sevenmaker gain-of-function mutation of ERK resulted in an increased and prolonged 1 Introduction  9 
activation which was later shown to be at least in part due to the abolishment of KIM PTP 
binding (Brunner et al., 1994; Oh-hora et al., 1999). 
Taken together, KIM PTPs are specific inactivators of MAPKs and therefore able to 
participate in the regulation of diverse cellular functions. 
 
1.2.3 ‘Sequential  Phosphatase Model’ 
 
In order to integrate three different types of phosphatases acting on MAPKs in a single 
unifying hypothesis, Saxena and Mustelin proposed the following model (Saxena and 
Mustelin, 2000). All these enzymes act in a sequential manner and downstream of different 
external stimuli (Fig. 4). In the resting state MAPKs reside in the submembraneous cytosol, 
partly tethered to scaffolding proteins (Garrington and Johnson, 1999). Even under these 
conditions there would be some basal activity in the kinase cascade that would drive MAPK 
phosphorylation. The control of this background activity is attributed to the action of PP2A 
and PP2C in concert with KIM PTPs. 
 
Figure 4: Phosphatases in the regulation of MAPKs. Activated MAPK is phosphorylated on 
tyrosine and threonine. The serine/threonine-specific phosphatase PP2 and KIM containing 
phosphotyrosine-specific phosphatases dephosphorylate and inactivate MAPK in the cytosol. 
Active MAPK having translocated to the nucleus induces immediate early genes including those 
coding for dual specificity phosphatases MKPs. Once translated MKP completely 
dephosphorylates MAPK and abrogates signalling.  
 
Even upon stimulation the combination of serine/threonine and tyrosine-specific phosphatases 
might be able to control the activity of MAPKs during an initial phase in the cytosol. But 1 Introduction  10 
since PP2A/C as well as KIM PTPs are exclusively cytosolic those MAPKs that eventually 
manage to translocate to the nucleus, are free to phosphorylate their targets until MKPs are 
induced, synthesised and subsequently terminate signalling by dephosphorylating MAPKs. 
The existence of several MKPs with different modes of transcriptional activation, varying 
induction kinetics and distinct target preferences would further allow the cell to fine tune the 
activation profile of each MAPK and the balance between different MAPK family members. 
This ‘sequential phosphatase model’ provides an explanation for the multitude of 
phosphatases involved in the regulation of comparatively few MAPKs. By acting in different 
compartments of the cell they represent an exquisite regulatory machinery that can control 
amplitude and duration as well as the localization of MAPK function. All these parameters 
together are critical for the determination of an adequate cellular response to a distinct 
stimulus. 
 
1.3  Signalling by Tyrosine Kinases 
 
For a long time tyrosine phosphorylation was considered to be functionally separate from 
serine/threonine phosphorylation. The addition of phosphate to a tyrosine residue was 
assumed to be mainly involved in the modulation of protein-protein interaction while the 
induction of conformational changes and the regulation of enzymatic activity were mainly 
attributed to serine/threonine phosphorylation. Although we today know that both kinds of 
phosphorylation are able to influence proteins in every and not mutually exclusive way, it is 
well established that protein tyrosine kinases play an important role in most fundamental 
cellular processes in part by their ability to regulate protein complex formation. 
 
1.3.1  Receptor and Cytoplasmic Protein Tyrosine Kinases 
 
In total the human genome contains 90 tyrosine kinase genes, of which 58 encode receptor 
tyrosine kinases (RTKs) distributed into 20 subfamilies (Blume-Jensen and Hunter, 2001; 
Manning et al., 2002b). RTKs contain a single transmembrane domain, a conserved 
cytoplasmic kinase domain and structural diverse ectodomains that determine their ligand 
specificity. The EGF receptor was the first surface signalling protein to be characterised by 
molecular biological methods and shown to be implicated in tumourigenesis (Ullrich et al., 
1984). The EGF signalling pathway is highly conserved and was shown to be critically 1 Introduction  11 
involved in the developmental pattern formation of the nematode Caenerohabditis elegans as 
well as the fruitfly Drosophila melanogaster (Schweitzer and Shilo, 1997). 
The human kinome further contains 32 cytoplasmic, non-receptor tyrosine kinases (NRTKs) 
grouped into 10 subfamilies: Src, Abl, Jak, Ack, Csk, Fak, Fes, Frk, Tec and Syk (Blume-
Jensen and Hunter, 2001). In addition to a tyrosine kinase domain NRTKs possess multiple 
domains that mediate the interaction with proteins, lipids or DNA (Fig. 5). 
The largest subgroup among NRTKs, with nine members, is the Src family of kinases. 
Depending on the context, members of this family were shown to regulate or at least to 
contribute to virtually all aspects of cellular function (Tatosyan and Mizenina, 2000; Thomas 
and Brugge, 1997). In fact, many NRTKs were first identified as cellular homologues of viral 
oncogene products with c-Src having been the very first to be described (Martin, 2001). The 
regulation of Src activity illustrates some principles of NRTK signalling (Bjorge et al., 2000; 
Schlessinger, 2000b). Src possesses two important regulatory tyrosine
 phosphorylation sites: 
The NRTK Csk phosphorylates a carboxy-terminal
  tyrosine of Src. This phosphotyrosine 
binds intramolecular to the SH2 domain and thus locks the kinase in its inactive conformation. 
The importance of this mechanism is underscored
 by the fact that viral, constitutively active 
v-Src lacks this regulatory site. Contrarily, autophosphorylation of another tyrosine in the 
activation loop leads to maximal activation. Deregulated Src signalling has been implicated in 
breast, lung and colon cancer (Biscardi et al., 1999; Frame, 2002; Irby and Yeatman, 2000). 
 
 
Figure 5: Human cytoplasmic protein tyrosine kinases. Adopted from Blume-Jensen and 
Hunter (Blume-Jensen and Hunter, 2001). The family members are indicated to the right and the 
family name to the left of each kinase. Kinases in bold and italic are implicated in human 
malignancies. 1 Introduction  12 
1.3.2 c-Abl 
 
C-Abl and Arg are the members of a second family of NRTKs: c-Abl, which was in analogy 
to Src identified as the cellular homologue of a viral oncogene, has been implicated in many 
cellular processes (Shaul, 2000; Van Etten, 1999; Wang, 2000). Since the c-Abl protein 
contains many functional domains besides its tyrosine kinase including SH2 and SH3 
domains, nuclear localisation and export sequences as well as binding sites for Actin, DNA 
and SH3 modules, c-Abl is likely able to simultaneously participate in or even to link 
numerous pathways by direct protein-protein interaction. Cytosolic and nuclear c-Abl kinases 
play distinct roles. For instance, one important function of nuclear c-Abl lies in the pathway 
linking DNA damage to the cell cycle machinery. It was shown that the induction of cell cycle 
arrest and apoptosis after UV-induced DNA damage involves the c-Abl-dependent 
stabilisation, acetylation and phosphorylation of p73, a member of the p53 tumour suppressor 
family (Agami et al., 1999; Costanzo et al., 2002; Gong et al., 1999). On the other hand, the 
cytoplasmic fraction of c-Abl and Arg were implicated in remodelling and stabilisation of the 
Actin cytoskeleton (Van Etten et al., 1994; Wang et al., 2001). In this context genetic studies 
in Drosphila suggested a role for the Abl orthologue Dabl as regulator of morphogenesis in 
the developing nervous system (Van Etten, 1999). Taken together recent findings have 
established a pivotal role for c-Abl in various and diverse cellular functions. However, most 
Abl research focuses on its oncogenic derivatives. The signalling of viral v-Abl and of the 
leukaemic fusion proteins Bcr/Abl and Tel/Abl will be discussed below in the context of 
chronic myeloid leukaemia. 
 
1.4  Molecular Characteristics of Cancer 
 
Cancer is the most common cause of death in the Western world affecting one third of its 
entire population. The development of tumours is a multistep process that involves genetic 
alterations which lead to the ‘loss of function’ of tumour suppressor genes and the ‘gain of 
function’ of oncogenes. These genetic changes which can be as subtle as point mutations or as 
striking as chromosomal rearrangements, consequently drive the progression of normal cells 
to malignant derivatives (Hanahan and Weinberg, 2000). 
Studies on familial predisposition to cancer led to the first models attempting to describe the 
underlying mechanisms of tumourigenesis. According to the simple ‘two hit’ model, 
dominantly inherited predisposition to cancer entails a germ line mutation, while development 1 Introduction  13 
of cancer requires a second, somatic mutation (Knudson, 1996). A non-hereditary cancer of 
the same type requires the same two, though somatic hits. Although applicable in many cases 
to simplify and explain familial predisposition to genetic diseases, this models holds only 
fully true for the pathogenetically simple retinoblastoma tumour. The development of both 
hereditary as well as sporadic forms of retinoblastoma is exclusively caused by the 
inactivation of both alleles of the retinoblastoma (Rb) 1 gene (Knudson, 1971). 
Observations of human cancers and animal models argue that tumour development proceeds 
via a process formally analogous to Darwinian evolution, in which a succession of genetic 
changes, each conferring one or another type of growth advantage, leads to the progressive 
conversion of normal human cells into cancer cells (Cahill et al., 1999). 
 
 
Figure 6: Six hallmarks of cancer. According to Weinberg and Hanahan most, if not all cancers 
have acquired the same set of functional capabilities during their development, albeit through 
various mechanistic strategies (Hanahan and Weinberg, 2000). 
This multistep process is well illustrated by colorectal cancers, which typically develop over 
decades and appear to require at least seven genetic events for completion. Even so, 
inheritance of a single altered gene can result in a marked predisposition to colorectal cancer 
in two distinct syndromes, Familial Adenomatous Polyposis (FAP) and Hereditary 
Nonpolyposis Colorectal Cancer (HNPCC) (Kinzler and Vogelstein, 1996). Recent evidence 
suggests that the genetic defect in FAP affects the rate of tumour initiation by targeting the 
proliferation control function of the APC gene. In contrast, the defect in HNPCC largely 
affects tumour progression by targeting the genome guardian function of DNA mismatch 
repair. According to their function we refer to these two types of affected genes as 
‘gatekeepers’ and ‘caretakers’, respectively (Kinzler and Vogelstein, 1997). The inactivation 
of repair mechanisms as in HNPCC plays an important role in many different tumours (Fodde 1 Introduction  14 
et al., 2001; Harfe and Jinks-Robertson, 2000). This consequentially leads to an increase in 
the incidence of mutations and genetic instability and thus accelerates the progression from 
benign stages to carcinoma and metastasis. 
The final cancer cell genotype and its resulting phenotype display six essential alterations in 
cell physiology that collectively dictate malignant growth. The six so-called hallmarks of 
cancer are self-sufficiency in growth signals, insensitivity to growth-inhibitory (cell cycle 
arrest) signals, evasion of programmed cell death, endless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Fig. 6). These six capabilities are 
presumably shared by most and perhaps all types of human tumours (Hanahan and Weinberg, 
2000). 
Cancer is not a single disease and tumours are indeed extremely diverse and heterogeneous, 
but underlying this variability is a certain number of ‘mission critical’ events including, for 
instance, the inactivation of the p53 gatekeeper gene product (Evan and Vousden, 2001). The 
challenge faced by the research community is to identify and understand the molecular 
anatomy of such pivotal steps in tumour progression and to develop therapies that directly 
target these points of convergence. The future combinational use of broadly applicable as well 
as cancer type-specific therapeutics might represent the most promising approach to 
suppression and cure of cancer. 
 
1.5  Chronic Myeloid Leukaemia 
 
1.5.1  Molecular Pathophysiology of Chronic Myeloid Leukaemia 
 
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative expansion of transformed 
haematopoietic progenitor cells. It involves myeloid, monocytic, erythroid, megakaryocytic 
and rarely B-lymphoid and T-lymphoid lineages (Faderl et al., 1999). CML progresses 
through distinct stages. The earliest stage is characterised by the expansion of terminally 
differentiated neutrophils. Over several years disease progresses to an acute phase termed 
blast crisis, characterised by maturation arrest with excessive numbers of undifferentiated 
progenitor cells. Although heterogeneous, CML is the best-described leukaemia at the 
molecular level and was the first human disease in which a specific genetic abnormality could 
directly be linked to the pathogenic events of leukaemogenesis. 
In 1960, Nowell and Hungerford identified an abnormal chromosome in 90% of chronic 
myeloid leukaemia patients (Nowell and Hungerford, 1960). This genomic abnormality was 1 Introduction  15 
later shown to be caused by the reciprocal chromosomal translocation of chromosomes 22 and 
9 (Rowley, 1973). The resulting shortened chromosome 22, commonly termed Philadelphia 
chromosome encodes a Bcr/Abl fusion product (Ben-Neriah et al., 1986). The reciprocal 
abl/bcr gene on chromosome 9, although transcriptionally active, does not appear to have any 
functional role and no translated product has been identified so far (Diamond et al., 1995; 
Melo et al., 1993). 
Depending on the breakpoint in the bcr gene three main types of resulting Bcr/Abl fusion 
proteins can be distinguished with the most common being the p210 Bcr/Abl protein (Melo, 
1996). Numerous experimental models have established that Bcr/Abl is
 sufficient to produce 
CML-like disease in mice (Daley et al., 1990; Elefanty et al., 1990; Heisterkamp et al., 1990). 
The oncogenic capacity of Bcr/Abl is based on two features, first its exclusively cytosolic 
localisation (Ben-Neriah et al., 1986) and secondly its constitutive kinase activity (Van Etten 
et al., 1989). Several functional domains have been identified and shown to be required for 
the full transforming potential of the oncogene. In the Abl portion these domains are the SH1 
tyrosine kinase, the SH2 and the Actin-binding domains. In the Bcr portion they include the 
coiled coil motif, the Grb2 binding site at tyrosine 177 and the phospho-serine/threonine-rich 
SH2 binding site (Fig. 7). 
 
 
Figure 7: Cellular c-Abl and its oncogenic variants. Scheme adopted from Zou and Calame 
(Zou and Calame, 1999): SH2 and SH3, Src homology domains 2 and 3; SH1, tyrosine kinase 
domain; NLS, nuclear localisation sequence; DB, DNA binding domain; AB, Actin-binding 
domain. Binding sites of some interacting proteins are indicated by bars.  
Oligomerisation mediated by the coiled-coil motif, membrane localisation and 
autophosphorylation of the Bcr/Abl kinase mimics an activated receptor tyrosine kinase. 
Bcr/Abl activates numerous signalling pathways by recruiting adaptor proteins such as Crkl 
and Grb2 as well as by directly phosphorylating target proteins. Thereby, Bcr/Abl interferes 
with basic cellular processes such as control of cell proliferation and differentiation (Jiang et 1 Introduction  16 
al., 2000; Puil et al., 1994), adhesion and cell survival (Cortez et al., 1995; McGahon et al., 
1994). Among these activated signalling pathways are Ras/MAPK, PI-3 kinase, c-Cbl, Jak-
Stat, and the Src pathway. Modulation of Crkl, Paxillin, Actin, Talin and Vinculin as well as 
Fak/Pyk2 is further considered to be responsible for adhesion defects and cytoskeletal 
abnormalities characteristically found in CML cells. 
Malignant transformation by Bcr/Abl is characterised by altered adhesion to stromal cells and 
extracellular matrix, activation of mitogenic signalling and reduced apoptosis (Gishizky, 
1996; Sattler and Griffin, 2001; Sawyers, 1997; Verfaillie, 1998). In haematopoietic cells 
Bcr/Abl was shown to induce mitogenesis (Deininger et al., 2000) and to protect cells from 
apoptosis (Cortez et al., 1995; McGahon et al., 1994; Nishii et al., 1996). 
Although a massive amount of information on Bcr/Abl signalling has been accumulated so 
far, the single pathway through which Bcr/Abl causes leukaemia, if it actually exists, has not 
yet been identified. Koh and Daley (Koh and Daley, 2001) argued that Bcr/Abl does not 
activate a single critical signalling pathway but rather a multifaceted communication network. 
Therefore, they have called Bcr/Abl the ‘ultimate oncogene’. If the mechanism by which 
Bcr/Abl causes leukaemia is indeed based on the attack of the cell’s normal anti-cancer 
defences from various angels, it is conceivable that other oncogenes will operate using similar 
strategies. 
The importance of the bcr/abl gene for CML progression was recently further exemplified by 
a study with transgenic mice and inducible expression of the oncogene. It was shown that 
besides initiating the disease bcr/abl was required for driving leukaemia progression 
throughout all stages, despite the appearance of numerous additional mutations in oncogenes 
as well as tumour suppressor genes (Huettner et al., 2000). Likewise, in comparable model 
systems Ras and Myc were also shown not only to be sufficient for tumour initiation but also 
essential for maintenance of the transformed phenotype (Chin et al., 1999; Felsher and 
Bishop, 1999). 
 
1.5.2  Therapy of Chronic Myeloid Leukaemia 
 
Therapy of CML is based on the use of standard chemotherapeutics as well as agents 
specifically targeting the Bcr/Abl kinase. Since the clinical course of CML is characterised by 
overproduction of differentiated myeloid lineages, it can be controlled for months to years by 
treatment with anti-proliferative agents. Hydroxyurea, for instance, is generally effective in 
normalizing peripheral blood counts. Unfortunately, cytogenetic responses are rare which 1 Introduction  17 
means that a significant percentage of bone marrow cells retain the Philadelphia chromosome. 
Hence, progression to blast crisis is not delayed. Allogenic transplantation of haematopoietic 
stem cells (HSCT) remains the only curative treatment of CML so far. But since substantial 
acute and chronic toxicities occur frequently, particular in older individuals, and the 
availability of HLA-matched donors is very rare, for most patients HSCT is not an option. 
Therefore, Interferon-α (IFN-α) has become the treatment of choice. IFN-α induces complete 
cytogenetic responses in 10-20% of treated patients and increases duration of chronic phase 
and long-term survival. A major disadvantage is the poor tolerance of IFN-α which may 
require discontinuation of treatment. 
Several more recent lines of investigation focus on the development of therapies based on the 
direct inhibition of Bcr/Abl including several anti-sense and RNA interference approaches. A 
milestone in CML research was the development of Imatinib, a small molecule inhibitor of 
the Bcr/Abl kinase (Buchdunger et al., 1996, Druker, 2002; Druker et al., 1996). Imatinib is a 
2-phenylamino pyrimidine and functions by binding to the highly conserved nucleotide-
binding pocket of the catalytic domain of the Abl tyrosine kinase and constitutively blocking 
the binding of ATP (Schindler et al., 2000). Preclinical studies have established that Imatinib 
specifically inhibits proliferation and restores cytokine-dependence of Bcr/Abl positive 
leukaemia cells but only minimally affects growth of normal cells (Carroll et al., 1997; 
Deininger et al., 1997; Druker et al., 1996; Gambacorti-Passerini et al., 1997). The efficacy of 
Imatinib is based on the inhibition of proliferation and to a lesser extent on the induction of 
apoptosis (Holtz et al., 2002). A series of phase I and phase II trials demonstrated the 
remarkable activity of Imatinib in CML therapy (Druker et al., 2001a; Druker et al., 2001b; 
Ottmann et al., 2002; Sawyers et al., 2002; Talpaz et al., 2002). Imatinib was shown to induce 
remissions in early chronic phase as well as in blast crisis. Whereas responses in chronic 
phase have been enduring, remissions in blast crisis patients were transient over a period of 2 
to 6 months. But since the majority of patients respond to Imatinib without showing any 
major side effects the Food and Drug Administration have recently approved it for CML 
treatment. Although patients in blast crisis benefit clinically from Imatinib application, 
treatment is hampered by the onset of resistance to the drug in virtually all cases. 
 
1.5.3  Mechanisms of Imatinib Resistance  
 
Resistance to Imatinib includes de novo resistance and relapse after initial response. Based on 
the mechanisms underlying drug resistance, patients can be divided into two subgroups: those 1 Introduction  18 
with persistent inhibition of the Bcr/Abl kinase and those with reactivation of the kinase. 
Patients with persistent Bcr/Abl inhibition would be predicted to have additional genetic 
abnormalities driving the growth and survival of leukaemic cells. In contrast, patients with 
unaffected Bcr/Abl kinase activity or those with reactivation of oncogenic Bcr/Abl signalling 
would be postulated to have developed mechanisms that prevent Imatinib from reaching its 
target or that render the target insensitive to the inhibitor. It can be further distinguished 
between systemic and cellular mechanisms of resistance. Enhanced drug metabolism or as 
recently shown sequestration of Imatinib by α1 acid glycoprotein (Gambacorti-Passerini et 
al., 2000; Gambacorti-Passerini et al., 2002) are two examples of systemic resistance. The 
most general mechanism for the development of cellular resistance is the increase of drug 
export rates which is often observed with various agents in cancer therapy. The latter is 
caused by an increased expression of membrane transport proteins such as the P-glycoprotein 
and the Multidrug Resistance Protein MRPI that act as real efflux pumps (Perek and Denoyer, 
2002). 
The majority of patients suffering from relapse after initial response to Imatinib, shows a 
reactivation of the Bcr/Abl kinase (Gorre et al., 2001). Two mechanisms have been shown to 
be responsible for cellular resistance, Bcr/Abl gene amplification and more important point 
mutations (Branford et al., 2002; Gorre et al., 2001; Hochhaus et al., 2002; le Coutre et al., 
2000). The mutations found in the kinase domain or P loop of Bcr/Abl either interfere directly 
with Imatinib binding or destabilise the conformation required for Imatinib intercalation 
(Schindler et al., 2000; Shah et al., 2002). The IC50 of Imatinib for mutant Bcr/Abl is up to 
10-fold higher than for the wild-type oncogene (Shah et al., 2002).  
It is conceivable that different cellular and systemic types of resistance, rather than being 
mutually exclusive, complement each other to effect their final objective: the generation of 
cells that can survive despite Imatinib treatment. Attempts to overcome this problem in 
chemotherapy will have to consider all aspects of resistance. Therefore, the development of a 
multifaceted therapeutic approach to CML is of great interest and subject of intense research. 
 
1.6  Aim of the study 
 
The traditional view of MAPK function distinguished between three structurally distinct 
subfamilies, the ERKs, the JNKs and p38 kinases. With the cloning of ERK5/big MAP kinase 
1, however, a yet untold chapter of MAPK signalling had been opened. Based on unique 
structural properties ERK5 could not be attributed to any of the three subfamilies. Since only 1 Introduction  19 
very limited information on ERK5 was available at the beginning of this study, the analysis of 
ERK5 expression, localisation and activation by diverse stimuli in various cell lines had to be 
approached. 
MAPKs pose a particular problem in signal specificity in that they serve as common conduit 
for multiple upstream events and still regulate distinct cellular functions. The explanation to 
this apparently paradoxical situation alludes to a tight, multifaceted and finely tuned 
regulation of MAPKs. ERK5 is one of the least characterised members of the MAPK family 
and its only so far known regulator was its activating kinase MEK5 (Zhou et al., 1995). The 
central part of this study concentrates on the question how ERK5 signalling might be 
regulated.  
First, in analogy to other MAPKs the activity of ERK5 was expected to be controlled by the 
phosphorylation state of its activation motif. In this context, the potential influence of the 
phosphotyrosine-specific phosphatase PTP-SL, a member of a PTP family previously 
implicated in the regulation of other MAPKs (Pulido et al., 1998; Saxena et al., 1998), was 
analysed. 
Secondly, C-terminally of the conserved MAPK domain ERK5 contains a 400 amino acid 
long tail of so far unknown function. Since ERK5 differs from all other MAPKs in this tail the 
question whether and how these unique domains could contribute to the regulation of ERK5 
or might affect its signalling had to be addressed. 
Finally, MAPKs were suggested to be indirectly involved in tumour development by 
contributing to acquired capabilities of cancer such as growth self-sufficiency or evasion from 
apoptosis. Whether ERK5 would be involved in oncogenic signalling and how its 
involvement could contribute to tumourigenesis was a final question to be considered. 
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2  Materials and Methods 
 
2.1 Materials 
 
2.1.1  Laboratory Chemicals and Biochemicals 
 
A c r y l a m i d e         S e r v a ,   H e i d e l b e r g  
Agar         Difco,  USA 
Agarose        BRL,  Eggenstein 
Ampicillin        Roche,  Mannheim 
Aprotinin        Sigma,  Taufkirchen 
APS  (Ammonium  peroxodisulfate)     Bio-Rad,  München 
ATP (Adenosine triphosphate)        Amersham Pharmacia, Freiburg 
[γ-
32P] ATP (>5000 Ci/mmol)        Perkin Elmer/NEN, Köln 
Batimastat        British  Biotech,  UK 
Bisacrylamide        Roth,  Karlsruhe 
Bromphenol  blue       Sigma,  Taufkirchen 
BSA (Bovine serum albumin)        Sigma, Taufkirchen 
Coomassie  G250       Serva,  Heidelberg 
Chloroquin        Biotrend  Chemikalien,  Köln 
Crystal  Violet        Sigma,  Taufkirchen 
Deoxynucleotides  (dG/A/T/CTP)     Roche,  Mannheim 
DTT  (Dithiothreitol)       Sigma,  Taufkirchen 
Ethidium  bromide       Sigma,  Taufkirchen 
Fibronectin        Calbiochem,  Bad  Soden 
Formaldehyde        PolySciences,  Eppenstein 
Geneticin  (G418,  GibCo)      Invitrogen,  Eggenstein 
GF109203X        Sigma,  Taufkirchen 
HEPES (N-(2-Hydroxyethyl)piperazine-N`-     Serva, Heidelberg 
  (2-ethanesulfonic acid)) 
Imatinib (Gleevec, STI571)          Dr. Keri, Vychem, Hungary 
IPTG (Isopropyl β-D-1-thiogalactopyranoside)   Biomol,  Hamburg 
L-Glutamine  (GibCo)       Invitrogen,  Eggenstein 
Leupeptin        Sigma,  Taufkirchen 
Lipofectamine®  (GibCo)      Invitrgen,  Eggenstein 
Lysozyme        Sigma,  Taufkirchen 
MBP  (Myelin  basic  protein)      Sigma,  Taufkirchen 
PMSF (Phenylmethanesulfonyl fluoride)      Sigma, Taufkirchen 
pNPP  (p-Nitrophenyl  phosphate)     Sigma,  Taufkirchen 
Polybrene (Hexadimethrine bromide)      Sigma, Taufkirchen 
Polyfect®        Quiagen,  Hilden 
PD98059        Alexis,  Grünberg 
Ponceau  S        Sigma,  Taufkirchen 
SDS (Sodium dodecyl sulfate)        Roth, Karlsruhe 
Sodium  azide        Serva,  Heidelberg 
Sodium  fluoride       Sigma,  Taufkirchen 
Sodium  orthovanadate     Sigma,  Taufkirchen 
Superfect®        Quiagen,  Hilden 
T4  gene  32  protein       Pharmacia,  Freiburg 2 Materials and Methods  21 
TEMED (N,N,N',N'-Tetramethylethylenediamine)    Serva, Heidelberg 
TPA (Tetradecanoyl-phorbol-13-acetate)    Sigma,  Taufkirchen 
Triton  X-100        Serva,  Heidelberg 
Tween  20,  40        Sigma,  Taufkirchen 
Tyrphostin  AG1478       Alexis,  Grünberg 
U0126         Calbiochem,  Bad  Soden 
 
All other chemicals were purchased in analytical grade from Merck (Darmstadt). 
 
 
 
2.1.2 Enzymes 
 
Calf Intestine Alkaline Phosphatase        MBI Fermentas, St. Leon-Rot 
DNAse  I,  RNAse  free       Roche,  Mannheim 
Restriction  Endonucleases      NEB,  Frankfurt/  Main 
        M B I   F e r m e n t a s ,   S t .   L e o n - R o t  
T4-DNA  Ligase         Roche,  Mannheim 
LA  Taq-DNA  Polymerase      Takara,  Japan   
Pfu DNA Polymerase           MBI Fermentas, St. Leon-Rot 
Trypsin  (GibCo)       Invitrogen,  Eggenstein 
 
 
 
2.1.4  „Kits" and Other Materials 
 
Cell  culture  materials        Greiner,  Solingen 
         Nunclon,  Dänemark 
         Falcon,  UK 
Cellulose nitrate 0.45 µm        Schleicher & Schüll, Dassel 
ECL  Kit        PerkinElmer/NEN,  Köln 
Dual-Luciferase
® Reporter Assay System    Promega, Mannheim 
Glutathione-Sepharose      Amersham  Pharmacia,  Freiburg 
Hyperfilm  MP       Amersham  Pharmacia,  Freiburg 
Micro BCA Protein Assay Kit       Pierce, Sankt Augustin 
Parafilm        Dynatech,  Denkendorf 
Poly Prep
® Chromatography columns     Bio-Rad, München 
Protein  A-Sepharose      Amersham  Pharmacia,  Freiburg 
Protein  G-Sepharose      Amersham  Pharmacia,  Freiburg 
QIAquick Gel Extraction Kit (50)      Qiagen, Hilden 
QIAquick PCR Purification Kit (50)      Qiagen, Hilden 
QIAGEN Plasmid Mini Kit        Qiagen, Hilden 
QIAGEN Plasmid Maxi Kit        Qiagen, Hilden 
Sephadex G-50 (DNA Quality)      Amersham Pharmacia, Freiburg 
Sterile filter 0.22 µm, cellulose acetate    Nalge Company, USA 
Sterile filter 0.45 µm, cellulose acetate    Nalge Company, USA 
Whatman  3MM       Whatman,  Rotenburg/Fulda 
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2.1.5  Growth Factors and Ligands 
 
EGF  (murine)         Toyoba,  Japan 
NGF        Becton  Dickinson,  Heidelberg 
αFGF        Pepro  Tech,  USA 
I n s u l i n         L i l l y ,   G i e s s e n  
 
 
 
2.1.6  Media and Buffers 
 
LB or 2xYT media were used for cultivation of all Escherichia coli strains. If and as required 
100 µg/ml Ampicillin or 70 µg/ml Kanamycin were added to media after autoclavation. For 
the preparation of LB-plates 1.5% Agar were also added. 
 
LB-Medium 1.0  %  Tryptone 
 0.5  %  Yeast  Extract 
 1.0  %  NaCl 
      pH  7.2 
 
2xYT-Medium 1.6  %  Tryptone 
 1.0  %  Yeast  Extract 
 1.0  %  NaCl 
      pH  7.2 
 
 
 
2.1.7  Cell Culture Media 
 
The following Gibco media and additives were obtained from Invitrogen (Eggenstein):  
 
Dulbecco’s modified eagle medium (DMEM) with 4.5 mg/ml glucose 
supplemented with 2 mM L-Glutamine. 
 
Minimum essential medium (MEM) with 2 mM L-Glutamine and 100 U/ml 
Penicillin/Streptomycin.  
 
RPMI Medium 1640 with 2 mM L-Glutamine and 100 U/ml 
Penicillin/Streptomycin. 
 
Nutrient mixture F12 (HAM) with 2 mM L-Glutamine and 100 U/ml 
Penicillin/Streptomycin. 
 
Media were supplemented with heat-inactivated Fetal Calf, Bovine Calf or Horse Serum 
according to the requirements of each cell line. Following the supplier’s instruction’s 1 mM 
Sodium Pyruvate and Non-essential amino acids were added to some media. 
 
Freeze medium: 90% heat-inactivated FCS, 10% DMSO. 
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2.1.8  Stock Solutions and commonly used buffers 
 
BBS (2x)  50.0  mM  BES 
 280.0  mM  NaCl 
 1.5  mM  Na2HPO4 
      pH  6.96 
HEBS (2x)  46.0  mM  HEPES 
 274.0  mM  NaCl 
 1.5  mM  Na2HPO4 
      pH  7.00   
 
HNTG  20.0   mM   HEPES, pH 7.5 
  150.0   mM   NaCl 
 0.1  %    TritonX-100 
  10 .0  %   Glycerol  
  10.0   mM   Na4P2O7 
 
DNA loading buffer (6x)  0.05  %  Bromphenol blue 
 0.05  %  Xylencyanol 
 30.0  %  Glycerol 
  100.0  mM  EDTA pH 8.0 
 
Laemmli buffer (2x)  65.0  mM  Tris/HCl pH 6.8 
 2.0  %  SDS 
 30.0  %  Glycerol 
 0.01  %  Bromphenol  blue 
 5.0  %  ß-Mercaptoethanol 
 
Laemmli buffer (3x)  100  mM  Tris/HCl pH 6.8 
 3.0  %  SDS 
 45.0  %  Glycerol 
 0.01  %  Bromphenol  blue 
 7.5  %  ß-Mercaptoethanol 
 
NET   50.0  mM  Tris/HCl pH 7.4 
 5.0  mM  EDTA 
 0.05  %  Triton  X-100 
 150.0  mM  NaCl     
 
PBS 137.0  mM  NaCl 
 27.0  mM  KCl 
 80.9  mM  Na2HPO4 
 1.5  mM  KH2PO4 pH 7.4 
 
SD-Transblot  50.0  mM  Tris/HCl pH 7.5 
 40.0  mM  Glycine 
 20.0  %  Methanol 
 0.004  %  SDS 
 
“Strip” buffer  62.5  mM  Tris/HCl pH 6.8 
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 100.0  mM  β-Mercaptoethanol 
 
TAE  40.0  mM  Tris/Acetate pH 8.0 
 1.0  mM  EDTA 
 
TE10/0.1  10.0  mM  Tris/HCl pH 8.0 
  0.1  mM  EDTA pH 8.0 
 
Tris-Glycine-SDS   25.0  mM  Tris/HCl pH 7.5 
 200.0  mM  Glycine 
 0.1  %  SDS 
 
 
2.1.9  Bacterial Strains, Cell Lines and Antibodies 
Names of people given as reference without further designation were members of this group. 
 
2.1.9.1  E. Coli Strains 
 
E. Coli strain  Genotype Description  Origin/ Reference 
 
DH5αF’  F’ endA1 hsd17 (rk
-mk
+) supE44 recA1  Genentech, USA 
  gyrA (Nal) thi-1 ∆(lacZYA-argF196) 
 
CJ236  dut ung thi-1 relA  (Kunkel, 1985) 
 
BL21 Codon+  F' ompT hsdS(rB– mB–) dcm+ Tet
r gal λ Stratagene,  NL 
  (DE3) endA Hte (argU ileY leuW Cam
r) 
 
SCS110 rpsL  (Str
r) thr leu endA thi-1 lacY galK galT  Stratagene, NL 
  ara tonA tsx dam dcm supE44D (lac-proAB)  
  (F' traD36 proAB lacI
qZ∆M15)  
 
 
2.1.9.2 Cell  Lines 
 
Cell Line  Description  Origin/ Reference 
BV-173   Human B cell precursor leukemia  DSMZ, Braunschweig 
 
COS-7  African green monkey, SV40-transformed kidney   Genentech, USA 
 
EM-2  Human chronic myeloid leukaemia in blast crisis  DSMZ, Braunschweig 
 
HEK 293T  Human embryonic kidney fibroblasts, transformed   ATCC, USA 
  with adenovirus Typ V DNA 
 
K562  Human chronic myeloid leukaemia, blast crisis  ATCC, USA 
 
Ku 812  Human chronic myeloid leukaemia, blast crisis  DSMZ, Braunschweig 
 
MEG-01  Human chronic myeloid leukaemia, blast crisis  DSMZ, Braunschweig 2 Materials and Methods  25 
M1/LX  MEG-01 infected with pLXSN  this study 
 
M1/WT  MEG-01 infected with pLXSN HA-ERK5 WT  this study 
 
M1/AEF  MEG-01 infected with pLXSN HA-ERK5 AEF  this study 
 
M1/KM  MEG-01 infected with pLXSN HA-ERK5 KM  this study 
 
M1/pRS  MEG-01 infected with pRetroSUPER  this study 
 
M1/pRS E5  MEG-01 infected with pRetroSUPER ERK5  this study 
 
Phoenix A  Packaging cell line for the generation of helper free  G. Nolan, Stanford, 
  amphotropic retroviruses, based on HEK 293T  USA 
 
Phoenix E  Packaging cell line for the generation of helper free  G. Nolan, Stanford, 
 ecotropic  retroviruses  USA 
 
PC12  Rat phaeochromocytoma cells  P. Cohen, UK 
 
PC12/pc  PC12, transfected with pcDNA3  M. Sommer 
 
PC12/WT  PC12, transfected with pcDNA3 PTP-SL WT  M. Sommer 
 
PC12/CS  PC12, transfected with pcDNA3 PTP-SL CS  M. Sommer 
 
Rat-1  Immortalised rat fibroblasts  R. Friedrich, Giessen 
 
Rat-1/lx  Rat-1, transfected with pLXSN  this study 
 
Rat-1/WT  Rat-1, transfected with pLXSN HA-ERK5 WT  this study 
 
Rat-1/AEF  Rat-1, transfected with pLXSN HA-ERK5 AEF  this study 
 
Rat-1/KM  Rat-1, transfected with pLXSN HA-ERK5 KM  this study 
 
R1vA  v-Abl transformed Rat-1  this study 
 
Swiss 3T3  3T3 - Swiss albino, mouse embryo fibroblasts,  ATCC, USA 
 immortalised   
 
All other cell lines were obtained
 from either the American Type Culture Collection (ATCC, 
Manassas, USA) or the German Collection of Microorganisms and Cell Lines (DSMZ, 
Braunschweig) and were cultivated following the supplier’s recommendations. 
 
 
2.1.9.3 Antibodies 
 
The following antibodies were used for immunoprecipitations or as primary antibodies in 
immunoblot and immunofluorescence analysis. 
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Antibody   Description/  Immunogen     Origin/  Reference 
 
Abl (SC-23)    Mouse, monoclonal, recognises the C-terminus  Santa Cruz, USA 
   of  Abl  kinases 
Actin      Rabbit, polyclonal, directed against a C-terminal  Sigma, Taufkirchen 
   p e p t i d e  
 
ERK2 (C-14)    Rabbit, polyclonal, peptide at C-terminus of rat   Santa Cruz, USA 
ERK2, used for IP 
 
ERK2 (K-23)   Rabbit, polyclonal, peptide from sub-domain XI   Santa Cruz, USA 
of rat ERK2, used for WB     
 
ERK5 (CT)    Rabbit, polyclonal, directed against a fusion of  this study 
      GST and human ERK5 aa 710 – 815 
 
ERK5 (PR1)    Rabbit, polyclonal, directed against a fusion of  this study 
      GST and human ERK5 aa 410 – 558 
 
HA.11     Mouse, monoclonal, recognises the influenza   BAbCo, USA 
hemagglutinin epitope   
 
HA (12CA5)    Mouse, monoclonal, recognises the influenza  Roche, Mannheim 
   hemagglutinin  epitope 
 
Histone  H1   Mouse,  monoclonal        Santa  Cruz,  USA 
 
JNK (C-17)    Rabbit, polyclonal, directed against a C-terminal  Santa Cruz, USA 
   peptide  of  human  JNK1 
 
p38 (C-20)    Rabbit, polyclonal/ peptide at C-terminus of   Santa Cruz, USA 
murine p38 
 
P-Tyr (4G10)   Mouse, monoclonal, recognises phospho-     UBI, USA 
   tyrosine  residues 
 
P-ERK2    Rabbit, polyclonal, recognises phospho-ERK1/2   NEB, Frankurt/M 
(Thr-202/ Tyr-204) MAPK   
 
P-p38      Rabbit, polyclonal, recognises phospho-p38   NEB, Frankfurt/M 
(Thr-180/Tyr-182) MAPK   
 
P-JNK    Rabbit,  polyclonal,  recognises phospho-JNK  NEB, Frankfurt/M 
   (Thr183/Tyr185) 
 
P-ERK5    Rabbit, polyclonal, recognises phospho-ERK5  BioSource, Solingen 
   (Thr218/Tyr220) 
 
PTP-SL    Rabbit, polyclonal, direct against the peptide  M. Sommer 
   CHSMVQPEQAPKVLN  coupled  to  Keyhole 
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RanGAP  Goat,  polyclonal      F.  Melchior, 
Martinsried 
          (Pichler  et  al.,  2002) 
Tubulin   Mouse,  monoclonal,  ascites     Sigma,  Taufkirchen 
 
VSV (P5D4)    Mouse, monoclonal; recognises an epitope of   Roche, Mannheim 
eleven amino acids derived from the vesicular  
stomatitis virus glycoprotein VSV-G 
 
 
For immunoblot and immunofluorescence analysis corresponding secondary antibodies 
conjugated with horseradish peroxidase (HRP) or the fluorescent dye C2 were utilised. 
 
Antibody      Dilution    Origin 
 
Goat anti-mouse-HRP  1 : 20,000      Sigma, Taufkirchen 
 
Sheep anti-goat-HRP   1 : 10,000      Sigma. Taufkirchen 
 
Goat anti-rabbit-HRP   1 : 40,000      BioRad, München 
 
Goat anti-rabbit-Cy2  1 : 1000      Jackson ImmunoResearch Labs, 
USA 
Goat anti-mouse-Cy2  1 : 1000      Jackson ImmunoResearch Labs, 
USA 
 
 
2.1.10  Plasmids and Oligonucleotides 
 
2.1.10.1 Primary  Vectors 
 
Vector    Description      Origin/  Reference 
 
pcDNA3    Mammalian expression vector, Amp
r, Invitrogen,  USA 
   N e o
r, CMV promotor, BGH poly A, 
      high copy number plasmid, F1+ origin 
 
pcDNA3-Fc    Modified pcDNA3 containing cds for Fc  C.Cant 
      chain 5’ of the multiple cloning site 
 
pBlueScript KS+  Cloning vector, F1 origin, Amp
r   Stratagene,  USA 
 
pGEX5X1-3    Prokaryotic expression vectors for the   Amersham Pharmacia, 
   generation  of  glutathione-S-transferase  Freiburg 
   fusion  proteins,  Amp
r, IPTG inducible 
 
pLXSN    Expression vector for retroviral gene    Clontech, USA 
   transfer,  Amp
r, Neo
r, ori from pBR322, 
       5’-LTR and 3’-LTR from MoMuLV, 
   SV40  promotor 2 Materials and Methods  28 
 
pLXSN-ESK    pLXSN vector with modified multipe   J. Ruhe 
   cloning  site 
 
pLXSN-EKS    pLXSN vector with modified multipe   J. Ruhe 
   cloning  site 
 
pRK5    Expression  vector,  Amp
r, CMV     Genentech 
   promoter,  SV40  poly  A 
 
pRetroSUPER   SiRNA generating vector, H1 RNA    (Brummelkamp  et  al., 
2002a) 
   promotor,  pBabe  backbone 
 
2.1.10.2 Constructs 
 
Vector      Insert  description    Reference 
 
pcDNA3-HA-ERK5      cDNA of human ERK5,    this study 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK5 AEF    cDNA of human ERK5,     this study 
TEY218-220 to AEF, 
uncoupled from MEK5 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK5 KM    cDNA of human ERK5,     this study 
K83 to M, kinase dead, 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK5 713    cDNA of human ERK5,     this study 
truncated at codon for aa 713, 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK5 575    cDNA of human ERK5,     this study 
truncated at codon for aa 575, 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK5 464    cDNA of human ERK5,     this study 
truncated at codon for aa 464, 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK5 409    cDNA of human ERK5,     this study 
truncated at codon for aa 409, 
     N-terminal  HA-tag 
 
pcDNA3-HA-MEK5     cDNA of human MEK5,     this study, 
     N-terminal  HA-tag 
 
pcDNA3-HA-MEK5 AA    cDNA of human MEK5,     this study, 
          S311, T315 to AA,  2 Materials and Methods  29 
     constitutively  inactive 
     N-terminal  HA-tag 
 
pcDNA3-HA-MEK5 DD    cDNA of human MEK5,     this study, 
          S311, T315 to DD,  
     constitutively  active 
     N-terminal  HA-tag 
 
pcDNA3-HA-ERK2/5    cDNA of murine ERK2 fused  this study 
          via GG linker to C-terminus 
of human ERK5 aa 410-815 
 
pcDNA3-HA-ERK5-Fc    cDNA of human ERK5,    this study 
     C-terminal  Fc  chain, 
     N-terminal  HA  tag 
 
pcDNA3-HA-ERK5 409-Fc    cDNA of human ERK5,    this study 
truncated at codon for aa 409, 
     C-terminal  Fc  chain, 
     N-terminal  HA  tag 
 
pcDNA3-VSV-ERK5     cDNA of human ERK5,    this study 
     N-terminal  VSV-tag 
 
pLXSN-HA-ERK5      cDNA of human ERK5,    this study 
     N-terminal  HA-tag 
 
pLXSN-HA-ERK5 AEF    cDNA of human ERK5,     this study 
TEY218-220 to AEF, 
inactivatable, 
     N-terminal  HA-tag 
 
pLXSN-HA-ERK5 KM    cDNA of human ERK5,     this study 
K83 to M, kinase dead, 
     N-terminal  HA-tag 
 
pGEX5X3 ERK5 PR1    cDNA of GST and human ERK5  this study 
     aa  410  -  558 
 
pGEX5X2 ERK5 CT     cDNA of GST and human ERK5  this study 
     aa  710  -  815 
 
pRetroSUPER ERK5     19 bp of human ERK5 cDNA  this study 
 
pGEX5X1 MEK5      cDNA of GST and human MEK5  this study 
     complete  cds 
 
pcDNA3-HA-ERK2      cDNA of mouse ERK2,    (Daub et al., 1997) 
     N-terminal  HA-tag 
 
pcDNA3-HA-p38    cDNA  of  human  p38,    this  study 2 Materials and Methods  30 
     N-terminal  HA-tag 
pRK5-PTP-SL      cDNA of murine PTP-SL,    (Pulido et al., 1998) 
     cytosolic  form,  aa  147-549, 
pRK5-PTP-SL CS      cDNA of murine PTP-SL,    (Pulido et al., 1998) 
     cytosolic  form,  aa  147-549, 
catalytic C480 to S, inactive  
 
pGEX-PTP-SL      cDNA of GST and PTP-SL    (Pulido et al., 1998) 
     aa  147-549,  cytosolic  form 
 
pGEX-SL juxta 1      cDNA of GST and PTP-SL    (Pulido et al., 1998) 
     aa  147-288,  juxtamembrane 
 
pGEX-SL juxta 2      cDNA of GST and PTP-SL    (Pulido et al., 1998) 
     aa  147-255,  juxtamembrane 
 
pGEX-SL juxta 1 ∆KIM    cDNA of GST and PTP-SL    (Pulido et al., 1998) 
     aa  147-288,  ∆KIM aa 224-239 
 
pGEX-SL PTP      cDNA of GST and PTP-SL    (Pulido et al., 1998) 
     aa  289-549,  PTP  domain 
 
pGEX-IA2-β        cDNA of GST and IA2-β fusion  this study 
     aa  641-1015,  cytosolic  domain 
 
pGEX-STEP        cDNA of GST and PTP STEP  (Pulido et al., 1998) 
     c o m p l e t e   c d s  
 
pGEX-NC-PTP      cDNA of GST and NC-PTP    J. Eickhoff 
     aa  245-670,  cytosolic  form 
 
pGEX-HePTP       cDNA of GST and He-PTP    K. Spiekermann 
     aa  1-339,  complete  cds 
 
pcDNA3-HA-PTP-SL    cDNA of PTP-SL WT,    M. Sommer 
     c y t o s o l i c   f o r m ,    
N-terminal HA  
 
pcDNA3-HA-PTP-SL CS    cDNA of PTP-SL C480S,    M. Sommer 
     c y t o s o l i c   f o r m ,    
     N - t e r m i n a l   H A    
 
pcDNA3-GFP-PTP-SL    cDNA of PTP-SL WT,    J. Eickhoff 
     c y t o s o l i c   f o r m ,    
     N - t e r m i n a l   G F P    
 
pcDNA3-GFP-PTP-SL CS    cDNA of PTP-SL C480S,    J. Eickhoff 
     c y t o s o l i c   f o r m ,    
     N - t e r m i n a l   G F P    
 
pEGFP-C2        cDNA of the enhanced green   Clontech 2 Materials and Methods  31 
     fluorescent  protein  (EGFP) 
pGL-3-CMV     cDNA  of  luciferase, CMV     B. Biesinger 
     promotor  driven   
 
pRK5-c-Abl        cDNA of murine c-Abl IV    (Jackson  et  al., 
1993) 
 
pRK5-c-Abl KM      cDNA of murine c-Abl IV    R. Herbst 
     K271  to  M,  kinase  dead 
 
pRK5-v-Abl        cDNA of p160 v-Abl from    (Gishizky  et  al., 
1995) 
     Abelson  leukaemia  virus 
 
pLXSN-v-Abl     cDNA  of  v-Abl    this  study 
 
pRK5-Bcr/Abl      cDNA of p210 Bcr/Abl, human  (Hallek et al., 1996) 
     fusion  product  of  Philadelphia   
     chromosome  translocation  in   
     chronic  myeloid  leukaemia   
 
pcDNA3-Tel/Abl      cDNA of p145 Tel/Abl, human  (Spiekermann,  
     fusion  product  of  a  chromosomal    2002) 
     rearrangement  in  leukaemia 
 
pRK5-c-Src     cDNA  of  p60  c-Src    (Luttrell  et  al., 
1997) 
 
pRK5-Lck YF       cDNA of murine p56 Lck    (Marth et al., 1988) 
     constitutively  active  variant 
 
pRK5-Fyn     cDNA  of  p59  Fyn    (Margolis  et  al., 
1992) 
 
Names given as reference without further designation were members of this group.  
 
 
2.1.10.3 Important  Oligonucleotides 
 
Sequence  (description)        Name 
 
CGG GAT CCG CCG AGC CTC TGA AGG AGG AAG  ERK5s/Norb2 
(Cloning of ERK5 into pc-DNA3 with HA tag, forward) 
 
GCT CTA GAA CTG TGG CAG CAA GGC ACA GG  E5as/Norb1 
(Cloning of ERK5 into pc-DNA3 with HA tag, reverse) 
 
AGA AGG CAC AGT CGA GGC TGA  pc rev 
(PCR subcloning from pcDNA3, reverse) 
 
ACC CAC TGC TTA CTG GCT TAT CG  pc fwd 2 Materials and Methods  32 
(PCR subcloning from pcDNA3, forward) 
 
GCC AAG CGG ACC CTC AGG  ERK5 seq1 
(sequencing primer) 
 
CTG TGA GCT CAA GAT TGG  ERK5 seq2 
(sequencing primer) 
 
CGG GAT CCC CCT GTG GCT AGC CCT TGG CCC C  GST-M5 s/Norb4 
(Cloning of MEK5 into pGEX5X1, forward) 
 
CCG CTC GAG CTG GGC TTT CAG TGC CCT GCG   GST-M5 as/Norb3 
(Cloning of MEK5 into pGEX5X1, reverse) 
 
GCC GGA TCC CTG TGG CTA GCC CTT GGC CCC  HaMEK5 s 
(Cloning of MEK5 into pcDNA3 with HA tag, forward) 
 
CCG TCT AGA CTG GGC TTT CAG TGC CCT GCG  HaMEK5 as 
(Cloning of MEK5 into pcDNA3 with HA tag, reverse) 
 
GCC CAA GCT TCC ACC ATG TAC ACC GAC ATC   VSV-ERK5 s 
GAG ATG AAC CGG CTG GGC AAG GGA TCC GCC  
GAG CCT CTG AAG GAG (Cloning of ERK5 and addition 
of N-terminal VSV-tag, fwd) 
 
CTA CTA GAT ATT ACA CTG G   M5seq 
(Sequencing primer) 
 
AGC ATT AGG GAT CTT CAT GAT GGC CAC CTG CTG  E5KM 
(Mutagenesis of K83 to M of ERK5) 
 
CGG TAC CAG CGC GTG GCC ACA AAC TCA GCC ATG  E5AEF 
AAG TAC TGA TGT TCA G (Mutagenesis of T218AY220 to 
AEF of ERK5) 
 
GCA TTT GTT CCA ACA TAC GCC TTG GCT ATA GCA  M5AA 
TTC ACC AGC TGA G (Mutagenesis of MEK5 S311 and 
T315 to AA) 
 
GCA TTT GTT CCA ACA TAA TCC TTG GCT ATA TCA  M5DD 
TTC ACC AGC TGA GTG C (Mutagenesis of MEK5 S311  
and T315 to DD) 
 
GCGCTC GAG GGG GTC CTG GAG GTC AGG CAG  E5Fc 
(Cloning of Fc tagged ERK5, reverse) 
 
GCG CTC GAG ACT AGC CAC AGG CTG TAG AGA AG   E5kinFc 
(Cloning of Fc tagged ERK5 409, reverse) 
 
GGG GAT CCT CTC AGG AGA GGC CCA CG  p38fwd 
(Cloning of human p38, forward) 2 Materials and Methods  33 
 
GCT CTA GAA ACC AGG TGC TCA GG   p38rev 
(Cloning of human p38, reverse) 
 
GGT CTA GAT CAC TGG GTC ACA AGG TTG ACA TCA   E5-713 
(Truncation of ERK5 at codon for aa713) 
 
GGT CTA GAT CAG GCC ATT CGA GTC CAG CGT TCC  E5-575 
(Truncation of ERK5 at codon for aa575) 
 
GGT CTA GAT CAT GGT GGG GCA GGC TCA CTG AC   E5-464 
(Truncation of ERK5 at codon for aa464) 
 
GCC TCT AGA TCA ACT AGC CAC AGG CTG TAG AGA  HaE5kin as 
AGG CTG G (Truncation of ERK5 at codon for aa 409) 
 
GGC TCG AGC CTG GCT GTC CAG ATG TTG   E5-CT fwd 
(Cloning of ERK2/5 chimera) 
 
GGC TCG AGC CCC CCA GAT CTG TAT CCT GGC TGG   E2-rev 
AAT C (Cloning of ERK2/5 chimera) 
 
GAT CCC CAG CTG CCC TGC TCA AGT CTT TCA AGA   E5 1435 fwd 
GAA GAC TTG AGC AGG GCA GCT TTT TTG GAA A 
(Cloning of ERK5-specific siRNA generating pRS) 
 
AGC TTT TCC AAA AAA GCT GCC CTG CTC AAG TCT  E5 1435 rev 
TCT CTT GAA AGA CTT GACG CAG GGC AGC TGG G 
(Cloning of ERK5-specific siRNA generating pRS) 
 
 
 
2.2  Methods in Molecular Biology 
 
 
2.2.1  Plasmid Preparation for Analytical Purpose 
 
Small amounts of plasmid DNA were prepared from 2 ml of E.Coli culture using the Qiagen 
Plasmid Mini Kit. 
 
 
2.2.2  Preparative Scale Plasmid Preparation  
 
If larger amounts of DNA were required, 100 –1000 ml of bacteria culture were inoculated 
and DNA was prepared with the Qiagen Plasmid Maxi Kit following the manufacturer’s 
instructions. 
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2.2.3  Enzymatic Manipulation of DNA 
 
2.2.3.1 Specific Digestion of DNA Samples by Restriction Endonucleases 
 
DNA samples were incubated with one or more restriction endonucleases. The ratio of 
Enzyme/DNA, the temperature, the buffer and the time of incubation were adjusted to each 
application. Usually, incubations for 1 hour at 37°C with a calculated 5-fold overdigestion 
and the buffers as supplied by the manufacturers were chosen. 
 
2.2.3.2  Dephosphorylation of DNA 5'-Termini 
 
In order to prevent self-ligation of vector termini generated by restriction digest, 5´-termini of 
vector were dephosphorylated with Calf Intestine Alkaline Phosphatase (CIAP). This 
phosphatase removes 5´-phosphate residues from DNA as well as RNA. 
For dephosphorylation, 1 µg of cut vector DNA was incubated with 5 units CIAP in adequate 
reaction buffer (e.g. 50 mM Tris/HCl pH 8.0, 0.1 mM EDTA pH 8.5) at 37°C for 10 minutes. 
Either reactions were stopped by heat inactivation at 85°C for 10 minutes or DNA was 
directly purified using the QIAquick PCR Purification Kit. 
 
2.2.3.3  Phosphorylation of Primer 
 
The phosphorylation of synthesised oligonucleotides was required for direct ligation into 
vectors as well as for primer extension. For these purposes 200 pmol oligonucleotide were 
incubated with 5 units T4 Polynucleotide Kinase, supplied buffer and 10 mM ATP for 30 
minutes at 37°C. The reaction was stopped by heat inactivation for 10 minutes at 70°C. 
 
2.2.3.4  Ligation of Vector and Insert DNA  
 
Catalyzing the formation of a phosphodiester bond between adjacent 5'-phosphate and 3'-
hydroxyl termini in duplex DNA, T4 DNA Ligase is able to join double-stranded DNA with 
cohesive or blunt ends. Purified, digested and dephosphorylated vector DNA (40 ng), the 
designated insert DNA, 1 µl 10x T4 DNA Ligase buffer (0.66 M Tris/HCl pH 7,5, 50 mM 
MgCl2, 50 mM DTT, 10 mM ATP) and 1 unit T4 DNA Ligase were combined. A molar ratio 
between insert and vector of 3 to 1 was usually chosen. Reactions were either left on 14°C 
over night or at 37°C for 2 hours and subsequently transformed into competent bacteria. 
 
2.2.3.5 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis is a simple and highly effective method for the separation DNA 
fragments ranging from as small as 200 bp to as big as several tenth kb. Depending on the size 
of the fragments of interest 0.7-2% agarose gels were prepared in horizontal chambers. TAE 
buffer was used for the electrophoresis. Voltage was usually set to 4-10 V per cm width of the 
gel. After separation DNA fragments were stained by gently agitating gels in TAE containing 
0.5 µg/ml ethidium bromide and were subsequently viewed under UV light. 
 
2.2.3.6 Isolation of DNA Fragments from Agarose Gels 
 
Following gel electrophoresis gel slices bearing DNA fragments of interest were cut out of the 
gel. Agarose was dissolved and DNA was purified using the QIAquick Gel Extraction Kit 
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2.2.4  Introduction of Plasmid DNA into E.coli 
 
2.2.4.1  Preparation of Competent Cells 
 
The preparation of competent cells was according to the procedure described by Chung and 
Miller (Chung and Miller, 1993). Competent cells were shock frozen in liquid nitrogen and 
stored for up to one year at –70°C. Transformation frequency ranged between 10
5 and 10
7 
colonies/µg DNA.  
 
2.2.4.2  Transformation of Competent Bacteria 
 
A 50 µl aliquot of competent bacteria was added to a 50 µl mixture of DNA usually ligation 
cocktails, 10 µl 5x KCM solution (500 mM KCl, 150 mM CaCl2, 250 mM MgCl2) and water. 
After thoroughly mixing, samples were incubated on ice for 20 minutes, 10 minutes at room 
temperature and after addition of 300 µl LB broth at 37°C for 1 hour while constantly 
shaking. Bacteria were streaked out on appropriate agar plates containing Ampicillin for the 
selection of transformants. 
 
2.2.5  Enzymatic Amplification of DNA by Polymerase Chain Reaction 
 
The polymerase chain reaction (PCR) is a rapid procedure for in vitro enzymatic amplification 
of a specific segment of DNA. With the dawn of the era of PCR a pleithora of applications 
has been developed and nowaday includes many standard techniques for analytical purposes. 
For long and accurate cDNA amplification Pfu Polymerase (MBI Fermentas) was used: 
 
1 µl     template cDNA, 1-10 ng 
1 µl     "forward" oligonucleotide, 10 pmol/µl 
1 µl     "reverse" oligonucleotide, 10 pmol/µl 
2.5 µl    10x PCR buffer II containing 20 mM MgCl2 
2 µl     dNTP-Mix, 2.5 mM each 
0.5 µl    Pfu DNA Polymerase (2.5 U/µl) 
ad 25 µl   H2O 
 
PCR reactions were carried out using an automated thermal cycler („Progene“, Techne). The 
following standard protocol was adjusted to each specific application: 
 
3 min   94°C  (initial denaturation) 
 
30 cycles: 
1 min  94°C  (denaturation) 
1 min  58°C  (hybridization) 
1.5 min/ kb  72°C  (extension) 
 
5 min  72°C 
PCR products were either separated by agarose gel electrophoresis, excised and subsequently 
purified or directly purified with QIAquick Gel Extraction or PCR Purification Kit, 
respectively. 
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2.2.6 Oligonucleotide-Directed  Mutagenesis 
 
For the analysis of DNA and protein function it is often desirable to specifically alter the 
DNA sequence and thus in case of open reading frames also the amino acid sequence of the 
encoded product. The desired mutations are introduced in oligonucleotides. Two methods are 
commonly used to convert these oligonucleotides carrying the mutation into biological active 
circular DNA. The protocol established by Kunkel et al. (Kunkel, 1985) requires an Uracil-
containing single-stranded template while for a nowadays more often used protocol (Braman 
et al., 1996) any circular double-stranded DNA can serve as template.  
 
 
2.2.6.1  Preparation of Uracil-Containing, Single-Stranded DNA Template  
 
CJ236 bacteria were transformed with circular DNA containing a F1 origin. Here only 
pcDNA3 and pBlueScript based DNAs were used. Samples of 2 ml 2xYT-medium were 
inoculated with several colonies of transformed CJ236 and grown at 37°C. When media 
appeared slightly hazy indicating that early log-phase was reached, cultures were infected 
with 2x10
7 M13K07 phages/ml (Amersham Pharmacia). After furher incubation for 90 
minutes 70 µg/ml kanamycin was added. Cultures were kept vigorously shaking at 37 °C over 
night.  
Supernatants were cleared from bacteria by two centrifugations (13000 rpm). After addition 
of 200 µl 2.5 M NaCl, 20% PEG 6000 and incubation for 15 minutes at room temperature, 
phages were collected by centrifugation. The phage sediment was resuspended in 100 µl 
TE10/0.1 buffer. After several phenol extractions (50 µl each) single stranded DNA was 
precipitated by addition of 10 µl 8 M LiCl and 250 µl pure ethanol to the aqueous phase over 
night at –20°C. After washing with 70 % ethanol single-stranded uracil-containing phage 
DNA was dissolved in 15 µl TE10/0.1. Quality and concentration was checked by agarose gel 
electrophoresis and spectrophotometrically at 260 nm.  
 
 
2.2.6.2  Primer Extension  
 
The single-stranded uracil-containing DNA was used as a template for the generation of 
mutation carrying strand. 200 ng single-stranded template DNA, 2 pmol phosphorylated 
oligonucleotide, 1 µl 10x hybridization buffer (20 mM Tris/HCl pH 7,4, 2 mM MgCl2, 50 
mM NaCl) in a total volume of 10 µl were incubated for 2 min at 90°C and allowed to cool 
down to room temperature. The mixture was supplemented with 1 µl 10x synthesis buffer (5  
mM dNTP-mix, 100 mM Tris/HCl pH 7.5, 50 mM MgCl2 and 20 mM DTT), 5 units T4 DNA 
Ligase, 1 µg T4 Gene 32 Protein and 3 units T4 DNA Polymerase. Reactions were incubated 
for 5 min on ice, 5 min at 25 °C and then for 90 min at 37°C. Finally 66 µl TE were added to 
reactions and aliquots containing approximately 100 ng of double-stranded DNA products 
were used for transformation of E.Coli. DNA was prepared from randomly chosen clones 
analysed by restriction digest and sequencing. Oligonucleotides were designed to contain an 
additional restriction side compared to the wild type sequence in order to facilitate the 
screening of larger numbers of clones. 
 
 
2.2.6.3  Site-directed Mutagenesis Using Double-stranded Template DNA 
 
The major advantage of this protocol (also known as Stratagene’s QuikChange Protocol) is 
that any double stranded DNA without any further requirements such as helper phage origins 2 Materials and Methods  37 
can be used as template. Two complement oligonucleotides bearing the desired alterations are 
used in a PCR-like reaction. Differing from the above PCR protocol 5 ng template DNA and 
2.5 units Pfu Polymerase were used. A few microliter of product after 12 to 18 cycles were 
checked by agarose gel electrophoresis. Subsequently, methylated template DNA was 
digested with methyl-sensitive restriction endonuclease Dpn 1. The persisting mutant DNA 
was used for transformation of competent bacteria. Clones were analysed as described above. 
 
 
 
2.2.7 DNA  Sequencing 
 
Sequencing of DNA was performed following the “Big Dye Terminator Cycle Sequencing 
Protocol” (ABI). The following mix was subjected to a sequencing-PCR run: 
 
250   ng      DNA of interest 
10   pmol       sequencing primer 
4   µl       Terminator Ready Reaction Mix 
ad   20 µl       H2O 
 
25 cycles:  30   sec      94°C   
15    sec    45-60°C 
  4    min    60°C   
 
Sequencing reactions were diluted with 80 µl water and precipitated with 0.1 volume 3 M 
sodium acetate pH 4.8 and 3 volumes ethanol. Pellets were dissolved in 20 µl template 
suppression reagent, briefly boiled and analysed on a 310-Genetic Analyzer (ABI Prism). 
 
 
 
2.3  Methods in Mammalian Cell Culture 
 
2.3.1 General  Cell  Culture Techniques 
 
All cell lines were grown in a humidified 95% air and 5 % CO2 incubator (Heraeus, B5060 
Ek/CO2) at 37°C and routinely assayed for mycoplasma contamination using a bisbenzimide-
staining kit (Sigma). Cells were splitted every 2 – 4 days and were counted with a Coulter 
Counter (Coulter Electronics) before seeding. Adherent cells were splitted by trypsinization 
and reseeding, while suspension cells were directly diluted into fresh media. Generally 15 cm 
dishes were used for maintenance culture.  
The most often used cell lines were cultivated as follows: HEK 293T and COS-7 cells were 
grown in in Dulbecco's modified Eagle's medium (DMEM) and 10% FCS, while the medium 
for Swiss 3T3 cells was supplemented with 10% bovine calf serum. The rat 
pheochromocytoma cell line PC12 was cultivated with DMEM but containing 5 % FCS and 
10 % horse serum. Plastic dishes for PC12 cells were coated with collagen (Sigma).  
The leukaemic suspension cell lines K562, Ku 812, B-173, EM-2 and MEG-01 were grown in 
RPMI 1640 supplemented with 10-20 % FCS as recommended by DSMZ. All other cell lines 
used were cultivated according to the supplier’s instructions. 
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2.3.2  Transfection of Cultured Cell Lines 
 
2.3.2.1  Calcium Phosphate Precipitation Method 
  
4 hours prior transient transfection 600.000 HEK-293T cells were seeded in six-well dishes. 
Usually 1 to 4 µg DNA was transfected by using a modified calcium phosphate precipitation 
method as described by Chen and Okayama (Chen and Okayama, 1987). In this protocol, the 
capacity of cells to incorporate calcium phosphate-DNA complexes by a hitherto unknown 
mechanism is used for the transfer of genes in adequate expression vectors. Mostly, CMV 
promotor driven expression constructs were used. The calcium phosphate-DNA complexes 
were formed in water by mixing the components as follows: 
 
dish  6-well  6 cm   10 cm  
area 10  cm
2 21  cm
2 57  cm
2 
Volume of medium  1 ml  2 ml  4 ml 
DNA in H2Obidest  2 µg in 90 µl  5 µg in 180 µl  10 µg in 360 µl 
2.5 M CaCl2  10 µl  20 µl  40 µl 
2 x BBS (pH 6.96)  100 µl  200 µl  400 µl 
Total volume  200 µl  400 µl   800 µl 
 
Formation of precipiates was induced by addition of the adequate volume of 2x BBS to the 
DNA and CaCl2 containing aqueous solution. After throughly mixing reactions were 
incubated for 10 min at room temperature and then added to the cells. If required cells were 
starved on the day following transfection by serum withdrawal. Expression was occasionally 
analysed as early as 16 hours but usually 48 hours after transfection. 
 
 
2.3.2.2  Transfection of COS-7 Cells Using Polyfect® 
 
COS-7 cells were transiently
  transfected using Polyfect® (Qiagen) essentially following 
Qiagen’s protocol. In brief, 160.00 cells were seeded in 6-well dishes 24 hours prior gene 
transfer. For transfection 1.5 µg  DNA and 10 µl Polyfect were mixed and incubated in 100 µl 
serum-free and antibiotic-free medium for 10 minutes at room temperature. Reactions were 
diluted with 500 µl fully supplemented medium and added to the cells which were in 1.5 ml 
fresh medium. After 24 hours cells were starved by serum deprivation if assays requiring cell 
stimulation were to be performed. 
 
 
2.3.2.3  Transfection of Rat-1 Cells Using Superfect® 
 
Rat-1 cells were transfected with Superfect® (Qiagen). The day after seeding of 100.000 cells 
per 6-well dish, the medium was changed. Comparably to the Polyfect protocol 1 µg DNA 
and 2 µl Superfect were mixed in serum and antibiotics-free medium. Transfectable lipid-
DNA complexes were formed during 15 minutes incubation at room temperature. The 
transfection mix was added to the cells, which were assayed after 48 hours for exogenous 
expression. For the generation of stably transfected Rat-1 lines cells were selected with 1 
mg/ml G418 for 14 days.  
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2.3.2.4  Determination of Transfection Efficiency 
 
Tranfection effciency was determined using reporter plasmids, such as CMV promotor driven 
GFP and Luciferase expression constructs. While GFP expression was easily monitored by 
fluorescence microscopy, relative luciferase activity was measured using the Dual-
Luciferase® Reporter Assay System (Promega). 
 
 
2.3.3  Retroviral Gene Transfer into Cultured Cells 
 
High titer retrovirus was prepared as described previously (Pear et al., 1993). The packaging 
cell lines Phoenix A and Phoenix E were transfected
 with pLXSN or pRetroSUPER based 
expression vectors using calcium phosphate precipitation method. To enhance transfection 
efficiency cells were given 100 µM chloroquin. Target cell lines were seeded in 10 cm plates. 
After 48 hours supernatants
 of transfected Phoenix cells were collected, supplemented with 8 
µg/ml polybrene and filtered through
 a 0.45 µm filter. Usually two donor plates of Phoenix 
cells were used per plate of target cells and viral supernatants were alternatingly collected 
every two hours. Acceptor cells were incubated with the viral supernatants three to four times 
for 2 h. Since virus titers are best after 4 hours but infection is almost complete after 1 hour of 
incubation with target cells, this modification of the standard protocol was used to reach a 
high multiplicity of infection.
 Retroviral supernatant was then replaced with fresh
 medium. 
Two days following infection, target protein expression was monitored by immunoblot. Cells 
were usually selected using either 2 µg/ml puromycin or 1 mg/ml G418 for 3 and 14 days, 
respectively. 
 
 
2.4  Protein Analytical Methods 
 
2.4.1 Preparation  of  Crude Cell Lysates 
 
Cells were washed with PBS and lysed on ice by addition of ice-cold lysis buffer (50 mM 
HEPES pH 7,5, 150 mM NaCl, 1 mM EDTA, 10% glycerine and 1 % TritonX-100) 
supplemented with phosphatase and protease inhibitors (10 mM Na4P2O7, 1 mM PMSF, 1 
mM orthovanadate, 1 mM NaF and 0,5% aprotinin). Cellular debris were removed by 
centrifugation. 
 
 
2.4.2  Determination of Total Protein Concentration in Lysates 
 
The overall protein concentration was determined using the Micro BCA Protein Assay Kit 
(Pierce, Sankt Augustin) and the supplied standard protocol. 
 
 
2.4.3 Immunoprecipitation  and  in vitro Binding of Proteins 
 
Lysates were pre-cleared with 20 µl sepharose slurry. For immunoprecipitations adequate 
amounts of antibodies were added together with 20 µl of mixed protein A and G sepharose 2 Materials and Methods  40 
and one volume of HNTG. Fc-tagged proteins were directly precipitated with the mix of 
protein A and G sepharose.For in vitro binding studies, 1 µg of each Fc and GST fusion 
protein were incubated in 250 µl PBS (8 mM Na2HPO4, 1,5 mM KH2PO4, 137 mM NaCl, 2,7 
mM KCl, pH 7,3) for 20 minutes at room temperature under constant shaking. After addition 
of 0.3 volumes of HNTG, samples were pre-cleared and finally precipitated with 20 µl GSH 
sepharose beads. In general, precipitation samples were incubated for at least 3 h on a rotation 
wheel at 4°C. Precipitates were washed three times with 0.5 ml HNTG buffer and were finally 
suspended in 2x Laemmli’s buffer, boiled and processed to SDS-PAGE. 
 
 
2.4.4 SDS-Polyacrylamide-Gel-Electrophoresis  (SDS-PAGE) 
 
Separation of denatured proteins was accomplished using SDS-PAGE essentially as described 
by Sambrook et al (Sambrook et al., 1990). Depending on the size of proteins of interest gels 
with polyacrylamide content ranging from 7.5 – 15 % were prepared. The following proteins 
were used as molecular weight standards: 
 
Protein  MW (kDa)  Protein   MW (kDa)  
Myosin 205  Ovalbumin  29 
ß-Galaktosidase 116  Carboanhydrase 43 
Phosphorylase b  97  Trypsin-Inhibitor  21.5 
BSA 66  Lysozym  14.4 
 
 
2.4.5  Protein Transfer onto Nitrocellulose Membranes 
 
For Western blot or immunoblot analysis proteins were transferred onto nitrocellulose 
membranes after separation by SDS-PAGE (Gershoni and Palade, 1982; Gershoni and Palade, 
1983). Transfer was accomplished with Transblot-SD buffer in a ‘Semidry’-blotting chamber 
(in house manufactured) applying 0.8 mA/cm
2 for 3 hours. Immobilised proteins on the 
nitrocellulose membrane were visualised with Ponceau S stain (2 g/l in 2% aqueous TCA 
solution) and bands of standard proteins were marked. Membranes were easily destained in 
water. 
 
 
2.4.6  Immunoblot Detection  
 
Membranes with bound proteins can easily serve as platform for immuno reactions. NET 
supplemented with 0.25% gelatine served as buffer throughout the whole process and was 
first used to block the remaining binding sites of the positively charged nitrocellulose 
membranes. Membranes were probed with adequate primary antibody directed against the 
protein of interest typically over night. Common dilutions for primary antibodies were around 
1 to 1000. Membranes were then washed three times for 5 minutes and the Fc chain of bound 
primary antibody was detected by the appropriate secondary antibody coupled to horseradish 
peroxidase. After unbound antibody had been removed by washing three times for 10 minutes 
positive signals were detected by chemoluminescence using the ECL Kit (PerkinElmer/NEN). 
Membranes were either exposed to X-ray films or if quantification was necessary, filters were 
exposed to the LAS1000 chemiluminescence camera (Fujifilm) and analysed with the 
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second Western blot experiment, bound antibodies were removed by incubation with strip-
buffer for 1 hour at 50°C. Then, membranes were thoroughly washed with water, blocked and 
the whole process was repeated. 
 
 
2.4.7  Preparation of GST-fusion Proteins 
 
The E.Coli strain BL21 Codon+ was used for the expression of proteins that do not require 
eukaryont-specific modifications. Bacteria were transformed with pGEX based expression 
contructs and first grown as 1 ml culture over night. Then 100 ml LB medium were inoculated 
with 0.1 ml of the bacteria culture and incubated under vigorous shaking for 8h hours. After 
addition of 900 ml LB medium containing 0.2 mM IPTG bacteria were grown over night at 
room temperature. Cells were collected by centrifugation, resuspended in PBS supplemented 
with 0.5 mM EDTA, 1 mM PMSF, 0.5 mM DTT and 10 µg/ml Aprotinin and lysed by 
sonication. The detergent Triton-X100 was added to a final concentration of 1% to avoid the 
formation of protein coagulation. The lysate was then incubated with 10 µg/ml DNAse 1 for 
10 minutes at room temperature in order to degrade bacterial DNA. Lysates were then cleared 
by centrifugation and the desired fusion protein was bound to GSH-sepharose during 30 
minutes of incubation at room temperature. Beads were transferred to Poly Prep
® 
Chromatography columns and washed with PBS. GST fusion proteins were eluted with 50 
mM Tris, pH 8.8 containing 15 mM GSH and 20 mM DTT. Positive fractions were identified 
by SDS-PAGE and Coomassie G250 stain. For long term storage, purified proteins were 
dialysed into PBS/ 30 % glycerol and kept at –70°C. 
 
 
2.4.8  Purification of Fc-tagged Proteins 
 
Transfected HEK 293T cells were collected and lysed. Fc-tagged proteins were precipitated 
with protein A sepharose at 4°C for two hours. Beads were transferred to Poly Prep
® 
Chromatography columns and washed with PBS. Elution was accomplished with 1 ml 
aliquots of 100 mM glycine, 150 ml NaCl, pH 2.5. Elutes were collected in vials containing 
20 µl 2 M Tris, pH 8.8 for neutralisation. Positive fractions were pooled and dialysed into 
PBS with 30% glycerol. 
 
 
 
2.5  Biochemical and Cell Biological Assays 
 
2.5.1  Stimulation of Cells 
 
Cells were seeded in cell culture dishes of appropriate size and grown over night to about 
80% confluence. After serum withdrawal for 24 hours cells were stimulated with various 
agonists as indicated in the legends. If inhibitors such as Imatinib were used to reduce 
signalling activity, cells were kept under optimal growing conditions. Stimulations were 
stopped by washing cells with PBS and immediate lysis. 
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2.5.2 MAPK  Phosphorylation 
 
MAPK are generally activated by phopshorylation of threonine and tyrosine residues in their 
activation motif. Therefore phosphorylation state-specific antibodies can be used to monitor 
the activity of MAPKs by Immunblot analysis. Crude cell lysates were mixed with half a 
volume 3x Laemmli’s buffer and separated by SDS-PAGE. After transfer to nitrocellulose 
membranes rabbit polyclonal anti-Phospho-ERK2, Phospho-ERK5, Phospho-p38 and 
Phospho-JNK were used as primary antibodies. Membranes were usually reprobed with rabbit 
polyclonal anti-ERK2, anti-ERK5, anti-p38 and anti-JNK antibodies. In the case of ERK5, 
anti-ERK5 immunoprecipitates were used instead of crude cell lysates.  
 
 
2.5.3 Kinase  Assay 
 
The activity of isolated usually immunprecipitated kinases can be measured in vitro using 
radioactive [γ-
32P]ATP and autophosphorylation and/or substrate phosphorylation as read out. 
For measuring ERK5 activity, exogenous HA-tagged ERK5 was immunoprecipitated from 
transfected COS-7 cells. Precipiates were washed twice with HNTG and twice with kinase 
assay buffer (20 mM HEPES pH7,5, 10 mM MgCl2, 1 mM DTT and 0,5 mM orthovanadate). 
Samples were suspended in 30 µl kinase assay buffer supplemented with 50 µM ATP and 2 
µCi [γ-
32P]ATP and incubated for 20 minutes at 30°C under constant shaking. For the 
measurement of additional substrate phosphorylation reactions were also supplemented with 1 
µg of GST fusion proteins or 10 µg myelin basic protein. The reaction was extended to 30 
minutes if 1 µg purified ERK5 protein was used instead of immunoprecipitated kinase. 
Assays were stopped by addition of 2x Laemmli’s buffer and boiling. Samples were resolved 
on SDS-PAGE and transferred to nitrocellulose. Phosphorylation was detected by Phospho-
Imaging using the BAS2500 Reader (Fujifilm) and quantified with Image Gauge 3.3 
(Fujifilm). The amount of precipitated kinase was visualised by immunoblot analysis.  
 
 
2.5.4 Phosphatase  Assay 
 
The easiest way to gain some insight into the activity of tyrosine-specific phosphatases is the 
use of para-nitrophenyl-phosphate (pNPP) as widely accepted and colorimetrically 
measurable substrate. For the measurement of PTP-SL activity, 1 µg of purified PTP-SL 
protein was diluted into 20 µl PBS and incubated with 1 µg of different proteins for 10 
minutes at room temperature under constant shaking. Two 10 µl aliquots were then added to 
100 µl pNPP buffer (25 mM HEPES pH 7,5, 1 mM DTT, 1 mM EDTA) containing 3,7 mg/ml 
pNPP. After 2 hours at 37°C, the absorption at 405 nm was determined. To analyse the 
influence of PTP-SL on the activity of ERK5 coupled in vitro phosphatase-kinase assays were 
performed. ERK5 precipitates were washed twice with HNTG and twice with PTP assay 
buffer (25 mM HEPES pH 7,3, 10 mM DTT, 5 mM EDTA). Samples were resuspended in 20 
µl assay buffer containing the indicated amount of GST-PTP-SL fusion protein, and were 
incubated for 20 minutes at 30°C while shaking. As these reaction were followed by in vitro 
kinase assays they were stopped by washing with kinase assay buffer containing the 
phosphatase inhibitor orthovanadate. The kinase assay was carried out as described above. 
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2.5.5  Shift Analysis of Protein Phosphorylation  
 
The addition of negatively charged phopshoryl groups to proteins reduces its mobility in SDS-
PAGE. Hence, observed shifts can be used to deduce some information on the 
phopshorylation state of a protein. But since mobility shifts are not exclusively caused by 
phosphorylations, unspecific Calf Intestine Alkaline Phospatase (CIAP) can be used to 
remove any phosphoryl group and to clarify whether a certain shift is evoked by 
phosphorylation or not. The protein of interest was immunprecipitated and washed twice with 
HNTG and twice with CIAP buffer (50 mM Tris/HCl pH 8.0, 0.1 mM EDTA pH 8.5). Beads 
were resuspended in 20 µl CIAP buffer containing 20 units CIAP. Reactions were stopped 
after 20 minutes at 37°C by addition of 2x Laemmli’s buffer. 
 
 
2.5.6  Analysis of Subcellular Protein Localisation 
 
Cells were seeded at 2 x 10
4 cells/cm
2 on glass cover slips and if required transfected as 
described above. Cells were processed for immunofluorescence after 24 hours of further 
culture. Cells were washed twice with PBS and fixed with methanol at –20°C for 5 min, 
rinsed once with –20°C cold acetone and washed twice with PBS. Alternatively, cells were 
fixed with PBS, 4 % formaldehyde, 0.125 M sucrose for 10 minutes at room temperature and 
subsequently permeabilised with ice-cold 0.2% TritonX-100 in PBS for 10 minutes. 
All further steps were carried out at room temperature. Samples were incubated in PBG (PBS 
containing 0.5% BSA and 0.045% Teleostean Fish Gelatin) supplemented with 5% normal 
goat serum for 1 hour, washed twice with PBG and incubated with a 1:1000 dilution of anti 
ERK5 or anti-HA antibody for 1 hour. After three more washes with PBG, cells were 
incubated with the appropriate secondary Cy2-labelled antibody in a 1:1000 dilution for 1 h. 
After one more PBG and three more PBS washes, samples were rinsed in destilled water and 
mounted. DNA was stained for 10 min with 1 µg/ml bisbenzimid which was included in the 
penultimate washing step. 
 
 
2.5.7  Analysis of Nuclear Proteins 
 
Cells were trypsinated and collected by centrifugation at 500 × g. After washing twice with 
PBS cells were lysed in hypotonic lysis buffer (10 mM Tris pH 7,5, 10 mM NaCl, 3 mM 
MgCl2, 0,5 % NP-40) on ice for 5 minutes. Nuclei were precipitated by centrifugation at 500 
× g, washed once with hypotonic lysis buffer and finally dissolved in Laemmli buffer. The 
presence of a certain protein was tested by Immunoblot analysis. Since RanGAP exists in a 
nuclear 90 KDa and a cytosolic faster migrating form, anti-RanGAP (kindly provided by 
Frauke Melchior, Martinsried) immunoblotting was carried out to control equal loading and 
potential cytosolic contaminations.  
 
 
2.5.8  Cell Cycle Analysis and Cell Survival 
 
Leukaemic suspension cells were treated with various agents as indicated in the legends. Cells 
were collected by centrifugation and lysed in hypotonic buffer containing 0.1% sodium 
acetate, 0.1% Triton X-100 and 20 µg/ml propidiumiodide for 2 h on ice. Samples were 2 Materials and Methods  44 
analysed on a Becton Dickinson FACScalibur flow cytometer. Cells with sub-G1 DNA 
contents were considered as dead and substracted to get the percentage of cell survival.  
 
 
2.5.9 Growth  Assay 
 
Leukaemic suspension cells were seeded in duplicate at 200.000/ml in a total volume of 4 ml 
and were treated as indicated in respective figure legends. Every 24 or 48 hours cells were 
thoroughly mixed and aliquots were counted.  
 
 
 
2.6 Statistical  Analysis 
 
Student’s t-test was used to compare data between two groups. Values are expressed as mean 
± standard deviation of at least three independent experiments. P < 0.05 was considered 
statistically significant. 
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3 RESULTS 
 
3.1  Tyrosine-specific Phosphatase PTP-SL regulates ERK5 Signalling in 
multiple Ways 
 
MAPKs including ERK5 are generally activated by phosphorylation of threonine and tyrosine 
residues in their activation motif, however, dephosphorylation of either residue is sufficient 
for kinase inactivation (Canagarajah et al., 1997). This part of the study concentrates on the 
question of whether and how PTP-SL might be involved in the downregulation of the big 
MAP kinase 1/ ERK5 signal. PTP-SL (Hendriks et al., 1995; Ogata et al., 1995; Sharma and 
Lombroso, 1995; Shiozuka et al., 1995), like STEP (Lombroso et al., 1991) and HePTP 
(Zanke et al., 1994), belongs to the kinase interacting motif (KIM)-containing phosphatases 
that have previously been shown to bind, dephosphorylate and thereby inactivate signalling by 
ERK1/2 (Pulido et al., 1998; Saxena et al., 1999a; Saxena et al., 1998). KIM-containing PTPs 
are characterised by a very restricted expression pattern. They are not found in the nucleus 
and are generally considered to play a role in the short-term inactivation of MAPKs (Saxena 
and Mustelin, 2000). 
 
3.1.2  PTP-SL binds to ERK5 
 
To address the relevance of PTP-SL function in the regulation of MAPK cascades, the 
potential interaction between ERK5 and the cytosolic form of the STEP-like phosphatase was 
investigated. Co-precipitation experiments with polyclonal anti-PTP-SL antibody and lysates 
from transfected human embryonic kidney (HEK) 293 cells were performed. Figure 8A (first 
panel) shows PTP-SL association with hemagglutinin-tagged ERK5 (HA-ERK5) in those 
cells co-overexpressing both proteins. 
As can be further seen in the second panel of Fig. 8A, in addition to HA-ERK5 also 
endogenous ERK1/2 was detected in the immunoprecipitates in the presence but not the 
absence of overexpressed PTP-SL. It is conceivable that ERK1/2 might compete with ERK5 
for PTP binding. As expected from earlier studies describing the expression of PTP-SL 
predominantly in cell lines of neuroendocrine origin (Augustine et al., 2000; Ogata et al., 
1995; Shiozuka et al., 1995), we did not detect endogenous PTP-SL in HEK 293 cell lysates 
(Fig.8A, bottom panel). 
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Figure 8: Co-immunoprecipitation of ERK5 and PTP-SL in transfected HEK 293 cells. Cells 
were transfected with expression constructs of ERK5 and PTP-SL or the empty vectors and lysed 
after 48 hours. A, pcDNA3 HA-ERK5 and pRK5 PTP-SL were transfected. PTP-SL 
immunoprecipitations (IP) and crude lysates (CL) were resolved by SDS-PAGE, followed by 
Western blot (WB) analysis using anti-HA, anti-ERK2 and anti-PTP-SL antibodies. The 
unspecific band migrating below ERK5 is due to the combination of antibodies used for 
precipitation and immunoblot (top panel). B, pRK5 HA-PTP-SL and pcDNA3 HA-ERK5 409-Fc 
were transfected. Protein A/G sepharose was used to precipitate Fc-tagged ERK5 409 (aa 1-409). 
Precipitates and crude lysates were immunoblotted with anti-HA antibody. 
The interaction of ERK5 and PTP-SL was further demonstrated by performing the converse 
experiment as shown in Fig. 8B. When a truncated version of HA-ERK5 (HA-ERK5 409), 
that contained only the kinase domain but lacked the unique carboxy-terminal tail, was co-
expressed with HA-tagged PTP-SL (HA-PTP-SL), we were readily able to pull down PTP-SL 
by precipitating ERK5 409 (Fig. 8B, lane 4). Addition of the IgG-Fc portion to the carboxy-
terminus of the ERK5 409 construct was necessary to visualise the bound phosphatase, which 
would otherwise have been masked by the heavy chain of the precipitating antibody. 
Having established that both proteins were able to co-immunoprecipitate with each other, the 
questions whether the proteins interact directly was addressed by performing in vitro binding 
experiments. Both proteins were tagged and purified. While a fusion protein of PTP-SL and 
glutathione S transferase (GST) was bacterially expressed, Fc-tagged ERK5 was isolated from 
lysates of transfected HEK 293 cells. Correct folding of the proteins was verified by testing 
their phosphatase or kinase activities (data not shown). Figure 9A shows that full length ERK5 
as well as the truncated ERK5 409 protein directly interacted with both wild-type and 
catalytically inactive PTP-SL. Tanoue et al. and Tarrega et al. identified docking motifs in 
ERK2 that mediate interaction with substrates and regulators including phosphatases (Tanoue 
et al., 2000; Tanoue et al., 2001; Tarrega et al., 2002). These docking motifs are also present 
and conserved in the ERK5 kinase domain and thus are likely to mediate the binding to PTP-
SL. 3 Results     47 
 
Figure 9: Direct binding of ERK5 and PTP-SL. Purified Fc- and HA-tagged ERK5 and ERK5 
409 were incubated with fusion proteins of GST and PTP-SL (SL). After precipitation with GSH 
sepharose, samples were analysed by HA immunoblot. A, HA tagged ERK5 and ERK5 409 were 
incubated with PTP-SL WT or PTP-SL CS. B, schematic presentation of PTP-SL and used fusion 
proteins. Numbering of amino acids refers to the transmembrane form of PTP-SL and is according 
to Hendriks et al. (Hendriks et al., 1995). Kinase interacting motif (KIM) contains aa 224-239. C 
and D, ERK5 409 was precipitated with fusion proteins of GST and different domains of PTP-SL. 
E, ERK5 409 and PTP-SL WT were incubated in the presence of crude lysates (CL) of A431 and 
HEK 293T cells. Precipitates were additionally immunoblotted for ERK2 (bottom panel). 
In turn, to identify the domains of PTP-SL, which are involved and responsible for binding to 
ERK5, GST-fusion proteins that contained different portions of PTP-SL were prepared and 
tested for their ability to bind ERK5 409 (Fig. 9B). As shown in Figure 9C, not only the full 
cytosolic form of PTP-SL but also the juxtamembrane and the phosphatase domain alone 
were both interacting with ERK5. Interestingly, even the PTP-SL juxtamembrane construct 
lacking the KIM, a motif that was shown to mediate the interaction with ERK2 (Pulido et al., 
1998; Saxena et al., 1999a; Saxena et al., 1998), was still able to bind to ERK5 (Fig. 9D). In 
further binding experiments crude lysates of HEK 293 and A 431 cells were used as source 
for proteins that might possibly compete for PTP binding sites. In the presence of these 
lysates associated ERK5 decreased to a degree that correlated with the amount of endogenous 
ERK1/2 interacting with PTP-SL (Fig. 9E) 
Taken together, this set of data shows that the interaction between ERK5 and PTP-SL is direct 
and involves the kinase domain of ERK5 and – even though not exclusively – the KIM 
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3.1.2  ERK5 phosphorylates PTP-SL in vitro 
 
To examine whether PTP-SL itself could serve as ERK5 substrate, in vitro kinase assays were 
performed with several GST fusion proteins containing different portions of PTP-SL as 
potential substrates. Activated ERK5 was immunoprecipitated from EGF stimulated COS-7 
cells. As shown in Figure 10A wild type PTP-SL as well as those proteins containing the 
juxtamembrane domain was readily phosphorylated by ERK5. On the other hand, the 
phosphatase domain alone did not serve as a substrate. The identification of the 
juxtamembrane domain as site of phophorylation alludes to threonine 253 as modified amino 
acid in view of that it is also phosphorylated by ERK2. 
 
Figure 10: PTP-SL is an in vitro substrate for ERK5. HA-ERK5 was immunoprecipitated from 
lysates of transfected COS-7 cells that were stimulated with 15 ng/ml EGF for 5 min. Samples 
were subjected to kinase assays using 1 µg of different GST fusion proteins as substrate. After 
separation and transfer to a nitrocellulose membrane, samples were analysed by autoradiography 
and HA immunoblot. A, kinase substrates were GST-PTP-SL (SL) WT (aa 147-549), SL juxta 1 
(aa 147-255), SL juxta 2 (aa 147 – 288) and SL phos (aa 256 – 547). B, GST fusion proteins of the 
full cytosolic forms of PTP-SL, NC-PTP, STEP, HePTP and the unrelated IA2-β were used in the 
kinase assay as in A. Amount and size of the used fusion proteins are shown in replica gels stained 
with Coomassie G250 (A and B, bottom panels). 
Then the capability of ERK5 to phosphorylate additional KIM containing PTPs like NC-PTP, 
STEP (Lombroso et al., 1991) and HePTP (Zanke et al., 1992) was tested. According to the 
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fused to GST. The resulting fusion proteins were of comparable size and migrated around 65 
kDa on SDS-PAGE. All KIM containing phosphatases were phosphorylated in vitro, 
however, the cytosolic domain of the unrelated PTP IA2-β (Kawasaki et al., 1996) was – as 
expected – not modified by ERK5 (Fig. 10B). 
 
3.1.3  Binding of ERK5 enhances the Activity of PTP-SL 
 
Whether complex formation between ERK5 and PTP-SL would alter the enzymatic activity of 
the phosphatase was tested by measuring the activity of the bacterially expressed PTP-SL 
fusion protein upon binding to ERK5. As shown in Figure 11A, ERK5 as well as truncated 
ERK5 409 enhanced PTP-SL activity approximately 3.5-fold, whereas two control proteins 
namely GST and IgG had no effect. Although a similar increase in its activity was shown for 
the dual specific phosphatase MKP-3 in complex with ERK2 (Camps et al., 1998), the 
demonstrated influence of ERK5 binding on PTP-SL activity is the first ever observed for a 
PTP in association with a member of the MAPK family. 
 
Figure 11: Binding of ERK5 enhances the activity of PTP-SL. A, 1 µg GST-PTP-SL (SL) WT 
was incubated with 1 µg Fc-tagged ERK5, ERK5kin or other proteins as indicated for 10 min at 
room temperature. Subsequently, PTP activity was measured with pNPP as substrate. Data 
represent the mean of three independent experiments ± SD. The activity of SL WT alone was set 
as 100% reference. B,  in vitro kinase reactions in the presence and absence of ATP were 
performed with 1 µg each of purified Fc-tagged ERK5, ERK5 409 and SL WT. After 30 min at 
30°C PTP activity was quantified in pNPP assays. Values are the mean of two separate 
experiments ± SD. PTP activity was generally lower under these conditions compared to the data 
presented in A.  
Since PTP-SL was phosphorylated – although not quantitatively - by a preparation of ERK5 
protein isolated from transfected HEK 293 cells (data not shown), we tested the influence of 
this phosphorylation on PTP-SL activity by performing in vitro kinase reactions in the 
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As shown in Fig. 4B PTP-SL activity again was strongly enhanced in the presence of either 
wild-type ERK5, ERK5 409 or the kinase inactive mutant ERK5 KM, but was merely slightly 
decreased by addition of ATP in all cases. These results indicate that binding to – but not 
phosphorylation by – ERK5 makes a major impact on PTP-SL activity. 
 
3.1.4  PTP-SL modulates ERK5 Activity in vitro and in intact Cells 
 
To answer the question whether PTP-SL might regulate ERK5 activity, the influence of PTP-
SL on ERK5 kinase activity was analysed. In vitro phosphatase reactions with various 
amounts of GST-PTP-SL fusion proteins combined with a preparation of activated ERK5 
were performed and ERK5 activity was subsequently measured. COS-7 cells co-expressing 
the dominant active form of MEK5 were used as source for activated ERK5. MEK5 was 
shown to be the MAPK kinase specifically activating ERK5 and to possess constitutive 
activity if serine 311 and threonine 315 were mutated to aspartate (Kato et al., 1997; Zhou et 
al., 1995). Wild-type PTP-SL almost completely abolished ERK5 kinase activity, whereas the 
catalytically inactive CS mutant did neither affect autophosphorylation of ERK5 nor 
phosphorylation of the unspecific substrate myelin basic protein (Fig. 12A). As shown in 
Figure 12B, the degree of ERK5 inactivation correlated with the amount of utilised PTP-SL 
protein. 
In order to test whether PTP-SL would be capable of inactivating ERK5 in transfected COS-7 
cells, immuno complex kinase assays were performed after stimulation of cells with hydrogen 
peroxide or EGF. Whereas wild-type PTP-SL reduced ERK5 kinase activity to basal levels, 
the PTP-SL mutant lacking phosphatase activity seemed to further enhance ERK5 
autophosphorylation (Fig. 12C, upper panel). ERK5 appeared as doublet resulting from a 
mobility shift of a small fraction of the enzyme that was hardly detectable in Western blot but 
clearly visible in the autoradiograph. This shift is probably due to phosphorylation of ERK5 
since the amount of the upper band was found to correlate with the degree of kinase activation 
(Cavanaugh et al., 2001; Mody et al., 2001); when dominant active MEK5 was co-expressed 
this shift was virtually quantitative (Fig. 12A and B). 
Since the relative activation of ERK5 after EGF and hydrogen peroxide treatment of cells was 
only moderate, we additionally expressed the constitutively active MEK5 construct to achieve 
a more pronounced ERK5 activation. Wild-type PTP-SL partially counteracted the effect of 
MEK5 and reduced ERK5 activity to a level that may reflect the balance between the 
opposing actions of activating kinase and inactivating phosphatase in the cell. In turn, co-3 Results     51 
transfection of the catalytically impaired CS mutant of PTP-SL caused a profound increase in 
ERK5 activity which might be due to competition with endogenous phosphatases for ERK5 
binding sites. 
 
Figure 12: PTP-SL inactivates ERK5 in vitro and in transfected COS-7 cells.  A and B, 
pcDNA3 HA-ERK5-Fc and pcDNA3 MEK5(D) were co-transfected into COS-7 cells. After 48 
hours, Fc tagged ERK5 was precipitated with Protein A/G sepharose from crude cell lysates and 
subjected to in vitro phosphatase reactions in the presence of GST, GST-PTP-SL (SL) WT or SL 
CS. Residual ERK5 activity was measured in a kinase assay with MBP as additional substrate. 
The amount of SL protein was 3 µg if not indicated otherwise. Split samples were separated on 
two SDS-PAGEs and analysed by autoradiography (upper and middle panels) and by anti-HA 
immunoblotting (bottom panel). C, COS-7 cells were transfected with pcDNA3 HA-ERK5, pRK5 
PTP-SL WT, CS or the empty vector. After serum starvation, cells were stimulated for 15 min 
with 200 µM H2O2 or 5 min with 15 ng/ml EGF. Anti-HA immunoprecipitates were subjected to 
in vitro kinase assays and resolved on SDS-PAGE . Autophosphorylation and the amount of 
precipitated ERK5 were visualised by autoradiography and anti-HA immunoblot (upper and 
middle panel). The small numbers below the lanes represent the relative autophosphorylation 
activities of ERK5. Expression of PTP-SL in crude lysates is shown by immunoblot using anti-
PTP-SL (lower panel).  D, pcDNA3 HA-ERK5-Fc was co-transfected together with pcDNA3 
MEK5(D) and pRK5 PTP-SL WT, CS or the corresponding vectors into COS-7 cells. ERK5 was 
precipitated with Protein A/G sepharose followed by kinase assays. Samples were separated on 
SDS-PAGE and transferred to nitrocellulose membrane. The amount of precipitated and 
autophosphorylated ERK5 were quantified by HA immunoblot and phospho-imaging, 
respectively. Values represent the relative autophosphorylation activity normalised by the amount 
of precipitated ERK5 and are the mean of two independent experiments ± SD. ERK5 activity in 
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3.1.5  Endogenous ERK5 is inactivated by PTP-SL in PC12 Cells 
 
To evaluate the potential of PTP-SL to inactivate endogenous ERK5, PC12 cells stably 
expressing PTP-SL were stimulated with EGF and the activation state of immunoprecipitated 
ERK5 was analysed by Western blot. After stimulation, a reduced amount of active ERK5 
was detected in cells overexpressing wild-type PTP-SL (Fig. 13, top panel), whereas in 
analogy to the effect seen in transfected COS-7 cells, the inactive CS mutant of PTP-SL 
further enhanced the activation of endogenous ERK5 (compare Fig. 12C, D and Fig. 13). 
Notably, two more or less equally phosphorylated forms of ERK5 were detected in PC12 
cells. This indicates that additional modifications might be required for the mobility shift to 
the upper position. Figure 13 (top panel) further shows that PTP-SL reduced the amount of 
both activated forms of ERK5 to a similar extent. As it can be seen in the third panel of 
Figure 13, ERK1/2 were – as expected – also inactivated by wild-type PTP-SL. It has to be 
mentioned, that the expression of wild type PTP-SL when compared to its inactive mutant 
decreased with time during cultivation of cells indicating growth selection for cells with low 
phosphatase expression (Fig. 13, bottom panel). 
 
 
Figure 13: Endogenous ERK5 is inactivated by PTP-SL in PC12 cells. PC12 cells transfected 
with pcDNA3-HA-PTP-SL WT, CS or mock DNA were serum starved for 24 hours followed by 
stimulation with 30 ng/ml EGF for 5 min. Endogenous ERK5 was immunoprecipitated and split 
equally on two SDS-PAGEs. Samples were analysed by immunoblotting for ERK5 and for the 
active phosphorylated form phospho-ERK5 (top two panels). Activation of ERK2 was monitored 
by Western blot analysis of crude lysates using anti-Phospho-ERK1/2. The expression of HA-
PTP-SL was visualised by HA immunoprecipitation and Western blot (bottom panel). 
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3.1.6  PTP-SL retains ERK5 in the Cytosol 
 
When the subcellular localisation of endogenous ERK5 was examined in COS-7 cells by 
immunofluorescence, a major portion of ERK5 was found to reside in the nucleus (Fig. 14B, 
C). To test whether PTP-SL would have an influence on this subcellular localization, the 
phosphatase was fused to green fluorescent protein (GFP) and overexpressed. 
 
 
Figure 14: PTP-SL retains ERK5 in the cytoplasm. COS-7 cells were transiently transfected 
with pcDNA3 GFP-PTP-SL (SL) WT, CS or the empty vector and analysed by fluorescence 
microscopy after 24 hours. GFP autofluorescence is shown in the left panel (A, D and G). ERK5 
was visualised by immunofluorescence using anti-ERK5 antibodies (B, E and H) and DNA was 
stained with bisbenzimid (C, F and I). Each horizontal panel shows identical sections of COS-7 
cells. Arrows indicate nuclei with reduced ERK5 staining. J, isolated nuclei from the transfected 
COS-7 cells were separated on SDS-PAGE. The ERK5 content was analysed by anti-ERK5 
immunoblot. Equal loading was assured by reprobing the membrane with anti-RanGAP and anti-
Histone H1 antibodies.  3 Results     54 
It can be clearly seen in Figure 14D - F that only those cells that express PTP-SL as indicated 
by the autofluorescence of GFP show reduced ERK5 staining in the nucleus when compared 
with neighbouring untransfected cells. This reduction reflects the retention of ERK5 in the 
cytoplasm since expression of PTP-SL did not affect the overall levels of ERK5 protein in the 
cells (data not shown). Figure 14G - I further shows that not only the wild type PTP-SL but 
also its catalytically impaired CS mutant exerted this influence on ERK5. Accordingly, the 
amount of ERK5 protein was reduced in isolated nuclei from transiently transfected COS-7 
cells expressing either form of PTP-SL (Fig. 14J). The influence of PTP-SL on the 
localization of ERK5 was independent of phosphatase activity which demonstrates that PTP-
SL is able to modulate ERK5 action not only by dephosphorylating the kinase but also 
additionally by binding to it and thereby retaining it in the cytoplasmic department. Therefore 
the cellular PTP-SL expression level is an additional and critical parameter for MAPK 
regulation. 
Taken together, PTP-SL is not only able to modulate the signalling of ERK5 by 
dephosphorylation and inactivation but also by imposing localisational constraints. 
 
 
3.2  Oncogenic Abl Mediates Leukaemia Cell Survival by MEK5 
independent Stabilisation of ERK5 
 
Chronic myeloid leukaemia (CML) is a pluripotent haematopoietic stem cell disorder which is 
characterised by the Philadelphia chromosome translocation. This genomic abnormality gives 
rise to the Bcr/Abl fusion protein, a strictly non-nuclear protein tyrosine kinase with 
constitutive signalling activity. The Bcr/Abl oncogene is sufficient to initiate CML-like 
disease in mice (Daley et al., 1990; Elefanty et al., 1990; Heisterkamp et al., 1990), and is 
responsible for leukaemia progression (Huettner et al., 2000). Treatment of patients with the 
Abl-specific kinase inhibitor Imatinib (also termed Gleevec, Glivec and STI571) induced 
remission in the early chronic leukaemic phase as well as in late blast crisis (Druker et al., 
2001a; Druker et al., 2001b). Whereas responses in the chronic phase were enduring, 
remission in blast crisis patients were only transient over a period of 2 to 6 months due to 
development of resistance to the kinase inhibitor. Point mutations in the Bcr/Abl gene can 
severely decrease the sensitivity for Imatinib and have been shown to be responsible for 
cellular drug resistance (Gorre et al., 2001; Shah et al., 2002). It is conceivable that due to 
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resistant cells will lead to relapse. Combinational therapy by additionally targeting survival 
pathways might thus be a powerful tool in preventing tumour progression that is caused by the 
expansion of resistant clones. One major survival signal is mediated by mitogen-activated 
protein kinases (MAPKs) (Ballif and Blenis, 2001) and inhibition of MAPK pathways by 
chemical compounds synergistically enhanced Imatinib-induced apoptosis (Yu et al., 2002). 
 
 
 
Figure 15: Dose-dependent effects of MAPK pathway inhibitors on Leukaemia cells. A, K562 
and MEG-01 cells were grown in the presence of the MAPK inhibitors U0126 (1 and 10 µM, U1 
and U10, respectively) and PD98059 (25 and 100 µM, PD25 and PD100, respectively). Control 
cells were grown in medium containing either no additive, the solvent DMSO alone or 1 µM of 
the Abl kinase inhibitor Imatinib. B, after 72 hours nuclear DNA content of cells was analysed by 
flow cytometry. The fraction of cells with less DNA than diploid cells was used as measure for 
apoptotis. C, the activity of ERK2 was monitored by anti-Phospho-ERK2 immunoblot of crude 
lysates. Cells were treated with the same concentrations of inhibitors as under A for four hours. 
To gain some preliminary insight into the function of MAPKs in leukaemia, the two p210 
Bcr/Abl positive cell lines MEG-01 and K562 were treated with the two most commonly used 3 Results     56 
inhibitors of the MAPK cascade PD98059 and U0126. Both compounds were known to 
interfere with MEK1 and MEK2 (English and Cobb, 2002) and thus to prevent the activation 
of ERK1 and ERK2 and downstream targets (Dudley et al., 1995; Favata et al., 1998). 
The influence of the MAPK inhibitors on cell growth and survival was measured. Two 
concentrations of each inhibitor were used of which the lower had an only moderate effect on 
MEG-01 cell growth and virtually none on K562 cells (Fig. 15A). Raising compound 
concentration, however, strongly reduced proliferation as well as survival of both cell lines 
(Fig. 15A and B). Imatinib treated cells were used as control and showed strong induction of 
apoptosis and impaired proliferation. Interestingly, even lower inhibitor concentrations almost 
completely abolished the activity of ERK2 (Fig. 15C). Similar discrepancies in the dose-
dependent influence of MAPK inhibitors on ERK2 activity on one hand and proliferation and 
survival on the other have been reported before (Woessmann and Mivechi, 2001). 
Noteworthy, the same inhibitors also – but less effectively – inhibited the MEK5-ERK5 
pathway (Mody et al., 2001). This finding together with recent observations that implicated 
ERK5 in doxorubicin resistance of MCF-7 breast cancer cells (Weldon et al., 2002), led us to 
the question whether ERK5 might play a role in oncogenic Abl signalling in general and 
leukaemia cell survival in particular. 
 
3.2.1  ERK5 interacts with oncogenic Abl Kinases 
 
ERK5 expression was readily detected in the Bcr/Abl positive cell lines MEG-01 and K562 
by Western blot (Fig. 16A, bottom panel). Signalling activity of both cell lines was highly 
sensitive to Bcr/Abl inhibition as monitored by the drastic reduction of overall tyrosine 
phosphorylation in crude lysates upon treatment with Imatinib (Fig. 16A, right upper panel). 
This correlates with the strong anti-proliferative effects of Imatinib seen above. 
Immunoprecipitation of ERK5 indicated that ERK5 itself as well as several associating 
proteins were tyrosine phosphorylated in an Abl kinase dependent manner in both cell lines, 
albeit to a different extent. Tyrosine phosphorylation levels of ERK5 were more pronounced 
in K562 than in MEG-01 cells. Sizes of detected associating proteins ranged from 
approximately 160 to 210 kDa. A p210 protein was clearly enriched in ERK5 
immunoprecipitates when compared to its relative abundance in crude cell lysates. Similarly, 
overexpression of Bcr/Abl, c-Abl, v-Abl and the less abundant leukaemic fusion protein 
Tel/Abl induced tyrosine phosphorylation of the protein complex precipitating with ERK5 in 
HEK 293T cells (Fig. 16B). Interestingly reprobing with pan-Abl antibody revealed some 
binding of different Abl forms to ERK5. Noteworthy, the p145 Tel/Abl protein was the most 3 Results     57 
potent in binding ERK5. The absence of Abl in precipitates with preimmune serum or control 
antibody demonstrated that the interaction of ERK5 and Abl is specific (Fig. 16C). 
 
 
Figure 16: Abl kinases bind and phosphorylate ERK5. A, MEG-01 and K562 cells were treated 
with 10 µM Imatinib for one hour and lysed. ERK5 immunprecipitates (IP) and crude cell lysates 
(CL) were analysed by anti-phosphotyrosine and anti-ERK5 immunoblot. Arrows indicate ERK5. 
B, HEK 293T cells were transfected with expression constructs of different Abl kinases. ERK5 
was immunoprecipitated and immuno complexes were analysed by anti-phosphotyrosine, anti-
ERK5 and anti-Abl immunoblot. C, lysate from c-Abl expressing HEK 293T cells was prepared. 
Anti-ERK5 immunoprecipitates were compared to control antibody and preimmune serum. Bound 
c-Abl was visualised by anti-Abl immunoblot. 
 
3.2.2  Abl Kinases activate ERK5 
 
To test whether Abl activates ERK5, cells were co-transfected with different Abl kinases and 
ERK5. Immuno complex kinase assays were performed and ERK5 autophosphorylation was 
taken as read out. While Bcr/Abl and Tel/Abl over-expression had only minor effects (Fig. 
17A and B), c-Abl and v-Abl strongly induced ERK5 activation to a similar level as the 
constitutively active mutant of the upstream kinase MEK5 (Buschbeck et al., 2002). 3 Results     58 
Src-family kinases, Fyn, Src and Lck, although much more potent in inducing overall tyrosine 
phosphorylation, did not activate ERK5 (Fig. 17C). As shown in Figure 17D Abl induced 
activation of ERK5 was blocked by Imatinib and is thus clearly dependent on intact Abl 
kinase activity. 
 
 
Figure 17: Abl activates ERK5. A, COS-7 cells were co-transfected with expression constructs 
for HA-tagged ERK5 and Abl kinases or constitutively active MEK5 DD. The activity of ERK5 
was monitored by autophosphorylation in an anti-HA immuno complex kinase assay (top panel). 
The amount of immunoprecipitated (IP) ERK5 and the expression of c-Abl in crude cell lysates 
were analysed by anti-HA and anti-Abl immunoblot, respectively (middle and  bottom panel, 
respectively). B, a quantitative view of ERK5 activation is shown. Autophosphorylation signals 
were normalised for the amount of precipitated ERK5. Data represents the mean of three 
experiments ± SD. C, HEK 293T cells were transfected with constructs for Src- family kinases or 
c-Abl. ERK5 was immunoprecipitated and its activation state was analysed by anti-Phospho-
ERK5 immunoblot which specifically detects the activated form of the kinase (top panel). 
Membranes were reprobed with anti-ERK5 and the induction of overall tyrosine phosphorylation 
was monitored by anti-phosphotyrosine immunoblot of crude cell lysates (middle and bottom 
panel). D, HEK 293T cells transfected with c-Abl were treated with 0.1, 1.0 and 10 µM Imatinib. 
ERK5 activity was analysed as in C. 3 Results     59 
The roles of the many different MAPK family members in oncogenic Abl signalling are 
somewhat controversial. It has been convincingly demonstrated that the proto-oncogene 
product c-Abl acts in the pathway downstream of DNA damage that includes activation of the 
pro-apoptotic kinases p38 and JNK (Kharbanda et al., 2000; Kharbanda et al., 1998). 
However, the exact function and the subset of MAPKs preferentially targeted by deregulated 
Abl signalling remain widely elusive. 
 
Figure 18: Abl preferentially activates ERK5 among MAPKs. The activation of different 
MAPKs was analysed in cells that were either overexpressing Abl kinases or that were treated 
with 20 ng/ ml EGF for 15 minutes and 0.5 M sorbitol (osmotic stress) for 30 minutes. A, HEK 
293T cells were used. ERK5 immunoprecipitates (IP) and crude cell lysates (CL) were analysed 
by immunoblot using anti-ERK5, anti-ERK2, anti-p38, anti-JNK and the corresponding 
phosporylation state-specific antibodies, anti-P-ERK5, anti-P-ERK2, anti-P-p38 and anti-P-JNK. 
B, for analysis of MAPK activation in COS-7 cells HA-tagged ERK5 and p38 were co-
overexpressed with Abl kinases. ERK5 was immunprecipiated and its autophosphorylation 
activity was assessed in an immuno complex kinase assay (top panel). The corresponding anti-HA 
immunoblot is shown below. Activation of ERK2 and p38 was analysed by immunoblot of crude 
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The MAPK activity induced by overexpression of Abl kinases was compared to the activity 
reached upon stimulation of cells with EGF and osmotic stress. Known to activate MAPKs 
these two stimuli were included as internal reference for the degree of MAPK activation. 
First, activaty of ERK5, ERK2, p38 and JNK in HEK 293T cells was analysed by 
immunoblot (Figure 18A). As expected, in addition to ERK5 the other MAPKs were also 
activated by overexpression of the Abl kinases but to a significantly lower degree than by 
either stimulus. Not surprisingly, JNK and p38 were potently activated by osmotic stress, 
while ERK2 strongly responded to EGF. In contrast ERK5 was most potently activated by 
exogenous Abl but not detectably by either stimulation. In a second set of experiments COS-7 
cells were taken as overexpression system (Fig. 18B). ERK2 and p38 activation was analysed 
as before while ERK5 activity was measured in an immuno complex kinase assay. ERK5 was 
again found to be more strongly activated by overexpression of Abl kinases than by EGF or 
Sorbitol. According to the results obtained from HEK 293T cells ERK2 as well as p38 were 
best activated by standard stimuli. In order to amplify the otherwise weak signal the level of 
p38 was enhanced by moderate overexpression. Conclusively, these results indicate that at 
least under overexpression conditions Abl kinases preferentially activate ERK5 in comparison 
to other MAPKs. 
 
3.2.3  Abl Kinases regulate the Protein Level of ERK5 
 
To extend the results from leukaemic cells ERK5 was further analysed in MEG-01 cells. 
Surprisingly endogenous ERK5 levels were reduced after extended treatment with Imatinib 
while the control protein Tubulin was not affected (Fig. 19A). To generate a v-Abl 
transformed cell line, Rat-1 fibroblasts were infected with a retroviral expression construct for  
v-Abl and grown until the appearance of multilayered cell aggregates indicated the loss of 
contact inhibition. These so called foci were isolated and further cultivated. In these particular 
fibroblasts ERK5 levels also decreased with time of Imatinib exposure (Fig. 19B), whereas 
ERK2 and p38 were not or only moderately affected. Since inhibition of Abl kinase activity 
resulted in a decrease of ERK5 protein, we used again COS-7 cells as expression system to 
conduct the converse experiment. As shown in Figure 19C, increasing Abl kinase activity by 
over-expression enhanced the level of ERK5 whereas expression of wild-type Abl in the 
presence of Imatinib or expression of the kinase dead Abl KM construct had no effect. 
The amount of a certain protein in the cell reflects the balance between production and 
degradation. Thus many factors controlling promoter activity, mRNA stability, rate of 3 Results     61 
translation and of course the protein stability itself, define the abundance of a protein which 
can be observed in a simple immunoblot experiment. 
 
 
Figure 19: Abl kinase stabilise ERK5. A-E, Protein levels of ERK5, Tubulin, p38 and ERK2 
were analysed by immunoblot of crude cell lysates. A, prior lysis MEG-01 cells were incubated 
with 10 µM Imatinib. B, v-Abl transformed Rat-1 cells were treated with 5 µM Imatinib. C and E, 
COS-7 cells were co-transfected with constructs for HA-tagged ERK5 and wild-type or kinase 
dead (KM) c-Abl. Cells were treated with 10 µM Imatinib or 100 µM translation inhibitor 
cycloheximide as indicated. D, MEG-01 and K562 cells were treated with 10 µM Imatinib in 
combination with 100 µM cycloheximide as indicated. 
The fact that not only endogenous but also exogenous ERK5 which is expressed at a relatively 
constant rate were sensitive to Abl kinase activity, led us to speculating that the stability of the 
ERK5 protein was somehow affected. In order to test this hypothesis we blocked translation 
in MEG-01 and K562 cells by addition of cycloheximide and checked whether co-
administration of Imatinib would still be able to influence the cellular level of ERK5. As 
shown Figure 19D, ERK5 but not p38 was reduced in cells treated with the inhibitor. 
Accordingly, co-expression of Abl in COS-7 cells prolonged the half-life of exogenous ERK5 
but did not affect the protein levels of ERK2 (Fig. 19E). Abl kinases thus do not only regulate 
ERK5 by classical MAPK cascade activation but also by stabilisation of the protein itself. 3 Results     62 
3.2.4  Abl induced Stabilisation of ERK5 is MEK5-independent and involves 
the C-terminal Tail of ERK5 
 
ERK5 differs from all other MAPKs in that it contains a 400 amino acid long C-terminal tail 
which gave rise to its additional designation as big MAP kinase 1. Although this portion of 
ERK5 is its most striking feature its function remains largely elusive. 
 
 
Figure 20: The C-terminus of ERK5 is involved in Abl mediated stabilisation. A and C-E, 
requirements for Abl mediated stabilisation were analysed in transfected COS-7 cells expressing 
various HA-tagged ERK5 mutants in combination with Abl kinases. Crude cell lysates were 
analysed by anti-HA, anti-Tubulin and anti-Actin immunoblot. B, schematic presentation of used 
mutants: PR, Proline rich; WT, wild-type; AEF, not activatable but basally active - mutation of 
MEK5 phosphorylation sites; KM, kinase dead; numbers indicate the last amino acid of truncated 
mutants; ERK2/5, fusion of ERK5 C-tail to full length ERK2. 3 Results     63 
Since the ERK5 C-terminus is highly conserved among mammals it has been speculated for a 
long time that it might possess a regulatory role. Here, the ability of c-Abl to stabilise various 
C-terminally truncated mutants of ERK5 was tested. All ERK5 mutants except for the shortest 
ERK5 409 construct were effectively stabilised by Abl over-expression (Fig. 20A). The 409 
mutant lacks the entire C-terminal tail and reduces ERK5 to its MAPK domain that shares 
high homology with ERK2 (Fig. 20B). Fusion of the complete ERK5 C-terminus to ERK2 
results in potent stabilisation of the chimeric protein by v-Abl as shown in Figure 20C. 
Scanning the ERK5 sequence with the Scansite algorithm (Yaffe et al., 2001) identified a 
potential Abl SH3 binding site in the proline rich domain I which is absent in the 409 mutant. 
Together these results suggest that the C-terminal tail of ERK5 might be able to modulate 
kinase action by mediating the interaction with Abl which would subsequently stabilise the 
ERK5 protein. However, a precise dissection of the parameters that determine this interaction 
between ERK5 and Abl requires further studies. 
Figure 20D shows that over-expression of Abl elevated the amount of ERK5 AEF, a mutant 
which cannot be activated and is thus uncoupled from MEK5, and affected, although to a 
lower extent, also the level of kinase dead ERK5 KM. Moreover, constitutively active MEK5 
DD – although potent in ERK5 activation (Fig. 17A and B) – did not enhance ERK5 protein 
levels (Fig. 20E). Stabilisation of ERK5 is thus independent of activation by MEK5 and 
represents a novel aspect in MAPK regulation besides the classical kinase cascade-mediated 
control. 
 
3.2.5  Synergy of v-Abl and enhanced ERK5 Levels in Transformation 
 
The oncogenic capacity of v-Abl is easily monitored in cell culture by the induction of foci in 
monolayers of rodent fibroblasts. To get some preliminary information about the functional 
connection of ERK5 and oncogenic Abl signalling, we compared the efficacy of v-Abl in 
transforming Rat-1 fibroblasts stably over-expressing either wild-type ERK5 or the AEF and 
KM mutants. Elevated ERK5 levels synergistically enhanced the amount of foci induced by 
v-Abl (Fig. 21). Strikingly, ERK5 AEF was as potent as the wild-type form, whereas kinase 
dead ERK5 KM had no influence at all. Although impaired in MEK5 dependent activation, 
the AEF mutant still harbours basal activity which is required and possibly sufficient for the 
observed potentiation of v-Abl induced transformation. In the absence of v-Abl, 
overexpression of any form of ERK5 alone did not lead to any transformation (data not 
shown). 
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Figure 21: Enhanced ERK5 levels enforce the transforming capacity of v-Abl. A, polyclonal 
Rat-1 fibroblasts overexpressing either wild-type (WT) or mutant (AEF and KM) ERK5 and 
control cells transfected with empty vector (pLX) were used. Monolayers of cells were infected 
with ecotrophic pLXSN-v-Abl retrovirus and further cultivated for 14 days. The number of 
induced foci was determined. Data represents three independent experiments + SD. Cells infected 
with control virus did not produce any foci (not shown). B, anti-ERK5 immunoprecipitates were 
analysed by anti-ERK5 immunoblot. 
 
3.2.6  ERK5 mediates Leukaemia Cell Survival  
 
To approach the question whether ERK5 has a role in leukaemogenesis, the expression of 
ERK5 was analysed in five Bcr/Abl positive and ten Bcr/Abl negative leukaemia cell lines. 
ERK5 expression was readily detected in all Bcr/Abl positive and all but two Bcr/Abl 
negative cell lines (Fig. 22). The erythroleukaemia HEL and the histiocytic lymphoma U937 
cell lines contained the lowest ERK5 levels. As expected ERK2, p38 and JNK as 
representatives of the three other main subgroups of MAPKs were ubiquitously expressed. 
Most interestingly, levels of JNK and even more pronounced of ERK5 differed much more 
between different cell lines than the levels of ERK2 or p38. 
Having established the presence of ERK5 in Bcr/Abl positive lines, MEG-01 and K562 cells 
were stable transfected with expression constructs of either wild-type ERK5 or interfering 3 Results     65 
AEF and KM mutants in order to gain some information on the function of ERK5. 
Overexpression of any form of ERK5 did not affect the growth nor the cell cycle distribution 
of either cell line (not shown). 
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Figure 22: MAPK expression in Leukaemia. Crude cell lysates of Bcr/Abl positive and negative 
leukaemia cell lines were analysed by immunoblot using anti-ERK5, anti-ERK2, anti-p38, anti-
JNK and anti-Tubulin antibodies. 
This indicated that under normal conditions ERK5 is most likely not involved in the control of 
proliferation. However, taking recent findings into account implying ERK5 in 
chemoresistance (Weldon et al., 2002) the question was raised whether ERK5 might have a 
role in challenged cells, for instance during therapy. Therefore, the dose-dependent effects of 
the Abl kinase inhibitor Imatinib on the cell cycle distribution of all five Bcr/Abl positive cell 
lines were assessed. Cells were treated with Imatinib or control vehicle for three days, lysed 
and the DNA content of their nuclei was analysed by flow cytometry. The direct correlation 
between DNA content of a cell and its position in cell cycle allows to draw conclusions on the 
actual distribution among G1, S and G2/M phase and on the percentage of living cells by 
excluding sub-G1 cells. Under optimal growth conditions more than half of all cells were in S 
or G2/M phase indicating the highly proliferative character of these leukaemic cell lines (not 
shown). Treatment with Imatinib induced a strong cell cycle arrest monitored in the relative 
increase in G1 cells (Fig. 23, middle and left column). Since degradation of cellular DNA is a 
hallmark of apoptosis the appearance of a sub-G1 peak moreover indicated the induction of 
apoptosis in a significant fraction of cells. MEG-01 and Ku 812 were most sensitive to 
Imatinib treatment in terms of showing the largest percentage of sub-G1 cells. 3 Results     66 
 
Figure 23: Imatinib induces cell cycle arrest and apoptosis. Five Bcr/Abl positive leukaemia 
cell lines were treated with Imatinib or solvent alone (DMSO) for three days. Cell cycle 
distribution was monitored by flow cytometric analysis of nuclear DNA content. Graphic settings 
are DNA content on x-axis and number of cells on y-axis. The central peak represents the 
population of diploid cells in G1. 
To answer the question whether ERK5 is involved in survival pathways of Bcr/Abl positive 
leukaemia cells, endogenous ERK5 levels of MEG-01 cells were reduced by stable 
transfection of an ERK5-specific small interfering RNA (siRNA) generating vector (Fig. 
24B). The phenomenon of RNA interference (RNAi) was first discovered in the nematode 
Caenorhabditis elegans as a response to double-stranded RNA which results in sequence-
specific gene silencing based on directed mRNA degradation (Fire et al., 1998). Nowadays 
RNAi has also found multiple applications in mammalian cells. The design of vectors using 
the H1-RNA promoter to generate siRNAs has further broadened the field of application and 
allows the study of long-term phenotypes (Brummelkamp et al., 2002a; Brummelkamp et al., 
2002b). 3 Results     67 
 
Figure 24: ERK5 mediates cell survival after transient Imatinib treatment. A, MEG-01 cells 
were infected with a retroviral pRetroSUPER construct generating ERK5-specific siRNA and 
selected for three days with puromycin. Polyclonal lines were treated with 0.3 µM Imatinib for 
two days and cell survival was assessed 24 hours after drug removal by flow cytometric analysis. 
B, expression levels of ERK5 and Tubulin are shown by immunoblot analysis of crude cell lysates. 
C, MEG-01 infected with and selected for retroviral expression vectors for wild-type ERK5, KM, 
AEF or the empty vector (pLX) were treated and analysed as described in A. D, crude lysates were 
again analysed by anti-ERK5 and anti-Tubulin immunoblot.  
Cells were treated with low concentrations of Imatinib for two days and cell survival was 
analysed 24 hours after agent removal. As shown in Figure 24A survival was reduced by 
about one third in cells with reduced ERK5 expression. Over-expression of the kinase dead 
KM mutant was also able to negatively interfere with cell survival while wild-type ERK5 and 
the AEF mutant had virtually no effect (Fig. 24C and D). Comparably to the observations 
made in the focus formation study this underlines the difference between non-activatable AEF 
and kinase dead KM mutant and further indicates that basal activity of ERK5 but not MEK5 
dependent activation is required for cell survival. 
Contrary to many cellular signalling pathways which are transiently switched on by diverse 
stimuli, survival pathways should be constitutively active in order to fulfil their anticipated 
function. Since basal kinase activity of ERK5 seems to be sufficient for cell survival, 
stabilisation and destabilisation of the ERK5 protein could comprise a way of regulation. 3 Results     68 
3.3  Patterns of ERK5 Expression, Localization and Activation  
 
3.3.1  Expression and Localisation of ERK5 
 
Diverse tissues were tested positive for ERK5 and MEK5 mRNA transcripts (English et al., 
1995; Lee et al., 1995) and the ERK5 protein was further detected in many and diverse cell 
types including cortical neurons and myoblasts (Cavanaugh et al., 2001; Dinev et al., 2001). 
In order to analyse ERK5 expression specific antibodies were generated. A stretch of about 
100 amino acids taken from the unique C-terminus of ERK5 was fused to glutathione-S-
transferase and subsequently used for immunization of rabbits.  
 
 
Figure 25: Expression of ERK5. Crude cell lysates from different human and non-human cancer 
and non-cancer cell lines as well as mouse liver and breast tissues were analysed by immunoblot 
using anti-ERK5 and anti-Tubulin antibodies: A, breast cancer cell lines (BT 20 to ZR 75-30) and 
ovary cancer cells (2774 to SkOv 8) and B, various human cell lines (HaCaT to HEK 293T), avian 
COS-7 and rodent PC 12, MEF and Rat-1 cells. 
As shown in Figure 25A and B the generated antibody readily detected a specific band 
migrating at approximately 112 kDa in SDS-PAGE. Albeit to different extents, ERK5 was 
expressed throughout in all cell lines tested. 
The detected levels of ERK5 were highest in several breast cancer lines and in rat 
phaeochromocytoma PC12 cells. Since the domains of ERK5, which were used as antigens, 3 Results     69 
are highly conserved among mammals, not surprisingly, rat and murine othologues of ERK5 
were detectable in three tested rodent cell lines. Contrary to murine breast tissue, ERK5 
expression was lowest and hardly detectable in liver. In agreement with earlier reports that 
implicated ERK5 in tumourigensis of breast cancer significant amounts of protein were found 
in 19 breast cancer cell lines as displayed in Figure 25A. One line of research suggested that 
ERK5 might mediate mitogenic signalling from neuregulin-activated HER2/HER3 receptors 
(Esparis-Ogando et al., 2002), others obtained evidence for the involvement of ERK5 in the 
onset of resistance to the chemotherapeutic drug doxorubicin (Weldon et al., 2002). 
 
Figure 26: Immunofluorescence analysis of ERK5 subcellular localisation in Swiss 3T3 
fibroblasts. Cells were fixed with paraformaldehyde, permeabilised with Triton-X100 and 
incubated with either anti-ERK5 or the corresponding preimmune serum (B and D, respectively). 
DNA counterstain of same sections of cells is shown in A and C, respectively. 
Localisation of ERK5 was determined by immunofluorescence analysis. Due to their flat and 
stretched out shape fibroblasts are commonly used cells for these studies. Permeabilised Swiss 
3T3 cells were stained with anti-ERK5 antibodies and the corresponding preimmune serum as 
control. As shown in Figure 26B specific staining for ERK5 was found in cytosol and nucleus, 
the latter being marked by its DNA stain (Fig. 26A). In particular perinuclear regions were 
strongly stained. Strikingly, most nuclear ERK5 resided in discrete spots, between 2 and 12 in 
number per nuclei. This could indicate that ERK5 might be concentrated in distinct 
subnuclear compartments. The best characterised nuclear bodies namely the nucleoli, 
however, can be excluded for two reasons: First, the number of observed spots exceeds the 
usual number of nucleoli and secondly, ERK5 does not colocalise with points of strongest 
chromatide stain. Nuclear ERK5 was also found in COS-7 and A431 cells (Fig. 14 and data 
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3.3.2  Activation of ERK5 
 
In order to study the activation of ERK5 transfected COS-7 cells were treated with different 
agonists and exogenous HA-tagged ERK5 was immunprecipitated. Its capability to 
autophosphorylate in immuno complex kinase assays was used as measure for the degree of 
its activation. Figure 27A shows that osmotic as well as oxidative stress (imposed onto cells 
by addition of 0.4 M Sorbitol and 200 µM H2O2, respectively) enhanced ERK5 activity. 
Mitogenic stimuli like EGF and fetal calf serum were also able to activate ERK5. 
 
 
Figure 27: Activation of ERK5. A, transfected COS-7 cells expressing HA-tagged ERK5 were 
starved by serum deprivation over night and subsequently stimulated for 20 minutes as indicated. 
Autophosphorylation activity of anti-HA immunoprecipitates was monitored in a kinase assay 
(upper panel). Precipitated ERK5 was visualised by anti-HA immunoblot. B, COS-7 cells were 
either transfected with constructs for wild-type or mutant forms of HA-ERK5 alone or with Fc-
tagged HA-ERK5 in combination with wild-type or mutant MEK5. The mutants used were: AEF – 
not activatable, KM - kinase dead, AA – not activatable and DD - constitutively active. HA-ERK5 
and HA-ERK5-Fc were precipitated by anti-HA immunoprecipitation and by protein A sepharose 
pull down, respectively. The autophosphorylation activity of ERK5 was assessed as above (upper 
panel). The corresponding anti-HA immunoblot is shown in the middle panel. ERK2 activity was 
analysed by anti-Phospho-ERK2 immunoblot of crude cell lysates (bottom panel). 3 Results     71 
These results together with similar observations made by others (Abe et al., 1996; Kamakura 
et al., 1999; Kato et al., 1997) positions ERK5 between the mitogenic MAPKs ERK1 and 
ERK2 on one side and the stress-activated p38 and JNK subfamilies of MAPKs on the other 
side. 
Although most components involved in the signalling cascade that ultimately leads to the 
activation of ERK5 are unknown, MEK5 has clearly been shown to be the MAPK kinase 
directly upstream of ERK5 and to specifically phosphorylate and thereby activate ERK5 
(Kato et al., 1997; Lee et al., 1995). In order to interfere with the connection of MEK5 and 
ERK5 and to elucidate the importance of this pathway, mutants of both kinases were used. 
Since ERK5 is activated in analogy to other MAPKs by phosphorylation of threonine and 
tyrosine in its TEY activation motif, mutation of these two residues yielded the AEF mutant 
which cannot be activated.  
As shown in Figure 27 B in comparison to the wild-type form the activity of ERK5 AEF was 
strongly reduced to a level that most likely reflected the basal activity of the kinase. The KM 
mutant of ERK5 bearing an exchange of the catalytically invariant lysine involved in ATP 
binding to methionine was rendered completely inactive. Similar to MAPKs MEKs are also 
activated by two phosphorylations, in the case of MEK5 on serine and threonine. Mutation of 
these residues to negatively charged aspartic acids (DD) mimics the phosphorylated form and 
results in constitutive activity. On the other hand exchanging these amino acids to alanines 
(AA) consequently creates a not activatable mutant. When co-expressed with ERK5 only 
constitutively active MEK5 DD potently activated ERK5 (Fig. 27B). A C-terminally Fc-
tagged variant of ERK5 was used that allowed direct precipitation with protein A sepharose. 
The intriguing specificity of MEKs for only one or two MAPKs is a characteristic in MAPK 
signalling and is here exemplified since overexpression of neither form of MEK5 did 
influence the activity of ERK2, which is the closest homologue of ERK5 (Fig.27B, bottom 
panel). 
To extend the results obtained from ectopic expression experiments the activation pattern of 
ERK5 was further analysed in rat phaeochromocytoma PC12 cells and murine Swiss 3T3 
fibroblasts. Almost a decade ago amplitude and duration of MAPK activity were shown to be 
critical for the determination cell fate. In the very same cell, MAPKs can be involved in the 
control of different and even opposing functions. In these cases the profile of MAPK 
activation specifies signal identity (Marshall, 1995). In PC12 cells EGF as well as nerve 
growth factor (NGF) activate ERK2, however, cells proliferate in response to the first 
stimulus and differentiate in the presence of the latter (Cowley et al., 1994; Traverse et al., 3 Results     72 
1994). These distinct responses were attributed to the ability of NGF but not EGF to cause a 
sustained activation of MAPK. 
 
 
Figure 28: ERK5 activation in PC 12 and Swiss 3T3 cells. A and B, cells were starved over night 
by serum withdrawal and stimulated as indicated. Swiss 3T3 cells were stimulated for 15 minutes. 
Anti-ERK5 immunoprecipitates (IP) were analysed by anti-Phospho-ERK5 (P-ERK5) and anti-
ERK5 immunoblot. Activation of ERK2 was assessed by anti-Phospho-ERK2 (P-ERK2) 
immunoblot of crude cell lysates (CL).  
Here, the activation of ERK5 and ERK2 in PC12 cells was analysed by Western blot again 
using the phosphorylation state-specific antibodies that exclusively detect the activated forms. 
ERK5 was activated by NGF and EGF and to a lower extent by FGF and Insulin. Activation 
was transient and strongly reduced but still detectable after 4 hours (Fig. 28A). 
Phosphorylation correlated with the mobility shift of a small fraction of ERK5. These shifts 
had been widely used as measure for MAPK activation before phosphorylation state-specific 
antibodies became commercially available. The ratio between shifted and unshifted ERK5 
indicates that only a minor fraction of all ERK5 was activated. Interestingly, an additional 
faint band of a faster migrating variant of ERK5 was also detected by anti-Phospho-ERK5 
immunoblot but was not resolved in the reblot below (Fig. 28A, top and middle panel). The 
pattern of ERK2 activation as shown in the bottom panel resembled the one of ERK5. 
Contrary in Swiss 3T3 cells, ERK5 was activated and almost completely shifted upon 
stimulation with various agents ranging from growth factors to osmotic stress (Fig. 28B). 
Further comparison of ERK2 and ERK5 revealed differential activation in that ERK2 but not 
ERK5 was potently activated by lysophosphatidic acid (LPA) and vice versa upon sorbitol 
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To answer the question whether the observed shift of ERK5 is indeed exclusively caused by 
phosphorylations, calf intestine alkaline phosphatase (CIAP) was used to quantitatively 
remove any phosphoryl group. About one half of all ERK5 was shifted when 
immunoprecipitated from exponentially growing COS-7 cells. 
 
 
Figure 29: Phosphorylation induced mobility shift of ERK5. ERK5 was immunoprecipitated 
(IP) from COS-7 cell lysates and treated with calf intestine alkaline phosphatase (CIAP) to 
quantitatively remove phosphorylations. An anti-ERK5 immunoblot is shown. 
Treatment with CIAP resulted in the disappearance of the upper band and condensed the total 
ERK5 protein to an entity migrating as a single band. The observed shift of ERK5 is thus in 
fact solely caused by phosphorylations. However, it still remains possible that other 
phosphorylation events beside the activating modifications of the TEY motif might occur and 
contribute to the mobility shift of ERK5. 
 
3.3.3  Modulators of ERK5 Activation 
 
Various studies have shown that cellular responses to LPA and other ligands of G-protein 
coupled receptors (GPCRs) require the function of the EGF receptor (EGFR) in several cell 
systems (Daub et al., 1997; Luttrell et al., 1999; Marinissen and Gutkind, 2001). Further it 
was shown that this phenomenon termed EGFR signal transactivation involves the shedding 
of membrane bound EGFR ligand precursors by metalloproteinases (Prenzel et al., 1999), 
which can be blocked by the hydroxamic acid derivative batimastat (BB94). Depending on 
the cellular context different members of the metalloprotease-disintegrin (ADAM) family are 
responsible for EGFR transactivation (Geschwind and Hart, personal communication). 
Thereby, EGFR has been shown to be an integral component of the pathway linking GPCR 
activation to the MAPKs ERK1 and ERK2 (Gschwind et al., 2002; Zwick et al., 1997). 
In order to test whether ERK5 is also activated by GPCR ligands in an EGFR-dependent 
manner, transfected and serum deprived COS-7 cells were treated with thrombin and LPA. 
Both GPCR ligands as well as the control stimulus EGF potently activated ERK5 as again 
monitored by its capacity to autophosphorylate in a kinase assay (Fig. 30A). 3 Results     74 
 
Figure 30: EGFR mediates ERK5 activation by GPCR ligands. 16 hours after serum 
withdrawal, transfected COS-7 cells were stimulated with Thrombin and LPA for 15 minutes or 
EGF for 5 minutes. Cells were preincubated with 250 nM of EGF Receptor inhibitor AG1478 (A) 
or 10 µM Batimastat (B) for 30 minutes. Autophosphorylation activity of HA-ERK5 was assessed 
in anti-HA immuno complex kinase assays (upper panels). Lower panels show the corresponding 
anti-HA immunoblots. 
Pre-treatment of cells with the specific EGFR receptor inhibitor AG1478 blocked activation 
of ERK5 by either ligand. Most notably, the activity of ERK5 in unstimulated control cells 
was slightly enhanced upon addition of AG1478 which might comprise a stress stimulus itself 
under these conditions. Alternatively, this result might indicate that negative pathways that 
render ERK5 inactive, are controlled by basal EGFR activity. The involvement of 
transactivational events in ERK5 activation by LPA and Thrombin was further exemplified 
using the metalloprotease blocker batimastat, which impaired ERK5 activation by both GPCR 
ligands but not by EGF (Fig. 30B). 
 
 
Figure 31: PKC inhibits ERK5. Swiss 3T3 cells were serum starved over night, preincubated 
with 1 µM of the phorbolester TPA for 5 minutes (‘) and up to 16 hours as indicated and then 
stimulated with 20 ng/ml EGF for 5 minutes. Alternatively, unstarved cells were treated with the 
PKC inhibitor GF-109203X for 30 minutes. ERK5 immunoprecipitates were analysed by anti-
Phospho-ERK5 (P-ERK5) and anti-ERK5 immunoblot (top and bottom panels, respectively). 3 Results     75 
In the search for effectors of ERK5 various commercially available inhibitors were screened 
for their ability to interfere with the activation of ERK5 (not shown). Treatment of unstarved 
Swiss 3T3 fibroblasts with the GF109203X inhibitor of the protein kinase C (PKC) family of 
kinases resulted in the induction of ERK5 activity. As shown in Figure 31 activation of PKC 
by addition of the phorbol ester TPA completely counteracted activation of ERK5 by EGF. 
Addition of PKC inhibitor to unstarved cells induced ERK5 activity. In line with these 
observations it was shown that ERK5 was activated by granulocyte colony-stimulating factor 
in murine BAF-3 cells and that this activation was also inhibited by TPA and reinforced by 
co-administration of PKC inhibitor, while ERK2 activation was not affected (Dong et al., 
2001). These results indicate that members of the PKC family are involved in the negative 
regulation of ERK5. 
 
3.3.4  The C-Terminus of ERK5 determines Kinase Activity and 
Localisation 
 
The most pronounced difference between ERK5 and other members of the MAPK family is 
certainly its unique C-terminal tail. Two proline-rich domains are the only striking features 
within this 400 amino acid long extension. To gain some information on its function, various 
C-terminally truncated mutants were created. Numbers given in Figure 32 indicate the last 
amino acids of each shortened ERK5 variant. The shortest 409 form reduces ERK5 to its 
MAPK domain which shares high homology with ERK1 and ERK2. All mutants were readily 
detected in crude lysates of transfected COS-7 cells by Western blot using antibodies directed 
against an N-terminal hemagglutinin (HA) tag (Fig. 32A). Performance of in vitro kinase 
assays revealed that each truncated mutant was at least 6-fold more active than the wild-type 
form (Fig. 32B). Removal of the last 100 amino acids was sufficient to potentiate ERK5 
activity. Likewise, it was reported elsewhere that dominant active RasV12 more potently 
activated a mutant lacking the C-terminal 400 amino acids than full-length ERK5 (English et 
al., 1998). 
Taken together this leads to the hypothesis that the tail of ERK5 might have an autoinhibitory 
domain. Since the C-terminal tail contains several consensus phosphorylation sites for 
MAPKs and since ERK5 was shown to autophosphorylate, the incorporation of negatively 
charged phosphoryl groups into C-terminal domains might be a trigger for conformational 
changes and subsequent release of autoinhibition. However, validation of this hypothesis will 
require a more detailed analysis of kinetics underlying kinase activation. Elucidation of the 3 Results     76 
ERK5 crystal structure will be of great value in order to clarify the exact role of the C-
terminal tail in ERK5 kinase action. 
 
 
Figure 32: Autoinhibition of ERK5 by its C-terminus. COS-7 cells were transfected with 
contsructs for HA-tagged ERK5 and different truncated mutants (numbers refer to the last amino 
acid).  A, expression is shown by anti-HA immunoblot of crude cell lysates. B, anti-HA 
immunoprecipitates were subjected to kinase assays and autophosphorylation activity was 
assessed. Data represents normalised relative activity ± SD. C, schematic presentation of ERK5 
with indicated points of truncation: I and II, proline rich domains. 
MAPK substrates are located in the cytoplasm as well as in the nucleus. The translocation of 
MAPKs to the nucleus is a requirement for the phosphorylation of many transcription factors 
and thus the regulation of transcription (Karin and Hunter, 1995; Whitmarsh and Davis, 
2000). 
Having shown that ERK5 indeed resides in both major cellular compartments, cytosol and 
nucleus, the truncated mutants were used to address the question whether the C-terminus does 
contribute to the subcellular localisation of ERK5. Transfected COS-7 cells were analysed by 
immunofluorescence using the HA-tag as epitope. Localisation of ectopic wild-type ERK5 
was predominantly cytosolic as shown in Figure 33A. 3 Results     77 
 
Figure 33: The C-terminus of ERK5 regulates nuclear localisation. COS-7 cells were 
transfected with wild-type ERK5 or different deletion mutants. 24 hours after gene transfer cells 
were fixed with methanol and incubated with anti-HA antibodies (A, C, E, G and I). Right panels 
show the DNA counterstain of the same sections. 3 Results     78 
In contrast the 713 mutant that lacked only the last 100 amino acid was primarily found in the 
nucleus. While similar results were obtained for the 575 mutant, further truncation led to a 
distribution that strongly resembled the wild-type form. Among the plethora of possibilities 
the easiest explanation would be the following: Localisation of ERK5 mutants is determined 
by active import and export sequences within the C-terminus and removal of one or the other 
directly affects the equilibrium of ERK5 shuttling in and out the nucleus. The recent 
identification of a putative nuclear localisation in the linker between the two proline rich 
domains provides some evidence to the credibility of this hypothesis (Yan et al., 2001). 
The C-terminus of ERK5 is an unique feature among MAPKs and has been the fundament for 
the classification of ERK5 as a fourth and self-contained MAPK subgroup besides the 
families of JNK, p38 and ERK2. Future studies unravelling the unknown functions of this tail 
can be expected to largely contribute to the understanding of the very particular role of ERK5 
in cellular signalling. 4 Discussion 
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4 DISCUSSION 
 
MAPKs are crucial elements in the process converting extracellular signals into distinct 
transcriptional changes. Although virtually all kinds of extracellular stimuli lead to the 
activation MAPKs they evoke very distinct cellular responses. The activation profile of 
MAPKs and the pattern created by the activation of a certain subset of MAPK family 
members critically determine signal identity and ultimately cell fate. Therefore, understanding 
the mechanisms of MAPK regulation will elucidate some fundamental aspects of how cells 
are able to adapt to a constantly changing environment. 
The role and the regulation of ERK5 were studied in various cellular systems and diverse 
contexts. The study highlights two mechanisms of ERK5 regulation: control of activation loop 
phosphorylation and regulated protein stability. Phosphotyrosine-specific phosphatases 
(PTPs) and Abl kinases were shown to interact with and consequently to modify the activity 
of ERK5. On one hand so called KIM containing PTPs were demonstrated to be involved in 
the negative regulation of ERK5. The non-receptor tyrosine kinase Abl on the other hand and 
in particular its oncogenic forms activated and stabilised ERK5 which contributed to 
transformation and leukaemia cell survival. 
 
4.1  Aspects of ERK5 Expression, Activation and Localisation 
 
For along time MAPKs were divided into three subfamilies, ERKs, JNKs and p38 kinases. 
The cloning of ERK5 in 1995 gave rise for the introduction of a fourth MAPK subgroup. In 
contrast to the other three types of MAPKs, orthologues of ERK5 do not exist in yeast, the 
nematode Caenerohabditis elegans or Drosophila melanogaster. From the evolutionary point 
of view ERK5 is thus a younger gene product. ERK5 comprises two major domains of 
comparable size: a MAPK domain sharing high similarity with full-length ERK2 and a unique 
C-terminal tail. In the following, the characteristics of ERK5 will be discussed in comparison 
to its closest homologue ERK2. 
ERK5 expression was detected in various and virtually all cell types tested. Similar to other 
MAPK ERK5 thus seems to be ubiquitously expressed. Notably, levels of ERK5 varied more 
strongly between different cell lines than those of ERK2. Though, the most striking 
differences between ERK5 and ERK2 lay in the profile and the dynamics of their activation. 
As indicated by shift and phosphorylation analysis, only a small fraction of all ERK5 was 
activated, whereas strong mitogens for instance EGF induce the activation of virtually all 4 Discussion 
 
80 
cellular ERK2. The low percentage of activated ERK5 might be the reason why many 
laboratories encountered problems in detecting active and phosphorylated species of ERK5 
(M. Burow and J. Barros, personal communication). Furhermore, activation of ERK5 is not 
only induced by mitogens but also by cellular stress such as high osmolarity and reactive 
oxygen species. This particular responsiveness to such different external stimuli positions 
ERK5 between the mitogen-activated ERK family and the stress-activated JNK and p38 
kinases. 
Finally, ERK5 was found to localise in the cytosol as well as in the nucleus. This was 
surprising because MAPKs are usually localised in the cytosol and thereby in the same 
compartment as the components of the activating cascade until they become activated and 
transiently translocate to the nucleus. In contrast, ERK5 resided in the nucleus even under 
unstimulated conditions. The identification of a putative nuclear localisation sequence in the 
C-terminal tail of ERK5 might account for its particular cellular distribution. The use of 
different C-terminally truncated mutants of ERK5 implied that its unique domains do not only 
regulate nuclear import but also the export albeit by an unknown mechanism.  
The C-terminal tail structurally distinguishes ERK5 from any other MAPK and was thus 
expected to account at least for some functional differences as well. Further results of study as 
well as observations reported elsewhere (English et al., 1999b) suggest that the C-terminal tail 
might be involved in kinase regulation by an autoinhibitory mechanism. Intramolecular 
binding of domains that lock a kinase in an inactive conformation is a common theme in 
kinase regulation and has most extensively been studied for the tyrosine kinase Src (Tatosyan 
and Mizenina, 2000). Whether the C-terminal tail of ERK5 is also responsible for the 
relatively low percentage of activated ERK5 proteins remains to be elucidated. 
In summary, ERK5 differs in its activation pattern and its subcellular localization from other 
MAPKs and can thus be expected to play a particular and at least partially autonomous role in 
cellular signalling. 
 
4.2  PTP-SL in the negative Regulation of ERK5 
 
ERK5 is one of the least examined members of the MAPK family. Similar to ERK1 and 
ERK2, dual phosphorylation of threonine and tyrosine residues in the kinase-activating motif 
TEY is crucial for ERK5 activation. Since in analogy to ERK1/2 dephosphorylation of either 
residue is potentially sufficient for inactivation of ERK5 (Canagarajah et al., 1997), the 4 Discussion 
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question was addressed whether protein tyrosine phosphatase PTP-SL might be involved in 
the regulation of the ERK5 pathway. 
PTP-SL did not only bind to ERK5 but also modulated kinase activity in vitro and in vivo. 
Overexpression of wild-type PTP-SL in PC12 and COS-7 cells reduced endogenous as well as 
exogenous ERK5 activity, whereas the catalytically inactive CS mutant of PTP-SL obviously 
enhanced kinase activity. The positive effect of the inactive phosphatase on kinase activity 
might be due to the competition between PTP-SL and endogenous phosphatases for ERK5 
binding sites which suggests that ERK5 might be under permanent control of phosphatases 
that presumably belong to the KIM-containing PTP family. 
Whereas inactivation of ERK5 by PTP-SL monitored in vitro is most probably simply due to 
the dephosphorylation of tyrosine 220 in the activating TEY motif (Lee et al., 1995; Zhou et 
al., 1995), the in vivo situation might be much more complex. PTP-SL is potentially able to 
affect the ERK5 pathway in several ways. Overexpression of wild-type as well as catalytically 
inactive PTP-SL, for instance, reduced the amount of ERK5 in the nucleus. Zuniga et al 
described a similar influence of PTP-SL on the localisation of ERK2 (Zuniga et al., 1999). 
Since translocation of MAPKs to the nucleus is essential in order to phosphorylate 
transcription factors that subsequently regulate gene activity (Karin and Hunter, 1995; 
Marshall, 1995), retention of ERK5 in the cytoplasm might reflect an additional mechanism 
by which PTP-SL can modulate the action of ERK5. 
A further consequence of the interaction of ERK5 with PTP-SL is the phosphorylation of the 
phosphatase. The fact that phosphorylation could be localised to the juxtamembrane domain 
of PTP-SL alludes to threonine 253 as modified amino acid in view of that it is also 
phosphorylated by ERK2. Not only PTP-SL but also other members of this PTP family were 
phosphorylated by both ERK2 (Pulido et al., 1998; Saxena et al., 1999a) and ERK5. Even 
though it has been shown that phosphorylation of a specific serine residue in the KIM of PTP-
SL and HePTP by PKA triggers the release of ERK2 (Blanco-Aparicio et al., 1999; Saxena et 
al., 1999b), it is unlikely that the observed phosphorylation of PTP-SL by ERK5 directly 
influences the binding properties between these two enzymes since no change in complex 
formation of purified PTP-SL and ERK5 protein was observed after in vitro phosphorylation 
(data not shown). Interestingly, phosphorylation of PTP-SL by ERK5 had only a minor 
influence on enzymatic activity; binding of the kinase to the phosphatase, however, enhanced 
phosphatase activity substantially. A similar effect was shown for the MAP kinase 
phosphatase (MKP) 3, a dual specificity phosphatase that is readily activated by formation of 
a stable complex with ERK2 (Camps et al., 1998). 4 Discussion 
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The effects on MAPK signalling exerted by MKPs and by KIM containing PTPs are generally 
considered to be temporarily and spatially distinct from each other (Keyse, 2000). Saxena and 
colleagues (Saxena and Mustelin, 2000) have proposed a ‘sequential phosphatase model’ in 
which KIM containing PTPs control MAPK activity during their initial cytosolic phase 
whereas, after translocation to the nucleus, termination of a sustained MAPK signal would be 
accomplished by MKPs. We found that PTP-SL does not only reduce ERK5 activity but also 
hampers its translocation to the nucleus. This result adds a new aspect to the regulation of 
MAPK by KIM-containing PTPs. 
Unlike ERK5 which was detected in tissues and cell lines of various origin and thus seems to 
be ubiquitously expressed (Abe et al., 1996; Cavanaugh et al., 2001; Dinev et al., 2001) PTP-
SL expression was shown to be restricted and predominantly found in brain and 
neuroendocrine cells (Augustine et al., 2000; Hendriks et al., 1995; Ogata et al., 1995; Sharma 
and Lombroso, 1995; Shiozuka et al., 1995). Since other members of the same PTP family 
such as HePTP (Zanke et al., 1992) show a similarly restricted expression pattern, it is 
conceivable that specificity of the ERK5 signal is further determined by different KIM 
containing PTPs in a cell type dependent manner. 
The direct control of MAPK activity by phosphatases is one of the most important regulatory 
mechanism in MAPK signalling. In analogy to other MAPK family members different types 
of phosphatases tightly regulate the activity of ERK5. The cytosolic KIM containing PTPs 
affect ERK5 not only by dephosphorylation but also by interfering with the nuclear 
translocation of ERK5. 
 
4.3  ERK5 and Abl Tyrosine Kinases 
 
4.3.1  Oncogenic Abl activates and stabilises ERK5 
 
The non-receptor tyrosine kinase (NRTK) c-Abl and its oncogenic forms were shown to 
interact with ERK5. This association resulted in the activation, tyrosine phosphorylation and 
stabilisation of ERK5. 
Abl kinases and in particular the Bcr/Abl fusion protein were known to activate multiple 
MAPK pathways. Bcr/Abl dimerises and autophosphorylates and thus mimics an activated 
receptor tyrosine kinase (RTK). Activation of the ERK1 and ERK2 occurs then in analogy to 
EGF receptor signalling by recruitment of adaptor proteins, Sos mediated activation of Ras 4 Discussion 
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and subsequently Raf activation. Raf is the first kinase in the three-tethered MAPK cascade 
and thus consequently leads to the activation of ERK1 and ERK2.  
As shown in this work and by others many RTKs also activate ERK5 (Buschbeck et al., 2002; 
Dong et al., 2001; Kamakura et al., 1999; Karihaloo et al., 2000; Kato et al., 1998). Although 
some of the components of the pathway activating MEK5 and consequently ERK5 are not 
known, the whole mechanism is presumably similar to the one described for ERK1 and 
ERK2. Thus Bcr/Abl also most likely activates ERK5 by its ‘RTK mimicry’ via the MAPK 
cascade containing MEK5 (illustrated in Fig. 34). 
 
 
Figure 34: Abl kinases regulate ERK5 by activation and stabilisation. Activation of ERK5 by 
c-Abl or its oncogenic variants most likely occurs in analogy to receptor tyrosine kinase signalling 
via adaptor proteins, Ras and the MAPK cascade. Stabilisation on the other hand does not involve 
the MAPK cascade and thus represents an alternative way of regulation. TK, tyrosine kinase 
domain; X stands for the variable N-terminal domains of various Abl kinases e.g. Bcr portion. 
Moreover, the ERK5 protein was shown to be stabilised by Abl kinases. Stabilisation was 
dependent on the kinase activity of Abl and could be blocked by the addition of the specific 
inhibitor Imatinib. Overexpression of c-Abl or any oncogenic variant of the kinase potently 
raised the level of ERK5. Abl kinases do thus not only regulate ERK5 by MAPK cascade 
mediated activation but also by stabilisation of the protein itself. Both mechanisms were 
independent of each other as shown by using mutants that were uncoupled from MEK5 
mediated activation but still readily stabilised. 
Protein domain mapping pointed to the proline rich domain I within the C-terminal tail of 
ERK5. by The identification of a putative Abl SH3 domain binding site within the proline rich 4 Discussion 
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domain I of ERK5 with the Scansite algorithm (Yaffe et al., 2001) supported this result. 
Together these observations lead to the hypothesis that the C-terminal tail of ERK5 might be 
able to modulate kinase action by binding the SH3 domain of Abl which would subsequently 
stabilise the ERK5 protein. 
The MEK5-independence of this mechanism is particularly interesting since stabilisation of 
ERK5 could still occur in compartments where ERK5 is separated from its activating kinase 
cascade. ERK5 shuttles in and out the nucleus, whereas MEK5 is exclusively cytosolic. In the 
nucleus Abl-mediated stabilisation of ERK5 could still occur and hence comprise an 
important parameter in ERK5 regulation. 
Taken together, Abl kinases regulate ERK5 by at least two independent mechanism: first, 
activation via MEK5 dependent phosphorylation and second, by stabilisation of the ERK5 
protein. 
Analysis of ERK5 in Bcr/Abl expressing leukaemia cells indicated that basal activity but not 
MEK5 dependent activation is crucial for cell survival. MAPKs are involved in a multitude of 
cellular responses elicited by a broad variety of external stimuli. The amplitude and duration 
of MAPK activation determine signal identity and ultimately cell fate (Marshall, 1995). While 
strong stimuli such as mitogens are inducing a pulse of MAPK activity, stabilisation of the 
MAPK protein should be reflected by a persisting activation profile of low amplitude. 
Contrary to many cellular signalling pathways which are transiently switched on by diverse 
stimuli, survival pathways should be constitutively active in order to attain their anticipated 
function. Since basal kinase activity of ERK5 seems to be sufficient for cell survival, 
stabilisation and destabilisation of the ERK5 protein could represent a way of regulation. The 
recent observation that ERK2 degradation but not its inactivation by phosphatases is a 
prerequisite for sorbitol-induced apoptosis in fibroblasts (Lu et al., 2002) again substantiates 
the importance of regulating MAPK protein levels in the control of cell survival. 
 
4.3.2 Tyrosine  Phosphorylation  and a potential Mechanism of ERK5 
Stabilisation 
 
The mechanism underlying the stabilisation of ERK5 by Abl remains largely elusive. Since 
stabilisation is dependent on the integrity of the Abl kinase domain, tyrosine phosphorylation 
is most presumably involved one way or the other. ERK5 itself was found to be tyrosine 
phosphorylated in Bcr/Abl positive leukaemia cells as well as in cells overexpressing any 4 Discussion 
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other Abl kinase. Whether the phosphorylation of ERK5 contributes to its stabilisation is not 
known. Mapping and mutation of phosphorylation sites will help to answer this question. 
Most cytosolic proteins are ubiquitinoylated by specific E3 ligases and subsequently degraded 
by the proteasome, a huge multiprotein complex. How could the addition of a phosphoryl 
group to a tyrosine residue interfere with this machinery? It is conceivable that such a 
chemical modification might hinder the binding of specific E3 ligases to their substrate. For 
instance, the immediate early gene product c-Fos has been shown to be indeed stabilised by 
phosphorylation (Chen et al., 1996; Okazaki and Sagata, 1995).  
ERK5 contains seven tyrosine residues with reasonable phosphorylation probability according 
to the program Netphos (Blom et al., 1999). The phosphorylation of any of these sites of 
which all are located in the MAPK part and none in the C-terminal tail, could somehow 
influence protein stability. At least one of these seven tyrosine residues, namely the one in the 
activation motif, can be excluded from further analysis since the corresponding mutant was 
readily stabilised. Noteworthy, one of the remaining six tyrosine residues is located in the so-
called MAPK docking motif. This motif is conserved among MAPKs from yeast to man and 
was shown to mediate the binding of ERK2 to regulators including phosphatases and the E3 
ubiquitin ligase MEKK1 (Lu et al., 2002; Tanoue et al., 2000; Tarrega et al., 2002). This 
motif is also present in ERK5 and could mediate the interaction of ERK5 to a protein of the 
degradation machinery. If so, phosphorylation of the tyrosine within the docking motif might 
disrupt or at least hamper such an interaction and could thus contribute to a prolonged half-
life of ERK5. 
C-terminal domains of ERK5 in particular the proline rich domain I were shown to be 
important determinants for protein stabilisation. Deleting the complete C-terminal tail of 
ERK5 strongly reduced Abl mediated stabilisation but did not abolish it completely. 
Likewise, ERK2 not having any comparable C-terminal domains was stabilised to a weak 
extent that could be amplified by the addition of ERK5’s tail. These observations lead to the 
speculation that although the C-terminal tail of ERK5 seems to mediate the interaction to Abl 
kinases, the resulting phosphorylation of one or more tyrosine residues within the MAPK 
domain might be required for stabilisation. 
 
4.3.3  Functional consequences of interacting ERK5 and c-Abl 
 
Although the involvement of ERK5 in signalling by oncogenic v-Abl as well as Bcr/Abl has 
been illustrated, the question what role a potential interaction of ERK5 and cellular c-Abl 4 Discussion 
 
86 
might have in untransformed cells remains unkown. c-Abl is spacially and functionally 
divided in a cytosolic and a nuclear fraction. The best characterised function of nuclear c-Abl 
lies within the pathway inducing cell cycle arrest if DNA is severely damaged by ionising 
radiation or ultraviolet light (Shaul, 2000; Van Etten, 1999). In this context c-Abl was shown 
to be activated and to stabilise the gatekeeper gene product p73 which in turn induces cell 
cycle arrest or even apoptosis (Agami et al., 1999; Costanzo et al., 2002; Gong et al., 1999). 
Two characteristics of ERK5 point to putative involvement in c-Abl signalling. First, a 
considerable fraction of ERK5 resides in the nucleus. Second, ERK5 was shown to be 
activated in various stress situations and might thus could be sensitive to ionising radiation as 
well. 
Most notably, p73 was recently shown to be phosphorylated on threonines adjacent to 
prolines which is the characteristic for MAPK phosphorylation consensus sites. This 
modification was clearly dependent on c-Abl and contributed to the stabilisation of p73 
(Sanchez-Prieto et al., 2002). This phosphorylation has been attributed to p38 kinases and 
thus indicates that members of the MAPK family can indeed contribute to the regulation of 
p73. Future studies will have to show whether and how the interaction of ERK5 and c-Abl 
might contribute to the pathway linking DNA damage to the cell cycle machinery. 
It is a long known fact that c-Abl has a DNA binding domain (Van Etten, 1999) and more 
recently the C-terminus of ERK5 was postulated to possess a transcriptional activation 
domain (Kasler et al., 2000). Whether a complex of both proteins could directly influence 
transcriptional processes remains speculative. 
Similar to the non-receptor tyrosine kinase Src, the c-Abl kinase is rendered inactive by 
autoinhibition based on intramolecular binding of domains that lock the kinase in an inactive 
conformation. In the case of Src this mechanism involves the binding of a C-terminal 
phosphotyrosine residue to the SH2 domain (Tatosyan and Mizenina, 2000). In contrast Abl 
kinase activity is largely independent of its phosphorylation state but seems to be blocked by 
binding of the N-terminal stretch of 81 amino acids to several regions ‘across’ the molecule 
(Pluk et al., 2002). Since ERK5 most likely binds to the SH3 domain adjacent to this N-
terminal cap, it might affect Abl activity by interfering with its autoinhibition. The product of 
the ataxia-telangiectasia-mutated gene Atm potently activates c-Abl and was shown to bind 
the SH3 domain (Shafman et al., 1997). However, Pag/Msp23 was also shown to bind to the 
SH3 domain of Abl but to exert an inhibitory influence on Abl kinase activity (Wen and Van 
Etten, 1997).  4 Discussion 
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Although it is clear that Abl could affect ERK5 signalling in several ways, whether ERK5 
may conversely influence Abl activity remains to be investigated. 
 
4.4  MAPKs as potential Intervention Points in Cancer Therapy 
 
Most anti-tumour agents despite having diverse mechanisms of action, ultimately mediate 
their effects by inducing apoptosis of tumour cells. The commitment of a cell to apoptosis or 
the ability to evade apoptosis after any kind of damage involves the integration of survival 
and death pathways. Under normal conditions survival signals are dominant over pro-
apoptotic signals and sustain cells, keeping the death machinery at bay. It is well established 
that cell death can be triggered by two different mechanisms, either rapidly by activation of 
strong pro-apoptotic pathways e.g. those downstream of death receptors, or relatively slow by 
suppressing survival pathways. Therefore, dual therapy activating both mechanisms can be 
considered to be the most promising approach to the treatment of cancer. Efficacy of many 
chemotherapeutics that should actively induce apoptosis is severely reduced by primary 
resistance or the onset of de novo resistance to the drug. Particular in these cases 
combinational therapies additionally targeting survival pathways might proof to be powerful 
tools in preventing cancer progression caused by expansion of resistant clones. 
One major survival signal is mediated by MAPKs ERK1 and ERK2 which are involved in 
transcriptional regulation of pro-survival factors (Ballif and Blenis, 2001; Fan and Chambers, 
2001). Chemical compounds that interfere with the pathway leading to the activation of these 
MAPKs may have potential as chemotherapeutics themselves or as resensitising agents. 
Various inhibitors targeting different components of this signalling cascade are currently 
tested. They include for instance farnesyltransferase inhibitors blocking the formation active 
Ras and the Hsp90 inhibitor geldanamycin that destabilises the MAPKKK Raf. In leukaemia 
cells MEK1 inhibitors such as PD98059 and U0126 were shown to synergistically enhance 
the induction of apoptosis by Abl kinase inhibitor Imatinib (Yu et al., 2002). Noteworthy, the 
same inhibitors also – but less effectively – inhibited the MEK5-ERK5 pathway (Mody et al., 
2001). This finding was the first hint that research on MAPK mediated survival has to be 
extended to ERK5. 
The here reported correlation of ERK5 protein levels with leukaemia cell survival is one but 
not the only indication for an involvement of ERK5 in pro-survival signals. In neurons ERK5 
was shown to mediate retrograde signals from axons to the cell body that also lead to cell 
survival (Watson et al., 2001). Further attention was drawn to ERK5 signalling by the analysis 4 Discussion 
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of differential expression patterns in doxorubicin resistant and sensitive MCF-7 breast cancer 
cells. The anthracycline doxorubicin is a widely used chemotherapeutic whose potency in 
apoptosis induction is mainly attributed to its inhibition of topoisomerase II (Fan and 
Chambers, 2001). Weldon and colleagues showed that mRNA levels of MEK5 were strongly 
increased in resistant and thus surviving cells (Weldon et al., 2002). This observation implies 
that the activation of ERK5 by MEK5 is important for the survival of doxorubicin-treated 
MCF-7 cells. In contrast, survival of Imatinib-treated leukaemia cells was at least in part 
MEK5 independent but clearly required the intrinsic basal activity of ERK5. Nonetheless, 
these results establish a role for ERK5 in pro-survival signalling.  
How could the knowledge about ERK5 signalling be applied in the context of cancer? In 
order to enhance the efficiency of Imatinib in the treatment of Bcr/Abl expressing leukaemia, 
inhibition of the ERK5 survival pathway could provide a potential way of chemotherapeutic 
intervention. Since ERK5 mediated survival is at least to some extent MEK5 independent, an 
effective therapeutic agent should directly impede ERK5 kinase activity rather than just 
interfere with the activating upstream kinase cascade like currently available compounds. 
The inhibition of survival pathways mediated by MAPKs or other signalling molecules is 
considered as a modality in cancer therapy in general. ERK5 and its stabilisation by Bcr/Abl 
contribute the survival of leukaemia cells and should therefore be considered as an additional 
aspect in the therapy of chronic myeloid leukaemia.  
 
 
4.5  ERK5 is a convergence point of Signal Transduction Pathways 
 
MAPKs are generally considered to be points of convergence and integration of multiple 
incoming signals. The resulting activation profile of MAPKs as well as the activated subset of 
MAPKs will determine the cellular response. Not surprisingly, many different signalling 
pathways thus also affect the action of ERK5. As shown in this study and elsewhere various 
stimuli ranging from growth factors to cellular stress activate the kinase cascade leading to 
ERK5 (Kamakura et al., 1999; Karihaloo et al., 2000; Kato et al., 1998; Watson et al., 2001). 
Although many components of the pathway that link activated receptors to ERK5 are not 
known, the dual phosphorylation dependent activation of ERK5 is exclusively attributed to 
MEK5. The remarkable specificity of MEKs for only one or two particular MAPKs is a 
hallmark in MAPK signalling. So far the two MAPKKKs MEKK2 and MEKK3 were shown 
to be able to activate MEK5 in a context dependent manner (Chao et al., 1999; Garrington et 4 Discussion 
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al., 2000). The alternate use of different MAPKKKs might couple the MEK5-ERK5 module 
to various activated receptors. Similar to JNKs and p38 kinases ERK5 is also activated by 
oxidative stress and hyperosmolarity (Abe et al., 1997). How these environmental stresses 
feed into the MAPK cascade is not clear. Since the activity of many kinases depends on their 
phosphorylation state inhibition of phosphatases by oxidation of their catalytical cystein is 
one possible mechanism for oxidative stress-induced MAPK activation. The molecular basis 
of osmolarity sensing is completely unknown. Moreover, this study shows that in addition to 
extracellular stimuli also the products of oncogenes evoke the activation of ERK5. 
Characterising the interaction of oncogenic Abl variants with ERK5 further revealed that 
ERK5 signalling can be modulated in more ways than just by MAPK cascade mediated 
activation. Protein stability for instance is an additional regulatory parameter and might be 
particularly important in survival pathways that do not require ERK5 activation but depend on 
its basal activity. 
 
 
Figure 35: Multiple pathways affect ERK5 signalling. Growth factors and stress activate the 
MAPK cascade leading to ERK5 activation. PTP-SL inactivates ERK5 and interferes with its 
subcellular localisation. PKA and PKC indirectly affect ERK5 in several ways. Abl kinases feed 
into MAPK cascade dependent activation but also directly interact with ERK5 resulting in its 
stabilisation. Full lines indicate direct protein-protein interaction, dotted lines indicate indirect 
effects. 4 Discussion 
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The finding that PTP-SL does not only dephosphorylate and inactivate ERK5 but also 
interferes with its translocation to the nucleus further exemplifies the multifaceted character 
of ERK5 regulation. To add to the complexity protein kinase A (PKA) was shown to 
phosphorylate PTP-SL and other members of its family on their kinase interacting motif and 
thereby to release MAPK from PTP dependent constraints (Blanco-Aparicio et al., 1999; 
Saxena et al., 1999b). Thus, PKA could indirectly contribute to ERK5 activity. Members of 
the protein kinase C (PKC) family were also implicated in the regulation of ERK5, their role, 
however, is rather ambivalent. On one hand, atypical PKC isoforms were shown to interact 
with MEK5 and to be sufficient for its activation (Diaz-Meco and Moscat, 2001). On the other 
hand as shown here and reported elsewhere (Dong et al., 2001) activation of PKC by 
phorbolesters inhibited ERK5 activation. 
In summary, a large and still increasing number of pathways influence the ERK5 signalling 
pathway. The activation profile but also the localisation and the stability of ERK5 result from 
the integration of all these converging signals and ultimately determine the contribution of 
ERK5 to the cellular response. 
 
4.6 Perspectives 
 
Expression of ERK5 has been found in virtually all kinds of cells and ERK5 signalling has by 
now been implicated in a large – and with ongoing research increasing – number of cellular 
functions. ERK5 is shown in this study to be involved in the survival of Bcr/Abl expressing 
leukaemia cells treated with Imatinib. This raises the question whether the function of ERK5 
in cell survival is restricted to this specific cellular context or whether it occurs in other 
cellular systems as well. Since research of two other groups focusing on neurons and breast 
cancer cells also attributed survival functions to ERK5 (Watson et al., 2001; Weldon et al., 
2002), a rather general role for ERK5 in cell maintenance can be anticipated. Thus, it might 
be worthwhile to evaluate the potential of ERK5 inhibition as supportive element in the 
therapy of other kinds of cancer besides chronic myeloid leukaemia. 
There is an increasing body of evidence that ERK5 is rather involved in developmental 
processes and cell differentiation than the regulation of proliferation as supposed previously. 
While an early report implied a function of ERK5 in cell cycle progression (Kato et al., 1998), 
the major part of current research points to a role for ERK5 in processes like cell 
specialization and differentiation. For example in C2C12 myoblasts ERK5 was shown to be 
essential for differentiation and myotube formation (Dinev et al., 2001). The importance of 4 Discussion 
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ERK5 in development is manifestated by the embryonically lethal phenotype of ERK5 
deficient mice. ERK5-/- embryos die between day E9.5 and E11.5 with angiogenic failure and 
severe cardiovascular defects (Regan et al., 2002; Sohn et al., 2002). This suggests an 
important role for ERK5 in the regulation of early angiogenesis. Further in vivo research 
applying conditional knock-out models or transgenic animals with inducible ERK5 expression 
will allow us to study the role of ERK5 in organogenesis and in later developmental stages. 
Analysis of ERK5 in leukaemia cells revealed that rather the protein level of ERK5 combined 
with its basal activity than its activation by MEK5 are critical parameters in mediating cell 
survival. The question to what extent MAPK cascade-mediated activation of ERK5 on one 
hand and its protein level on the other contribute to its more complex functions provides 
future research with an interesting aspect. 
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5. SUMMARY 
 
Mitogen activated protein kinases (MAPKs) are found in all eukaryotic cells and represent 
crucial elements in the signal transduction from the plasma membrane to the nucleus. 
Although a broad variety of extracellular stimuli activate MAPKs, they evoke very distinct 
cellular responses. The amplitude and duration of MAPK activation determine signal identity 
and ultimately cell fate. A tight and finely tuned regulation is therefore critical for a specific 
cellular response. 
The role and the regulation of extracellular signal-regulated kinase 5 (ERK5), a MAPK with a 
large and unique C-terminal tail, were studied in different cellular systems. The study 
highlights two aspects of ERK5 regulation: control of the phosphorylation state and regulated 
protein stability. 
In analogy to other MAPKs ERK5 is activated by dual phosphorylation of threonine and 
tyrosine residues in its activation motif. A first part of the study concentrates on whether and 
how the protein tyrosine phosphatase PTP-SL is involved in the downregulation of the ERK5 
signal. The direct interaction of both proteins is shown to result in mutual modulation of their 
enzymatic activities. PTP-SL is a substrate of ERK5 and, independent of its phosphorylation, 
binding to the kinase enhances its catalytic phosphatase activity. On the other hand, 
interaction with PTP-SL does not only downregulate enzymatic ERK5 activity but also 
effectively impedes its translocation to the nucleus. 
The second part of this study focuses on the interaction of ERK5 with c-Abl and its oncogenic 
variants Bcr/Abl and v-Abl. In this study these tyrosine kinases are demonstrated to regulate 
ERK5 by two mechanisms: first, by induction of kinase activity and secondly, by stabilisation 
of the ERK5 protein. Stabilisation involves the direct interaction of unique ERK5 domains 
with Abl kinases and is independent of MAPK cascade activation. The level of ERK5 and its 
intrinsic basal activity – rather than its activation – are essential for v-Abl-induced 
transformation as well as for survival of Bcr/Abl-positive leukaemia cells. Stabilisation of 
ERK5 thus contributes to cell survival and should therefore be considered as an additional 
aspect in therapy of chronic myeloid leukaemia. 
Taken together, the results obtained in this study demonstrate that diverse pathways regulate 
ERK5 signalling by affecting kinase activity, localisation and protein stability. While the 
phosphatase PTP-SL is involved in negative regulation of ERK5, Abl kinases potently 
activate ERK5 and increase its half-life. Protein stabilisation thus is presented as a novel 
mechanism in the regulation of MAPKs. 6 German Summary  93 
6 ZUSAMMENFASSUNG  (German Summary) 
 
Eine wesentliche Grundlage für jede Form von Leben ist die Fähigkeit auf eine sich ständig 
ändernde Umgebung reagieren zu können. Jede einzelne Zelle muss in der Lage sein, äußere 
Reize wie zum Beispiel die Präsenz eines Hormons wahrzunehmen und dann angemessen, 
meist mit einer spezifischen Änderung der Genexpression, zu reagieren. 
Auf molekularer Ebene nehmen die sogenannten Mitogen-aktivierten Proteinkinasen 
(MAPKn) eine zentrale Rolle in der Weiterleitung von Signalen von der Zellmembran zum 
Zellkern ein. Die Proteinfamilie der MAPKn lässt sich traditionell in drei Gruppen 
unterteilen, und zwar in die durch extrazelluläre Signale regulierten Kinasen (ERKs), die c-
Jun aminoterminalen Kinasen (JNKs) und die durch Stress aktivierbaren p38 Kinasen. Mit der 
Klonierung der strukturell einzigartigen ERK5 musste eine weitere Untergruppe definiert 
werden (Lee et al., 1995; Zhou et al., 1995). Als einziges Mitglied der gesamten MAPK-
Familie besitzt ERK5 C-terminal der homologen MAPK-Domäne einen etwa 400 
Aminosäuren umfassenden Anhang mit bislang unbekannter Funktion. Die vorliegende Arbeit 
untersucht die Rolle und die Regulierung der ERK5 in verschiedenen Zellsystemen. Im 
Besonderen werden hier zwei grundlegende Mechanismen der Regulierung hervorgehoben: 1) 
die Kontrolle der Kinaseaktivität durch Phosphorylierung und Dephosphorylierung und 2) die 
Modulation der Proteinstabilität.  
Analog zu anderen MAPKn wird ERK5 durch gleichzeitige Phosphorilierung eines Tyrosin- 
und eines Threoninrestes aktiviert (English et al., 1999a). Diese sogenannte duale 
Phosphorylierung von ERK5 wird ausschließlich der spezifischen Kinase MEK5 
zugeschrieben. Um eine MAPKn zu inaktivieren reicht es allerdings aus eine der beiden 
Phosphatgruppen wieder zu entfernen (Canagarajah et al., 1997). Phosphatasen sind daher die 
Hauptantagonisten von MAPKn, da sie nicht nur die Phosphorylgruppen von deren Substrate 
entfernen, sondern auch die MAPKn selbst dephosphorilieren und somit inaktivieren können. 
Die Anzahl von Phosphatasen, die an der Negativregulation der ERK5 beteiligt sein könnten, 
ist recht groß und steht damit im Gegensatz zu der einzelnen aktivierenden Kinase. 
Ein erster Schwerpunkt dieser Arbeit ist die Frage, ob und wie die phosphotyrosin-spezifische 
Phosphatase PTP-SL in die Modulation von ERK5-vermittelten Prozessen eingreifen könnte. 
Die PTP-SL gehört zu einer Familie von Phosphatasen, die ein sogenanntes Kinase-
interagierendes Motiv besitzen und bereits als potentielle Regulatoren der klassischen 
MAPKn ERK1 und ERK2 beschrieben wurden (Pulido et al., 1998; Saxena et al., 1998). In 
der vorliegenden Arbeit konnte gezeigt werden, dass ERK5 und PTP-SL sowohl in intakten 6 German Summary  94 
Zellen als auch in vitro miteinander interagieren. Letzteres deutet darauf hin, dass beide 
Proteine direkt aneinander binden können und keine zusätzlichen Faktoren benötigen. Die 
beiden Bindungspartner beeinflussen sich gegenseitig in ihrer enzymatischen Aktivität. So 
konnte einerseits gezeigt werden, dass die katalytische Aktivität der PTP-SL im Komplex mit 
der Kinase erhöht ist. Obgleich PTP-SL ein Substrat für ERK5 ist, war diese Erhöhung der 
Phosphataseaktivität unabhängig von etwaigen Phosphorilierungen. Auf der anderen Seite 
war PTP-SL in der Lage ERK5 in vitro sowohl als auch in transfizierten Zellen zu 
inaktivieren. Die in PC12 Zellen endogen exprimierte ERK5 wird durch Zugabe von 
Stimulanzien wie zum Beispiel dem epidermalen Wachstumsfaktor aktiviert. Die 
Überexpression der aktiven PTP-SL unterdrückt diese Aktivierung, während ganz im 
Gegensatz dazu die Expression einer katalytisch inaktiven Mutante der PTP-SL die 
Aktivierung der ERK5 zusätzlich verstärkt. Diese positiven Effekte der Mutante, die auch in 
anderen Zellsystemen beobachtet wurden, lassen sich vermutlich darauf zurückführen, dass 
die inaktive PTP-SL die zelleigene Inaktivierung der ERK5 beeinträchtigt, indem sie mit 
endogenen Phosphatasen um die Bindung an ERK5 kompetitiert.  
Weiterhin konnte gezeigt werden, dass die PTP-SL auch in der Lage ist, die subzelluläre 
Verteilung der ERK5 zu beeinflussen. Die gesamte Menge der ERK5 verteilt sich über das 
Zytosol und den Zellkern. Da eine Hauptaufgabe der MAPKn die Phosphorylierung und die 
Aktivierung von Transkriptionsfaktoren und somit die gezielte Veränderung der 
Genexpression ist, stellt die subzelluläre Lokalisation von MAPKn, insbesondere ihre Präsenz 
im Zellkern, einen ausschlaggebenden Parameter für die Signalweiterleitung dar (Whitmarsh 
and Davis, 2000). Die Überexpression der PTP-SL führt unabhängig von ihrer katalytischen 
Aktivität zu einer Umverteilung der ERK5 vom Kern hin zum Zytosol. PTP-SL ist demnach 
in der Lage in zweierlei Weisen in ERK5-vermittelte Prozesse einzugreifen, und zwar sowohl 
durch Dephosphorylierung und Inaktivierung der Kinase als auch durch Beeinflussung der 
Lokalisation von ERK5 innerhalb der Zelle. 
Ein weiterer Teil der Arbeit konzentriert sich auf die Wechselwirkung von ERK5 mit der 
Proteintyrosinkinase Abl und ihren onkogenen Varianten, welche für die Pathogenese von 
Blutkrebs mitverantwortlich sind. Die chronische myeloide Leukämie (CML) ist durch das 
abnormale Philadelphia Chromosom gekennzeichnet. Entstanden aus der Translokation der 
Chromosome 9 und 22 kodiert es für ein Fusionsprotein aus dem Transkriptionsfaktor Bcr 
und der Abl Kinase. Die Forschung der letzten Jahre konnte zeigen, dass das so entstandene 
Bcr/Abl Onkogen sowohl für die Entstehung als auch für die Progression der CML 
verantwortlich ist (Daley et al., 1990; Huettner et al., 2000). Im Gegensatz zu dem zellulären 6 German Summary  95 
Gegenstück c-Abl ist das Fusionsprodukt rein zytoplasmatisch und besitzt permanente 
Kinase- und Signalaktivität (Sawyers, 1997). Die Behandlung von CML Patienten mit dem 
seit 2002 zugelassenen Abl-spezifischen Inhibitor Imatinib führte zu einem 
Krankheitsrückgang in nahezu allen Fällen (Druker et al., 2001a; Druker et al., 2001b). 
Allerdings ist die Behandlung von Patienten in vorangeschrittenen Stadien der CML durch die 
rasche Entwicklung von Resistenzen gegen Imatinib limitiert (Druker et al., 2001a; Ottmann 
et al., 2002). Da die Wirkungsweise von Imatinib auf der Fähigkeit beruht, den Zellzyklus zu 
arretieren und das zelleigene Selbstmordprogramm auszulösen, könnte die Wirkungsweise 
von Imatinib unterstützt werden, indem man Signalwege, die zum Überleben der Zelle 
beitragen, inhibiert. Ein wichtiges Überlebenssignal wird in vielen Zellarten von MAPKn 
reguliert (Ballif and Blenis, 2001) und vorläufige Untersuchungen deuteten darauf hin, dass 
dies auch in Leukämiezellen der Fall sein könnte (Yu et al., 2002). Zusammen mit einer 
Studie, die ERK5 mit der Chemoresistenz von Brustkrebszellen in Zusammenhang brachte, 
führte dies zu der Frage, ob ERK5 eine Rolle in von onkogenen Abl-Kinasen vermittelten 
Prozessen spielen könnte. 
Zunächst konnte gezeigt werden, dass ERK5 in Bcr/Abl positiven Zellinien exprimiert wird. 
Bcr/Abl aber auch andere Abl-Kinasen wie zum Beispiel die virale Form v-Abl waren in der 
Lage, mit ERK5 zu interagieren. Die Konsequenzen dieser Wechselwirkung waren die 
Aktivierung, die Tyrosinphosphorylierung und interessanterweise eine Erhöhung der 
zellulären Proteinmenge von ERK5. Letzteres beruhte auf der posttranslationalen 
Stabilisierung des ERK5-Proteins, da dieser Effekt durch die Inhibierung der Translations-
maschinerie nicht beeinträchtigt wurde. Eine genauere Untersuchung zeigte, dass eine der 
beiden Prolin reichen Domänen, welche im C-terminalen Bereich von ERK5 liegen, für die 
Stabilisierung durch Abl-Kinasen benötigt wird. Die Identifizierung einer potentiellen 
Bindestelle für die sogenannte SH3 Domäne von Abl in eben dieser Region mit Hilfe des 
Scansite-Suchprogrammes (Yaffe et al., 2001) stützte dieses Ergebnis. Die Relevanz der 
einzigartigen Sequenzen von ERK5 wurde zusätzlich durch die Beobachtung bestätigt, dass 
eine Chimäre, welche aus der MAPK ERK2 und dem gesamten C-terminalen Schwanz von 
ERK5 bestand, in vergleichbaren Maße wie ERK5 stabilisiert wurde. 
Basierend auf folgenden zwei Beobachtungen konnte die Schlussfolgerung gezogen werden, 
dass Stabilisierung und Aktivierung unabhängig voneinander verlaufen. Erstens, eine 
konstitutiv aktive Mutante von MEK5, die ERK5 maximal zu aktiviert, hatte keinen Einfluss 
auf die zelluläre Proteinmenge der ERK5. Zweitens, eine AEF-Mutante von ERK5, deren 6 German Summary  96 
MEK5 Phosphorylierungsstellen mutiert wurden und die daher nicht aktiviert werden kann, 
wird ohne weiteres durch Abl-Kinasen stabilisiert. 
Ein erster Hinweis darauf, dass die Wechselwirkung von ERK5 mit Abl-Kinasen 
pathophysiologische Bedeutung besitzen könnte, wurde durch die Beobachtung geliefert, dass 
die Überexpression von ERK5 zu einer Erhöhung der Transformationsrate von viralem Abl 
führte. Das onkogene Potential von Abl-Kinasen lässt sich durch ihre Fähigkeit, 
Bindegewebszellen von Nagern zu transformieren, untersuchen. Transformierte Zellen 
verlieren die Kontaktinhibition, die sie normalerweise bei Erreichen einer geschlossenen 
einzelligen Schicht von weiteren Zellteilungen abhält, und sind daher an der Bildung von 
mehrschichtigen Aggregaten leicht zu erkennen. Während eine katalytische inaktive Mutante 
von ERK5 keine Auswirkung hatte, war der Effekt der AEF-Mutante vergleichbar mit dem 
des Wildtyps von ERK5. Die AEF-Mutante ist zwar nicht aktivierbar, besitzt aber basale 
Kinaseaktivität, welche vermutlich in Verbindung mit der zellulären Proteinmenge für die 
Verstärkung der Transformation ausschlaggebend ist. 
Um zu der anfänglichen Fragestellung, ob ERK5 in der Weiterleitung von Überlebenssignalen 
beteiligt sein könnte, zurückzukehren, wurde die Überlebensrate von Bcr/Abl positiven 
Leukämiezellen nach kurzer Imatinibbehandlung untersucht. Zellen, deren Expressionslevel 
der ERK5 mit Hilfe der RNS-Interferenz reduziert wurde, wiesen eine wesentlich verringerte 
Überlebensrate auf. Eine vergleichbare Reduzierung konnte durch die Überexpression der 
inaktiven ERK5-Mutante erzielt werden, welche vermutlich negativ mit dem endogenen 
ERK5-Signalweg interferiert. Im Gegensatz dazu konnte die Überexpression der 
inaktivierbaren Form von ERK5 das Zellüberleben nicht beeinflussen. Vergleichbar mit den 
Effekten in der Transformation sind also auch für die Überlebensrate von Zellen die basale 
Aktivität und die Proteinmenge der ERK5 und nicht die Aktivierung durch die MEK5 von 
Bedeutung. Die Stabilisierung der ERK5 durch Bcr/Abl könnte demnach zur Pathogenese der 
CML beitragen und ein zu berücksichtigender Aspekt in der Therapie sein. 
Wie im letzten Abschnitt der vorliegenden Arbeit gezeigt, wird ERK5 in der Präsenz sowohl 
von Wachstumsfaktoren als auch Stressfaktoren wie Hyperosmolarität aktiviert und sollte 
aufgrund dieses Aktivierungsprofils zwischen den mitogenen ERKs und den stress-sensitiven 
JNKs und p38 Kinasen eingeordnet werden. Im starken Gegensatz zu ERK2 wird zum 
Beispiel in PC12 Zellen nur ein sehr kleiner Prozentsatz der gesamten ERK5 aktiviert. Eine 
mögliche Erklärung für die reduzierte Aktivierbarkeit von ERK5 konnte durch die 
Beobachtung geliefert werden, dass der C-terminale Anhang in der Lage war, die Aktivität 6 German Summary  97 
der Kinase zu unterdrücken. Neben der Autoinhibierung konnte für die Domänen des C-
Terminus eine Rolle in der Regulation des Kernimports und Exports aufgezeigt werden. 
Obgleich MAPKn durch eine enorme Zahl verschiedenster Stimuli aktiviert werden, führen 
sie doch zu spezifischen und angemessen Reaktionen der Zelle. Die molekularen Grundlagen 
dieser auf den ersten Blick paradoxen Situation konnten bisher nur zum Teil entschlüsselt 
werden. Zumindest steht fest, dass die Dauer und die Amplitude der induzierten MAPK-
Aktivität zwei der Parameter sind, die das Schicksal der Zelle mitbestimmen (Marshall, 
1995). Starke Stimuli wie zum Beispiel mitogene Wachstumsfaktoren induzieren eine starke 
pulsartige Aktivierung von MAPKn. Im Gegensatz dazu ist anzunehmen, dass die 
Stabilisierung einer Kinase ein andauerndes Aktivierungsprofil mit niedriger Amplitude 
hervorrufen dürfte. Während viele Signalwege nur vorrübergehend angeschaltet werden 
müssen, ist es unabdinglich für die normale Zellfunktion, dass Überlebenssignalwege 
kontinuierlich aktiv sind. Da die basale Aktivität von ERK5 ausschlaggebend und vor allen 
Dingen auch hinreichend für das Überleben von Leukämiezellen war, könnte in diesem Falle 
die Stabilisierung und die Destabilisierung einen bedeutenden, wenn nicht sogar den 
wichtigsten, Regulationsmechanismus darstellen. Auch wenn die hauptsächliche Kontrolle 
von MAPKn durch ihren Phosphorilierungsstatus unumstritten ist, könnte in all jenen Fällen, 
die unabhängig von der Aktivierung der MAPKn sind, die Proteinstabilität als regulatorisches 
Moment dienen. Die kürzlich beschriebene Beobachtung, dass die Degradation und nicht die 
Dephosphorilierung von ERK2 eine Vorraussetzung für die Initiierung des zelleigenen 
Selbstmordprogramms ist (Lu et al., 2002), unterstreicht die Bedeutung, die der Kontrolle der 
Proteinmenge von MAPKn im Zusammenhang mit dem Überleben von Zellen zukommt. 
Zusammengenommen zeigen die Daten dieser Arbeit, dass zahlreiche Signalwege durch 
ERK5 vermittelt werden und dass nicht nur die Kinaseaktivität sondern auch die zelluläre 
Lokalisation und die Proteinstabilität wichtige Parameter der Regulation sind. 
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‘        M i n u t e  
aa       Amino  acid 
Ab       Antibody 
ADAM     A  disintegrin  and  metalloprotease  domain 
AEF       Not  activatable  MAPK  mutant 
AML       Acute  myeloid  leukaemia 
Amp
r       Ampicilline  resistence 
APC       Adenomatous  polyposis  coli  gene 
APS       Ammoniumpersulfate 
AR       Amphiregulin 
ATP       Adenosintriphosphate 
bp       Base  pairs 
BSA       Bovine  serum  albumin 
BCR       Break  point  cluster  region  gene 
Bcr/Abl      Leukaemic  fusion  protein 
°C       Degree  celsius 
c-Abl    Cellular form of v-Abl 
cAMP       Cyclic  adenosinmonophosphate 
Ca
2+       C a l c i u m   I o n s  
CaM  Kinase      Ca
2+-calmodulin-dependent kinase 
cDNA       Complementary  DNA 
cds   Coding  sequence 
CML       Chronic  myeloid  leukaemia 
C M V        C y t o m e g a l o   v i r u s  
c-jun            Cellular homologue to v-jun (avian sarcoma virus 
      17  oncogene) 
DMEM     Dulbecco's  modified  eagle  medium 
DMSO       Dimethylsulfoxide 
DNA       Desoxyribonukleic  acid 
dsDNA     Dooble-stranded  DNA 
DTT       Dithiothreitol 
ECL       Enhanced  chemiluminescence   
EDTA       Ethlendiamintetraacetate 
EGF       Epidermal  growth  factor 
EGFR       Epidermal  growth  factor  receptor 
E G T A        E thylene glycol-bis(2-aminoethyl)- 
N,N,N',N'-tetraacetic acid 
ERK       Extracellular  signal-regulated  kinase 
FAP       Familial  adenomatous  polyposis 
FAK       Focal  adhesion  kinase 
FCS       Fetal  calf  serum 
FGF       Fibroblast  growth  factor 
FGFR       Fibroblast  growth  factor  receptor 
F i g        F i g u r e  
g        G r a m m  
GDP       Guanosindiphosphate 
GFP       Green  fluorescent  protein 
GPCR         G  protein-coupled  receptor   8 Abbreviations 
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Grb2       Growth  factor  receptor  binding  protein  2 
GST       Glutathion-S-transferase 
GTP       Guanosintriphosphate 
h       Hour 
H A        H e m a g g l u t i n i n  
H2Obidest      Twice-destilled,  deionised  Water 
HEPES     N-(2-Hydroxyethyl)-piperazin-N‘-2- 
Ethansulfonic acid 
H E R        H u m a n   E G F R - r e l a t e d  
HNPCC      Hereditary  Nonpolyposis  Colorectal  Cancer 
HSCT       Hematopoietic  stem  cell  transplantation 
HRP       Horseradish  peroxidase 
IFN-α       I n t e r f e r o n - α 
Ig       Immunglobulin 
IP       Immunoprecipitation 
IPTG       Isopropyl-ß-thiogalactopyranoside 
JNK       c-Jun  N-terminal  kinase 
kb       Kilobase 
kDa       Kilodalton 
KIM       kinase  intercating  motif 
KIM  PTP      KIM  containing  tyrosine-specific  phosphatase 
l        L i t e r  
LPA       Lysophosphatydic  acid 
LTR       long  terminal  repeats 
µ        M i c r o  
m       Milli 
M        M o l a r  
MAP       Mitogen-activated  protein 
MAPK       MAP  kinase 
MAPKK      MAP  kinase  kinase 
MAPKKK      MAP  kinase  kinase  kinase 
MBP       Myelin  basic  protein 
MCS       Multiple  cloning  site 
MEK       MAPK/ERK  Kinase 
MEKK       MAPK/ERK  Kinase  Kinase 
m i n        M i n u t e  
MMP       Matrix  metalloprotease 
n        N a n o  
Neo
r       Neomycine  resistance 
NGF       Neuronal  growth  factor 
OD       Optical  density 
p.a.       Per  analysis 
PAGE       Polyacrylamide  gel  elektrophoresis 
PBS       Phosphate-buffered  saline 
PCR       Polymerase  chain  reaction 
PDGF       Platelet-derived  growth  factor 
PEG       Polyethylenglycole 
PI  3-Kinase      Phosphatidylinositol  3-kinase 
PIP2       Phosphatidylinositol-4,5-diphosphate 
PKA       Protein  kinase  A 
PKC       Protein  kinase  C 8 Abbreviations 
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PLC       Phospholipase  C 
PMSF       Phenylmethylsulfonyl-fluoride 
pNPP       p-Nitrophenyl-phosphate 
pRS       pRetroSUPER  vector 
PTP       Phosphotyrosine-specific  phosphatase 
PY       Phosphotyrosine 
Raf   Homologue to v-raf (MAPKKK) 
Ras       Homologue to v-ras (rat sarcoma viral oncogene) 
RNA       Ribonucleic  acid 
rpm       Rotations  per  minute 
RT       Room  temperature 
RTK       Receptor  tyrosine  kinase 
SAPK       Stress-activated  protein  kinase 
S.D.       Standard  deviation 
SDS       Natriumdodecylsulfate 
SH       Src  homology 
SHP-2       SH2-containing  PTP-2 
Sos       Son  of  sevenless 
Src       Homologue to v-src (sarcoma viral oncogene) 
SV40         Simian  virus 
Tel/Abl        Leukaemic  fusion  protein 
TEMED      N,  N,  N‘,  N‘-Tetramethyletylendiamine 
TNFα        Τ umor necrosis factor alpha 
TPA       12-O-Tetradecanoyl-phorbol-13-acetate 
Tris       Tris(hydroxymethyl)aminomethan 
Tween  20      Polyoxyethylensorbitanmonolaureate 
U       Enzymatic  activity  unit 
O/N       Overnight 
UV       Ultraviolett 
V        V o l t  
VSV       Vesicular  stomatitis  virus  glycoprotein  VSV-G 
v-Abl       Oncogene  of  Abelson  leukaemia  virus 
V o l        V o l u m e  
W T        W i l d   t y p e  
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